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The main function of the immune system is to combat invading pathogens. Two lines of 
defense are activated upon infection with a microorganism. The first one is the innate 
immune response, which is mediated by certain cell populations and soluble factors. These 
cells include neutrophils and macrophages that can recognize constituents of cell membranes 
of e.g. bacteria and engulf them, as well as natural killer (NK) cells which can directly or 
indirectly exert antiviral activity. Upon activation, neutrophils and macrophages secrete 
cytokines and chemokines such as type I interferons (IFN-α/β), interleukins (IL-1, IL-6, IL-
8) and tumor necrosis factor (TNF-α) that attract other cells to the site of infection and may 
elicit the specific immune response (1,2). Other soluble factors for opsonization of 
microorganisms, as well as elimination of cell debris and immune complexes, are acute 
phase proteins such as mannose binding lectin (MBL) and complement factors (3).   
The second line of immunity, the adaptive immune response, is initiated in the lymph nodes 
after presentation of specific epitopes to T and B lymphocytes. Antigens from the 
microorganisms, taken up in the infected tissues by specialized antigen-presenting cells 
(APC) - the dendritic cells (DC) - are processed to peptides and presented by major 
histocompatibility complex (MHC) molecules to T cells in the lymph nodes. These T cells 
can in turn provide help to B cells that recognize the tertiary structure of the antigen. Upon 
encounter with the specific antigen in the context of appropiate co-stimulation, both T and B 
cells become activated leading to extensive proliferation and differentiation by which cells 
gain effector functions (4). For B cells, this involves immunoglobulin class switching and 
affinity maturation in the germinal center reaction, resulting in the production of high 
affinity antibodies against extracellular pathogens such as the majority of bacteria and 
parasites. Antiviral antibodies also contribute to viral clearance mainly by blocking virus 
entry into susceptible cells, thereby preventing extracellular viral spread. Effector T cells 
produce cytokines and in some cases gain cytolytic activity which will lead to eradication of 
intracellular pathogens such as viruses or intracellular bacteria (1,4). After the infection is 
cleared, the size of the effector cell pool is reduced as most cells die, while some cells 
differentiate to long-living B and T memory cells which can confer protection of a host upon 
re-infection by more rapid and enhanced secondary responses. 
2. ALLOGENEIC STEM CELL TRANSPLANTATION 
2.1 Introduction 
Allogeneic stem cell transplantation (SCT) is a remedy to cure a number of inherited 
diseases of hematopoietic precursor cells, and can also be applied to rescue deficient 
hematopoiesis following intensive radio/chemotherapy for hematologic malignancies. 
Defects in one or more components of the immune system may result in immunodeficiency, 
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either primary or secondary. Primary immunodeficiencies are caused by a germ-line 
mutation affecting one of several genes that control the expression and activities of immune 
responses (5). Secondary immunodeficiencies are acquired as a consequence of 
environmental factors or other diseases, such as viral infections (e.g. HIV), malnutrion, or 
hematopoietic neoplastic tumors which suppress normal immune cell function or are treated 
with myeloablative medication (1).  
A great number of gene defects inducing primary immunodeficiency have been discovered, 
resulting in an absence of CD8+ or CD4+ T cells in for example MHC class I or II deficiency, 
respectively, or a lack of the total T cell population (sometimes accompanied by an absence 
of NK cells, and/or B cells) in severe combined immunodeficiency (SCID). In SCID, at least 
8 entities can be distinguished based on the genetic defect and according to their phenotype 
and inheritance pattern (5). Patients with one of these deficiencies have a clinical 
presentation which is characterized by an early onset of infections, mainly of the respiratory 
and intestinal tract. Persistent diarrhoea with growth impairment and/or interstitial 
pneumonia are the most frequent infectious manifestations, besides superficial Candida 
infections of the skin and mucous membranes. Opportunistic microorganisms as 
Pneumocystis jirovecii, intracellular microorganisms as Listeria and Legionella, as well as 
viruses such as those from the Herpes family can also lead to devastating disease in these 
patients. SCT with stem cells from bone marrow of an allogeneic healthy donor is in most 
cases the only option for curing these severely immunocompromised patients. Important 
properties of stem cells include self-renewal potential as well as pluripotency, implicating 
that all lineages of recipient hematopoiesis can be reconstituted following SCT.  
Immunodeficiencies were the first hematological disorders eligible for SCT in the late 
sixties. In the next decades, SCT has also proven to be an effective treatment for 
hematological malignancies and nonmalignant hematological disorders. Pediatric 
hematological malignancies for which SCT is part of a possible therapy are acute 
lymphoblastic leukemia (ALL, the most common form of leukemia in children), acute 
myelogenous leukemia (AML), and chronic myelogeneous leukemia (CML). When these 
patients are in first (for the high-risk type) or second remission after chemotherapy, SCT is a 
good therapeutic option for treatment which results in an increased disease-free survival as 
compared to conventional chemotherapy (6). Nonmalignant disorders curable by SCT are 
e.g. severe aplastic anemia (SAA), Fanconi anemia and β-thalassemia, in which SCT is 
given to correct the underlying hematological defect (7). More recently, SCT has been 
performed as experimental therapy for metabolic disorders and autoimmune diseases.  
Depending on the disease for which the SCT is performed, as well as the age of the patient, 
different conditioning regimens are used. Most myeloablative conditioning regimens are 
based either on total body irradiation (TBI) for older children, or busulfan for children under 
the age of 3 years. Non-myeloablative conditioning regimens (also indicated as reduced 
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intensity conditioning regimens) are not meant to eradicate malignant or normal 
hematopoietic precursor cells, but to suppress more mature cells together with the adaptive 
immunity of the host. Reduced intensity regimens consist mostly of cyclophosphamide-
based regimens in combination with anti-thymocyte globulins (ATG) or monoclonal anti-T 
cell antibodies, and may include moderate amounts of busulfan or TBI. 
 
2.2 HLA compatibility in SCT 
The degree of human leucocyte antigen (HLA)-matching between donor and recipient 
determines the feasibility and outcome of an allogeneic SCT to a large extent. The genes for 
the HLA antigens are located in the major histocompatibility complex (MHC) on 
chromosome 6. The HLA antigens are heterodimers grouped in 2 classes according to their 
chemical structure and function. For HLA class I, three loci are relevant in this respect, 
HLA-A, B and C. In 2001, 220 HLA-A, 460 HLA-B and 110 HLA-C alleles were described. 
Similarly, three loci are present for HLA class II, of which 360 alleles for DR, 70 for DQ, 
and 116 for DP, respectively, have been described (8). The enormous polymorphism of the 
HLA antigens makes it difficult to find a fully HLA-matched donor outside of the close 
family. The donor should share at least some HLA molecules with the graft recipient in order 
to assure proper positive and negative selection of precursor T cells in the thymus. In the 
case of an HLA-mismatched transplant, transfer of mature alloreactive donor T cells into the 
host may induce a severe complication, called graft-versus-host disease (GvHD) where T 
cells react against host HLA molecules, and attack tissues of the recipient. Alternatively, 
residual host hematopoietic cells may recognize donor cells as foreign and induce a host-
versus-graft disease (HvGD), resulting in failure of engraftment or graft rejection.  
In 1968, the first successful stem cell transplantations were performed for SCID patients 
with an HLA-identical sibling (matched family donor, MFD) (9,10). In this setting, patients 
did not require any conditioning prior to SCT because they were not at risk of graft rejection 
as a result of their intrinsic immune incompetence. Improved knowledge and experience has 
led to the use of SCT for the treatment of other diseases, such as other inborn errors and 
leukemia in the late 1970’s (11). To successfully engraft these patients, pretransplant 
conditioning therapy, usually consisting of chemotherapy with either TBI or busulfan, is 
needed in order to create space in the bone marrow, to suppress the allo-immune reactivity of 
the host, and eradicate malignant cells, e.g. in the case of leukemia. Because an HLA-
identical sibling donor is only available for approximately one third of all patients, 
alternative donors are required. These donors include partially HLA-mismatched (or haplo-
identical) family donors (MMFD) as well as (mis)-matched unrelated donors ((M)MUD). In 
these cases, one or more HLA mismatches (up to 6 out of 12 HLA loci for a haplo-identical 
parent) may be present between donor and recipient. In early studies, SCT with unrelated 
donors resulted in higher frequencies of graft rejection, an increased risk of GvHD and of 
General Introduction 
 13
infections post-SCT, and a lower disease-free survival (12-17). To circumvent these 
transplant-related complications, T-cell depletion of the graft and additional 
immunosupression prior to SCT (with ATG or Campath) and after SCT (with cyclosporin A 
(CsA) or tacrolimus) were applied in order to enhance engraftment and prevent GvHD 
(18,19). In this respect, suppression of the gut microflora by gastro-intestinal 
decontamination (GID) of pediatric recipients who were kept in a strict protective 
environment significantly reduced the incidence and severity of acute GvHD (20), also in 
MUD-SCT for children (Donker et al., personal communication). 
Further development of SCT-technology in recent years is the result of improved HLA 
matching by high-resolution DNA typing (21,22), and the use of alternative sources of stem 
cells. These stem cells can be obtained from umbilical cord blood (UCB) or CD34+ 
peripheral blood stem cells (PBSC), mobilized from the bone marrow by cytokines such as 
granulocyte colony stimulating factor (G-CSF). These strategies have comparable rates of 
engraftment and acute GvHD as following bone marrow transplantation, but a somewhat 
increased frequency of chronic GvHD and a delayed lymphocyte recovery, especially in the 
case of PBSCT (23-26). 
 
2.3 Immune reconstitution after SCT 
In the first months post-SCT, patients are immunocompromised because stem cells from the 
graft need to develop into all myeloid and lymphoid lineages. After SCT with a T-cell 
depleted graft, e.g. in the case of MMUD or MMFD transplants, immunological recovery is 
more delayed than in patients receiving a full graft of an HLA-identical MFD donor. 
Leukocyte recovery (usually assessed as granulocyte counts ≥ 0.5×109/L) following a T-cell 
depleted SCT is achieved around week 2-3 post-SCT, whereas lymphocyte recovery 
(≥ 0.5×109/L) can be observed at ≥ 1-2 months after SCT. This recovery (merely based on 
cell counts and not on cell function) is not statistically different between unrelated or related 
donors (MMUD vs MMFD) (27). Repopulation with different lymphocyte subsets after SCT 
from patients in our clinic is shown in Figure 1 (Jol-van der Zijde, unpublished data). 
NK cells constitute the major proportion of lymphocytes that repopulate the peripheral blood 
early after SCT, followed by CD8+ T cells and B cells. CD4+ T cell recovery is further 
delayed, which is most pronounced following a SCT from a T-cell depleted graft (17,28). 
These CD4+ T cells consist mainly of CD4+CD45RO+ cells characteristic for memory cells. 
As a consequence of the delayed CD4+ T cell recovery, the CD4/CD8 ratio is inverted 
compared to the situation in healthy persons. Naive CD4+ and CD8+ T cells only appear after 
6-9 months or later (29-31). This is also accompanied by a severely skewed T cell repertoire 
in the first 6-12 months following SCT as assessed by TCR-BV spectratyping, with 
normalization only after naive T cells have repopulated the blood (29,32,33). This reflects 
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Figure 1. Recovery of NK cells, CD20+ B cells, CD8+ T cells and CD4+ T cells in the first 12 
months after SCT. Open symbols represent MFD recipients (geometrical mean (GM): thin black 
line), gray symbols represent MUD transplant without T cell depletion (GM: gray dotted line), and 
black symbols represent MUD transplants with T cell depletion (GM: thick black line). The dotted 
lines indicate the 95% confidence interval (GM ± 2×SD) of healthy controls (including children and 
adults) (Jol-van der Zijde, unpublished data). 
compartment after SCT. The first regeneration develops from mature T cells in the graft that 
may expand in the host under antigenic stimulation (referred to as peripheral expansion) 
(34). The second regeneration consists of de novo maturation of naive T cells from the 
pluripotent stem cells via passage through the thymus (27). Furthermore, acquisition of full 
T cell function requires time and may be hampered by the prolonged use of immune 
suppressive drugs such as CsA administered to minimize the severity of GvHD (35).  
Immunoglobulin levels of IgM and IgG in serum of graft recipients are usually normal 
compared to healthy controls, whereas IgA levels are markedly reduced (26,31). However, 
intravenous immunoglobulin (IVIG) support is often applied after SCT, which could account 
for the normal levels of IgG in serum. Specific antibody production, such as following 
infection or vaccination, is severely delayed after MMFD/MMUD SCT in comparison to 
MFD SCT (36-38).  
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Figure 2. Viral complications in the first months after SCT. Patients are neutropenic during the 
first month, in which HSV reactivations occur. In the absence of T and B cellular immunity, DNA 
viruses such as EBV, CMV and HAdV are prominent. In a later phase after SCT, late CMV 
infections are reported as well as VZV infections (Adapted from refs (42,43)). 
The occurrence of GvHD and cytomegalovirus (CMV) reactivation has been reported to 
have an impact on immune recovery (31,39). For GvHD, this might be due to the fact that 
GvHD targets the lymphoid system besides the epithelial system of the skin, liver and gut, 
causing lymphoid hypocellularity. As a result of the prolonged immunodeficiency state of 
the patient after SCT, especially following MMFD or MMUD SCT, the risk of opportunistic 
infections is high (27,40,41). 
 
2.4 Infectious complications after SCT 
Infections are a major cause of morbidity and mortality after allogeneic SCT (42). Usually, 
allograft recipients are treated in a protective environment and receive (general or intestinal) 
antimicrobial prophylaxis to prevent infections with bacteria, fungi and P. jirovecii during 
the early post-transplant period, when the recipient is unable to mount an effective immune 
response to pathogenic microorganisms. By this means, de novo infections with these 
microorganisms and respiratory viruses are minimalized. On the other hand, the recipient 
might have encountered many DNA viruses prior to SCT, which persist in the recipient in a 
latent form and may reactivate after SCT. 
The sequential occurrence of infections is linked with the changing immunologic state of the 
graft recipient and is depicted for viral infections in Figure 2.  
Three phases of immune recovery can be observed: the first phase, up to 30 days post-SCT, 
is the neutropenic phase in which bacterial infections are the major concern, as well as 
clinically evident herpes simplex virus (HSV) reactivation due to disruption of the mucosal 
integrity by the preparative regimen (43). Appropriate antibiotics and acyclovir, respectively, 
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are usually effective. The second phase is the early post-transplant phase (30-100 days post-
SCT) that is characterized by impaired cell-mediated immunity in which mainly viral 
reactivations occur that may result in severe infections. Some of these viruses, such as 
varicella zoster virus (VZV), are rapidly diagnosed clinically in an early phase of infection 
and treatment with (val)acyclovir is adequate. However, other herpes viruses such as CMV 
and Epstein-Barr virus (EBV), which are most common in the population, can cause severe 
problems because signs and symptoms of a beginning infection are not evident (44). CMV is 
latently present in leukocytes and can be reactivated in host cells or it can be transferred by 
cells from a seropositive donor to a seronegative patient, inducing a primary CMV infection 
in the host. EBV latency is installed in B cells, which upon reactivation can cause the severe 
post-transplant lymphoproliferative disease (PTLD) (45). Morbidity and mortality due to 
CMV or EBV infections were high in MUD transplants (up to 85% and 100%, respectively) 
in the era prior to the development of sensitive laboratory detection methods and treatment 
(45,46). Recently, early detection of viral DNA by polymerase chain reaction (PCR) (47,48) 
as well as improved treatment with ganciclovir (given either prophylactically or pre-
emptively) or α-CD20 antibodies, for CMV and EBV infections, respectively, have resulted 
in a significant decrease in morbidity and mortality due to these infections (46,49-51). The 
third phase is the late post-transplant phase (>100 days) in which VZV infections frequently 
occur (43), as well as late CMV infection which has recently been described as causing late 
morbidity and mortality (52). 
In recent years, the human adenovirus (HAdV) has emerged as an important opportunistic 
pathogen in recipients of SCT, especially in pediatric recipients of a (M)MUD or MMFD 
donor (53-55). This virus is known to induce mild upper respiratory tract infections in 
immunocompetent individuals. However, in immunocompromised patients, HAdV 
infections are increasingly detected during the early phase after SCT and may cause severe 
and even lethal infections in viremic patients. HAdV infections, its detection, and HAdV-
specific immune responses are the focus of this thesis. 
3. HUMAN ADENOVIRUS (HADV) 
3.1 Structure of the virus 
In 1953, the virus was first identified by Rowes and colleagues who observed spontaneous 
degeneration of primary cell cultures derived from human adenoids (56). In 1956, Enders 
proposed to name the virus adenovirus, after the original tissue where the prototype strain 
was discovered (57).  
The adenoviruses belong to the family of Adenoviridae, which is divided into four genera: 
two genera were found in mammals and birds only, the Mastadenoviruses and the 
Aviadenovirus, respectively, while the other two genera, Atadenovirus and Sadenovirus, 
have a broader range of hosts, including reptiles and ruminants. Mastadenoviruses contain 
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human, simian, murine and many other adenoviruses (58). Within each genus, viruses are 
grouped into species, which are named from the host and supplemented with letters from the 
alphabet. For human adenoviruses (HAdV), 51 serotypes have been described to date that 
can be distinguished on the basis of neutralization by antisera. These serotypes are grouped 
into 6 species (A-F) based on their ability to agglutinate red blood cells of different animals, 
the percentage of DNA homology and their oncogenic potential in rodents (59). Within 
species, DNA homology ranges from 48% for species A to 99% for species C, allowing 
intra-species recombinations, whereas homology between species is less than 20%. Human 













The virus is non-enveloped and contains double-stranded DNA. The virus particles are ~70-
100 nm in diameter and have an icosahedral shape. The capsid, which is the protein shell 
surrounding the DNA, is composed of 252 subunits that consist of 240 hexon proteins and 12 
penton proteins. The penton protein is formed by a penton base that resides in the capsid 
surface, and a fiber which projects outwards. This fiber is the first to make contact with a 
receptor present on a cell to ensue cell-entry by the virus. In total, 11 virion proteins have 
been discovered and numbered II, III, IIIa, IV, V, VI, VII, VIII, IX, mu and terminal protein 
(59). The capsid contains 7 of these proteins, of which the hexon protein is the most 
abundant and is composed of three tightly associated polypeptides II. The second most 
abundant protein is the penton that is built up of five units of polypeptide III, while the 
projecting fiber is composed of three polypeptides IV. The hexon is further supported by 
three proteins, VI, VIII and IX to form a stable structure, as well as IIIa which is found 
adjacent to the penton base (59). The other 4 proteins are found in the core of the virus 
together with the viral DNA. Three proteins are in contact with the viral DNA, V, VII and 
mu, of which VII is the major core protein and serves as a histone-like center for the DNA. 
Polypeptide V can also bind to the penton to stabilize the core and capsid. Finally, the 
Table I. HAdV species and serotypesa 
Species Serotypes Hemagglutination type 
A 12, 18, 31 IV (none) 
  B b 3, 7, 11, 14, 16, 21, 34, 35, 50 I (monkey) 
C 1, 2, 5, 6 III (partial rat) 
D 8-10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, 42-49, 51 II (complete rat) 
E 4 III 
F 40, 41 III 
a  Adapted from refs (54,61,62). 
b  Serotypes in italics represent B1 serotypes, the other serotypes belong to the B2 species (54,63). 
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terminal protein is covalently attached to the ends of the viral DNA, and serves as a primer 



















3.2 Adenoviral replicative cycle 
HAdV requires infection of a host cell for its replication and production of progeny. The 
initial step is attachment of the knob of the trimeric fiber molecule to the receptor for HAdV. 
This receptor was discovered in 1997 and found to be shared with the Coxsackie virus; 
hence the receptor has been named the Coxsackie-Adenovirus receptor (CAR) as no other 
function of the receptor has been found (65,66). CAR belongs to the immunoglobulin 
superfamily and serves as a high-affinity receptor for HAdV from species A, C, D, E and F, 
but not species B (67). Recently, species B has been shown to bind and internalize via the 
CD46 molecule, which is a ubiquitously expressed complement regulatory protein (68-70). 
The distribution of CAR in rodents is more restricted to epithelial cells of several organs 
such as lung, liver, intestine, heart, pancreas and nervous system (71). In a study of human 
hematopoietic cells, CAR expression was only detectable on cells from myeloid origin (66), 
whereas CD46 is present on all hematopoietic cells. A second interaction between HAdV 
and the host cell, besides binding to CAR, is required for efficient entry, i.e. the binding of 
penton-base to integrins, such as αvβ3 or αvβ5, through an arginin-glycin-asparagin (RGD) 
motif in the penton-base (72,73). After adsorption, the virus is internalized by receptor-
mediated endocytosis via clathrin-coated pits in endosomes (74). HAdV can escape the early 
endosome prior to the formation of a lysosome, which is induced by the low pH in the 
 
Figure 3. Representation of an HAdV virion. Viral constituents are designated by their 




endosome and most likely occurs via conformational changes in the penton-base. The virion 
is subsequently stripped from some of its proteins in a selective manner while the virion is 
transported via microtubules towards the nucleus (75). At the nuclear membrane the DNA is 
released from the remaining virion and introduced into the nucleus (76) where replication of 
the virus can occur.  
This replicative cycle is by convention divided into 2 phases that are separated by the onset 
of viral DNA replication. The early phase contains adsorption, penetration and movement of 
viral DNA into the nucleus, and expression of an early set of genes. The function of these 
early genes is to facilitate DNA replication, to induce cell cycle progression, to block 
apoptosis and to antagonize the host immune response (see below) (59). In the human 
epithelial cell line HeLa, the early phase lasts about 5-6 h, whereas the cycle is complete 
after 20-24 h. 
The viral chromosome carries 5 early transcription units (E1A, E1B, E2, E3 and E4), 2 
delayed early units (IX and IVa2) and 1 late unit (major late), which is processed to generate 
5 families of late mRNAs, L1-L5. The early gene E1A is the first transcription unit to be 
expressed, followed by E1B, E4 and E2, which sets the stage for DNA replication. All these 
mRNAs are transcribed by RNA polymerase II, whereas the 1 or 2 virus-associated genes 
VA (depending on the serotype) are transcribed by RNA polymerase III (59). After DNA 
replication is initiated, late genes begin to be expressed in a single large transcription unit. 
After transcription by RNA polymerase II, multiple mRNAs are formed by alternative 
splicing, a phenomenon that was first discovered in adenovirus (77). When late mRNAs are 
synthesized, cytoplasmic accumulation of cellular mRNA is blocked, thereby shutting off the 
production of cellular proteins. Trimeric hexon capsomeres are rapidly assembled from 
monomers, followed by a slower assembly of penton capsomeres consisting of pentameric 
penton base and trimeric fiber in the cytoplasm. After transport to the nucleus, an empty 
capsid is formed which is subsequently entered by a viral DNA molecule. Release from the 
cell is in part mediated by the E3 11.6-kD protein, also called the adenovirus death protein, 
as it is able to lyse cells by an unknown mechanism (78). In HeLa cells, one virus infecting a 
cell may produce a progeny of 104 viruses (59).  
 
3.3 Immune evasion by HAdV 
HAdV has developed multiple mechanisms to escape from the antiviral defense of the host. 
These mechanisms aim at protecting the infected cell from apoptosis induced by the 
infection itself, or from cellular immune responses, such as reduced recognition of the 
infected cell by CD8+ T cells or reduced susceptibility of the infected cell to lysis induced by 
these cytotoxic T cells. These mechanisms are described below in more detail. 
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The E1A protein 
The E1A protein has several functions in establishing the balance of survival or death of the 
infected cell. On one hand, it affords protection from the antiviral effects of IFN-α, IFN-β 
and IFN-γ by blocking the activation of interferon response genes, partly by binding to the 
transcription factor STAT1 and interfering with the formation of IFN specific transcription 
factors, IFN-stimulated gene factor 3 for type 1 IFNs and γ-stimulated factor for IFN-γ 
(79,80). Also, E1A downregulates the expression of the transforming growth factor β1 
receptor on infected cells (81). On the other hand, E1A stabilizes the tumor suppressor 
protein p53, which could mediate cell cycle arrest or apoptosis upon DNA damage, which is 
unfavorable for survival of the virus (59).  
The E1B-55kD and E1B-19kD proteins 
As E1A induces the stabilization of p53, the virus has provided the proteins E1B-55kD and 
E1B-19kD to circumvent the subsequent intrinsic apoptosis. The 55kD protein forms a 
complex with p53 and thereby suppresses p53-mediated transcription (82). The E1B-19kD 
protein is a functional homolog of BCL-2 which can bind the pro-apoptotic members of the 
BCL-2 family such as BAX and BAK and prevent apoptosis through caspases (83,84). 
The E3-gp19kD protein 
The E3 transcription unit is responsible for maintaining cell viability by preventing cytolysis 
by CD8+ T cells. For recognition of an infected cell by CD8+ T cells, viral peptides need to 
be displayed on the surface in a complex with class I MHC molecules. E3-19kD is a 
transmembrane protein that resides in the endoplasmic reticulum where the luminal portion 
can bind the MHC class I α1 and α2 domains. The cytoplasmic tail of the protein contains 
an endoplasmic reticulum retention signal, which prevents the transport of the MHC 
molecules from the endoplasmic reticulum to the Golgi and the plasma membrane (85). As a 
consequence, MHC class I expression on the cell surface is greatly reduced. E3-19kD binds 
to different class I molecules with varying affinity (86). However, the protein is also 
involved in an alternative mechanism to delay overall class I presentation on the cell surface 
by binding to the TAP transporter, thereby preventing proper peptide-loading of MHC class I 
molecules (87). The E3-19kD gene is present in HAdV species B, C, D and E, but not in 
species A or F (88). Species A has developed an alternative mechanism of MHC class I 
reduction via the E1A protein, as has been shown for HAdV12 (89,90). The E1A protein of 
species A interferes with the transcription of class I genes via inhibition of precursors of 





The E3-RID complex (10.4kD and 14.5kD) 
When a T cell recognizes a viral peptide in the context of the right MHC molecule, this T 
cell can exert antiviral activity by inducing death signals to the virally infected cell. The E3-
RID (receptor internalization and degradation) complex inhibits one pathway of cytolysis by 
targeting receptors of the TNF receptor superfamily that contain Death Domains, such as 
TNF-RI, FAS and TRAIL-RI (92). These receptors are internalized from the cell membrane 
by RID and subsequently degraded in lysosomes (93,94). The ligands for these receptors are 
expressed on activated cytotoxic T lymphocytes (CTLs); upon ligation and oligomerization 
of the receptors, the death-inducing signaling complex is formed which initiates cleavage of 
caspases to induce apoptosis. Reduction in expression levels of FAS has been shown to 
partially protect HAdV-infected lymphocytes from FAS-induced apoptosis (95).  
 
It has been suggested that this resistance to lysis of HAdV-infected lymphocytes is a 
mechanism of viral persistence (93) since lymphocytes have been identified in the tonsils 
and adenoids as a source of adenoviral DNA (96). The question remains whether HAdV is 
capable of transforming into a true latent state in those infected lymphocytes as has been 
suggested by some authors (95,96), since no molecular mechanism of latency has been 
discovered. In EBV infection, latency is induced in infected B cells and results in expression 
of only a few early proteins to escape detection by the immune system of the host. For 
HAdV, evidence has been presented that HAdV viral DNA is present in lymphocytes of the 
tonsil and in the blood, but attempts to grow live virus out of these cells have failed (96,97). 
Nevertheless, even though the virus may not go into a latency state, it could be possible that 
some virus particles remain after most of the infection is cleared by the host’s immune 
response, as has been shown by shedding of the virus in feces for months after an infection 
(98). These viral particles might then cause a reactivation and severe infection when 
immunity is lacking in an immunocompromised host.  
 
3.4 Immune response to HAdV 
Upon HAdV infection, a variety of intracellular processes can be triggered in a target cell or 
resident macrophage that will lead to the production of cytokines and chemokines such as 
IFN-α, IL-6, IL-8, TNF-α and RANTES as has been observed both in vivo and in vitro 
(99,100). The early innate response that is initiated results in recruitment of effector cells, 
including neutrophils, monocytes/macrophages and NK cells, to the site of infection. These 
cells in turn will limit the infection directly by killing infected cells or indirectly by secreting 
antiviral cytokines (2). In addition, the recruitment and activation of antigen-presenting cells 
to the site of infection is essential for the development of an adaptive immune response. 
These adaptive responses have scarcely been studied in healthy donors experiencing an 
HAdV infection, simply because - due to the mild course - infection is often not diagnosed in 
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immune competent individuals. Adaptive immune responses in patients receiving HAdV-
based vectors for gene therapy trials, on the other hand, have been studied extensively in 
order to improve vector design for prolonged transgene expression. Results from studies in 
both settings (natural infection versus exposure to gene therapy vectors) will be discussed in 
this section.  
When B cells recognize a protein from HAdV and receive costimulatory signals from T 
cells, they will produce antibodies that can be divided into non-neutralizing antibodies (Ab) 
and neutralizing antibodies (NAb) (101). Non-neutralizing antibodies are not serotype 
specific and, therefore, bind to different serotypes. These antibodies were measured 
classically by the complement fixation test and more recently by ELISA in which the plate is 
coated with whole virus (irrespective of the serotype). NAb, on the other hand, are serotype-
specific and induce neutralization predominantly via binding to epitopes on the hexon 
protein and terminal knob portion of the fiber protein. Hypervariable regions have been 
identified in the hexon protein that make up serotype-specific loops on the surface of the 
protein which are recognized by these NAb (102,103). To determine the titer of the serotype-
specific NAb, a serum neutralization assay is performed in which addition of serum prevents 
infection of a permissive cell line by that specific serotype. The incidence and prevalence of 
several serotypes have been studied in healthy individuals by investigating the presence of 
NAb against those serotypes, indicative of exposure to that serotype in the past. NAb against 
HAdV1, 2, 3 and 5 are most common in the population; the majority of individuals (>85%) 
carry NAb against several of these serotypes when they reach adulthood. In an extensive 
epidemiological study, species A and C infections were mostly detected in infants, species B 
in infants and young children, while species D and E were mainly present in adults (104). A 
study on children with cystic fibrosis as well as healthy adult donors tested for NAb against 
HAdV1-7 showed the highest incidence (almost 100%) of HAdV3, followed by HAdV2, 1 
and 5 (105). In more recent studies, NAb against HAdV5 have been shown to be present in 
40-80% of healthy individuals (106-108). An exceptionally high risk for HAdV infections 
with serotypes HAdV4 and 7 is present in military recruits in the US army, due to the 
crowding and numerous stressors (109,110). A live attenuated vaccine containing HAdV4 
and 7 has been applied from 1971 until 1997, when the manufacturer ceased production. 
Promptly, an increase in infections with HAdV4 and 7 has been reported in military recruits 
in the US (110).  
The kinetics of humoral responses are mainly obtained from gene therapy trials, as the exact 
HAdV infection date in healthy persons is usually not known. In the latter case, a fourfold 
rise in Ab (either total Ab or NAb) in sera obtained several weeks apart is generally accepted 
as indicative of a recent exposure to HAdV. In one study on healthy children attending day 
care, HAdV infections as well as NAb were investigated and results showed that in 76% of 
HAdV-infected children a fourfold rise in NAb was observed (111). In gene therapy studies, 
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humoral responses are usually observed within 2-4 weeks after vector administration (112). 
However, variability between responses is observed, as delivery in the airway resulted in 
hardly any rise in titer, even following repetitive administration, whereas a single injection 
intradermally induced sustained responses (113). In this study, a striking positive correlation 
was found between the peak NAb titer that was evoked against the HAdV5 backbone of the 
vector and the level of pre-existing NAb against this serotype, i.e. high pre-existing titers 
resulted in the highest peaks after vector delivery.  
At the initiation of the work described in the current PhD thesis, reports on cellular immune 
responses against HAdV upon natural infection have also been limited. Studies on HAdV-
specific T cells in healthy individuals have been initiated with the aim to improve gene 
therapy strategies or alternatively, with the aim to eventually expand these T cells for 
adoptive immunotherapy in immunocompromised patients with severe HAdV infection. This 
strategy has already been pursued successfully for CMV and EBV infections (114,115). 
Proliferative responses by HAdV-specific CD4+ T cells were observed in a few reports 
(106,116), whereas another report also showed lytic activity against HAdV-infected targets, 
which was probably due to CD8+ T cells (117). After HAdV-vector delivery in gene therapy 
trials, proliferative responses have been observed against the vector itself (as well as against 
the transgene product) (112). In an additional report, the authors showed lysis of HAdV-
infected cells by CD8+ T cell lines obtained from patients after a single injection with 
replication-deficient HAdV5 (118).  
However, all of these vector studies are based on E1- (with or without E3-) deleted 
recombinant viruses in order to render them replication deficient, which might alter the 
immune response in vivo since these molecules are important for immune evasion properties 
of the virus as described above. In addition, many studies on gene transfer efficacy and host 
response to the viral vector have been performed in animal models, mainly mice and other 
rodents (119,120). However, these animals do not represent the natural host of the human 
AdV resulting in abortive HAdV replication upon infection of these animals. For example, 
since the full viral replicative cycle can not be completed in these animals, main immune 
targets for murine (C57B6) CD8+ T cells are peptides located in the E1A or E2A proteins 
which do get expressed by infected cells (121-123). In contrast, the T cellular immune 
response in humans seems to be mainly directed against the capsid proteins as de novo gene 
expression is not required (117,118). These differences in results cast a doubt on the validity 
of using human AdV in mice as a model system for the interaction between HAdV and the 
human immune system. 
 
3.5 Clinical symptoms, monitoring of HAdV infection and treatment 
HAdV is endemic in the human population and is known to infect humans via the 
respiratory, the fecal-oral or ocular conjunctival routes. The illness is generally acute and 
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nonfatal in immune competent individuals, and recovery is associated with development of 
specific immunity. HAdV infections are associated with a wide spectrum of disease 
symptoms. Respiratory tract disease is the most frequently reported condition associated 
with HAdV infection, although the gastrointestinal tract, urinary tract, central nervous 
system and the ocular conjunctiva may also be affected in HAdV infection (reviewed in 
(54,61,62)). Young children attending day care centers have a high risk of acquiring HAdV 
infections because the virus can be shed from the feces for prolonged periods of time (98). 
Nevertheless, HAdV is not the etiological agent of the common cold, as it is only responsible 
for 5-10% of respiratory illness in children (55).  
In immunocompromised patients, on the other hand, HAdV infections can progress towards 
severe disseminated disease, resulting in multi-organ failure and death. In these patients, 
mild symptoms include fever and diarrhea, which can progress to hemorrhagic cystitis, 
pneumonia and hepatitis and eventually death. Table II summarizes the main symptoms per 
HAdV species as well as the immune status of the infected person. 
Conventional tissue culture has for a long time been the most reliable diagnostic method for 
the detection of HAdV in clinical specimens. For definitive proof of HAdV as the cause of 
the infection, the presence of cytopathological effect (CPE) has to be combined with virus-
specific immunostaining. Specimens that are usually investigated include throat swabs, fecal 
and urine samples. Reports using this technique have shown incidences of HAdV infection 
in SCT patients between 3-21% (53,125-129). When the infected patients are divided 
according to age, the infection frequency differs markedly. The incidence is 3-14% in adults, 
whereas it is 23-31% in children (53,130,131). Reported risk factors for HAdV infection 
include SCT performed with grafts from mismatched or unrelated donors, T cell depletion of 
the graft or ATG in the conditioning, and the occurrence of GvHD (131,132). 
Table II. Clinical symptoms associated with HAdV infection of the different speciesa  
Species Symptoms Immune status of patients 
A Respiratory syndrome, gastroenteritis Competent and compromised 
B1 
B2 
Respiratory syndrome, pneumonia 
Acute hemorrhagic cystitis 
Competent and compromised 
Compromised 
C Respiratory syndrome, gastroenteritis, hepatitis Competent and compromised 
D Epidemic keratoconjunctivitis Competentb 
E Respiratory syndrome, conjunctivitis Competent 
F Gastroenteritis Competent 
a Adapted from (54,61,62). 




As the conventional culture technique is moderately sensitive, laborious and time-
consuming, delivering results at ~2 weeks, alternative detection methods for earlier detection 
as well as increased sensitivity have been developed in recent years. PCR strategies have 
been described to detect the presence of HAdV viral DNA in plasma, leukocytes or feces, as 
has been done for CMV and EBV (46,47). Due to the genetic variability within the group of 
HAdV, several strategies have been developed to detect all HAdV serotypes using 
degenerate (133,134) or non-degenerate primer pairs (135-137). Other approaches use 
species-specific (138) or serotype-specific (139) primer combinations. A preliminary report 
showed a correlation between the presence of viral DNA in serum and subsequent death of 
HAdV-infected patients (140).  
Several antiviral drugs for the treatment of HAdV infection have been applied, but results 
have not been unequivocally promising. Ribavirin is a synthetic guanosine analogue with in 
vitro inhibitory activity against a broad range of RNA and DNA viruses, including HAdV 
(141). Successful treatment with ribavirin has been described (142), but failures have also 
been reported (130,143-145). Cidofovir, a nucleotide homologue with potent reactivity 
against several DNA viruses, has also been applied in HAdV infection with varying success 
(132,146,147). However, treatment was usually initiated solely on the basis of HAdV 
infection with or without clinical symptoms, whereas data on the course of viral load in 
plasma (viremia) or immune recovery were lacking in these studies. Therefore, firm 
conclusions on the effectiveness of these antiviral drugs could not be drawn. These results as 
well as the shortcoming of contemporary antiviral drugs to combat HAdV are a stimulation 
to investigate the natural defense processes, e.g. neutralizing antibodies or T cell responses 
to HAdV, in order to explore the use of these natural tools to control the dissemination and 
fatality of HAdV in SCT recipients.   
4 SCOPE OF THE THESIS 
HAdV infection in pediatric SCT recipients is the main focus of this thesis. HAdV has 
become increasingly apparent as a severe infectious pathogen following SCT, with high 
morbidity and mortality in recent years. Nevertheless, at the initiation of this study only 
limited data on the optimal detection of the virus, the immune response that is invoked by 
HAdV, as well as successful treatment strategies using antiviral drugs or alternative 
treatment such as adoptive immunotherapy were available. 
Therefore, a semi-quantitative PCR has been developed based on a primer set published by 
Echavarria et al. (136) in order to quantify the viral DNA load that is present in patients with 
HAdV infection. In a retrospective cohort of pediatric SCT recipients, we were able to 
correlate the presence of high DNA loads in serum of HAdV-infected patients with a fatal 
outcome (Chapter 2). In collaboration with the Department of Medical Microbiology of the 
LUMC, this PCR strategy has been optimized resulting in a real-time quantitative PCR (RQ-
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PCR) in which viral loads were quantified with a quantitated HAdV5 stock. In a prospective 
study, pediatric patients receiving SCT have been monitored for HAdV infection on a 
weekly basis both by conventional culture of feces, throat swabs and urine samples as well 
as by RQ-PCR on plasma samples. Risk factors for HAdV infection and HAdV viremia, i.e. 
a sign of dissemination of the infection, were determined as well as the correlation between 
these parameters and immune reconstitution (Chapter 3). Detection of viral DNA in plasma 
as an early sign of dissemination permits early initiation of treatment. The efficacy of 
ribavirin treatment initiated upon two consecutive positive RQ-PCR signals above 1000 
copies/mL in the absence of immune recovery has been described in Chapter 4.  
Immune responses against HAdV have been extensively studied in patients as well as 
healthy donors. In patients surviving HAdV infection, NAb and HAdV-specific T cell 
responses were investigated (Chapter 3). Adoptive immunotherapy might be a promising 
therapy for patients with HAdV infection without immune recovery, who are at high risk of a 
fatal course of the infection. In healthy donors, a protocol to culture and expand HAdV-
specific CD4+ T cells with inactivated HAdV5 was developed and resulting T cell lines and 
clones were investigated for cross-reactivity against different species and serotypes 
(Chapter 5). To further dissect the immune response against HAdV in healthy donors, 
several recombinant proteins of HAdV5 were generated and tested as targets for recognition 
by T cells. The hexon protein was most often recognized and synthesized in overlapping 
peptides in order to select a peptide pool which is recognized by the majority of healthy 
individuals (Chapter 6). Finally, as the majority of HAdV-specific T cells were CD4+, the 
antiviral effect of HAdV-specific CD4+ T cell clones on infected target cells was 
investigated (Chapter 7).  
The results described in this thesis indicate that adoptive immunotherapy with HAdV-
specific CD4+ T cells, generated using a set of 5 hexon peptides, is feasible and should be 
considered for patients with HAdV viremia without immune reconstitution. 
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An increasing incidence of adenovirus (HAdV) infection leading to mortality in children 
after allogeneic stem cell transplantation has called for new ways to monitor HAdV 
infection. In this retrospective study, levels of HAdV DNA in serum from 36 HAdV feces 
culture positive transplant recipients were measured by PCR in a semi-quantitative way by 
making dilutions of the DNA template. Six out of 7 (86%) children with a fatal HAdV 
related outcome versus only 2 out of 29 (7%) of the remaining patients, had high levels of 
HAdV DNA (≥ 100-fold) in their sera (p < 0.0001). High serum levels of HAdV DNA were 
reached 18 days before death (range: 6-29 days). These results indicate that quantification of 
adenoviral DNA in serum may prove to be a valuable tool in clinical practice to diagnose 
and monitor HAdV infection and disease in these immunocompromised children.  
INTRODUCTION  
During the first months after transplantation, recipients of allogeneic stem cells are severely 
immunocompromised and, as a consequence, susceptible to viral infections and 
reactivations. Since about 1995 the frequency of adenovirus (HAdV) infections in pediatric 
stem cell recipients has increased remarkably (1-12) (van Tol et al., manuscript in 
preparation) leading to clinical manifestations like hemorrhagic cystitis, enteritis, hepatitis, 
encephalitis, pneumonitis and multi-organ failure (1-3,5,7,11,13,14). Disseminated 
infections frequently result in fatal outcome. In contrast, adenoviral infections in healthy 
children are usually not associated with serious clinical symptoms, indicating that effective 
immune responses to HAdV in humans contain the infection. During the first years of life, 
children develop neutralizing antibodies and T cell responses against various strains of 
HAdV (14,15). As a result, most adults have strong preexisting immunity to HAdV, which is 
a complicating factor in the use of adenoviral vectors for gene therapy (16).  
At present, 51 serotypes of HAdV able to infect human cells have been identified that are 
distinguished from each other on the basis of antigenic determinants recognized by 
neutralizing antibodies. The different serotypes are grouped into six species, A to F, 
according to their ability to agglutinate red blood cells as well as to their DNA homology 
(17,18). At the DNA level, homology within a species varies from 50% to almost 100%. 
Even strains belonging to the same serotype can still differ with respect to their DNA 
sequence (18). Between species the homology can be as little as 4% (18). Clinically, HAdV 
infections are detected and diagnosed using various techniques (14). Culture of virus and 
subsequent identification using immunofluorescence with HAdV-specific antibodies is the 
most common approach but takes several days depending on the viral load of the sample. 
Alternatives are direct immunofluorescence or detection of viral antigen by agglutination of 
antibody-coated latex beads, dot blot hybridization, and more recently detection of viral 
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DNA by PCR. Several PCR based strategies have been developed. Due to the genetic 
variability within the group of human HAdV, the choice of primers varies with the 
application. Some of the techniques detect HAdV strains belonging to almost all serotypes 
using degenerate (19-22) or non-degenerate (20,23-27) primer pairs. Sequences conserved in 
most of the 51 serotypes can be found in the hexon gene (19,20,22,26,27), E1A (20) and 
VA-RNA (21). Analysis of the PCR products by restriction enzyme analysis or sequencing 
can supply sufficient information to assign a species or serotype to an unknown isolate 
(19,21,22,27-30). Other approaches employ species (28,31) or serotype-specific (32) primer 
combinations.  
In the present study we have performed a retrospective analysis of 36 pediatric patients with 
adenoviral infection after allogeneic stem cell transplantation. A generic PCR amplifying a 
conserved part of the HAdV genome, allowing detection of all disease causing HAdV strains 
was employed (25,33) in a qualitative as well as in a semi-quantitative fashion. The presence 
of adenoviral DNA in serum as well as its level were determined at different time points 
after transplantation. Because high levels of HAdV DNA correlated with fatal outcome, 
quantification of the HAdV DNA load in serum may be a valuable tool to diagnose the 
dissemination of HAdV infection in immunocompromised patients.  
MATERIALS & METHODS 
Patients 
Thirty-six patients from a cohort of 328 stem cell transplant recipients treated at the pediatric 
transplantation unit of the Leiden University Medical Center between 1985 and 1998 had at least one 
HAdV positive feces culture. Feces were tested by culture on Hep-2 cells followed by 
immunofluorescence (Imagen HAdV, DAKO Diagnostics, Ely, UK). The 36 patients were classified 
into 3 groups based on clinical symptoms (Table 1). Group I consisted of 17 patients who did not 
show any clinical symptoms of HAdV infection. Group II consisted of 12 patients who developed 
local clinical symptoms that were most likely associated with HAdV infection. The localized clinical 
symptoms were enteritis (n=11), hemorrhagic cystitis (n=2) and hepatitis (n=1). Group III consisted 
of 7 patients who died of fatal disseminated disease caused by HAdV. Clinical symptoms in group III 
were enteritis (n=5), hemorrhagic cystitis (n=1), hepatitis (n=3), encephalitis (n=1) and pneumonia 
(n=1) and HAdV was cultured from multiple sites confirming dissemination. In 5 of the 7 cases 
dissemination was also confirmed after autopsy. Eight of the 36 HAdV isolates were not serotyped 
(due to the lack of available antisera or lack of original isolate). The remaining 28 were serotyped 
using standard techniques; 19 (68%) belonged to species C (HAdV1, 2, 5 and 6), 5 (18%) belonged 
to species A (HAdV12, 31), 2 (7%) belonged to species B (HAdV7) and 2 (7%) to F (HAdV41). No 
significant differences in serotypes were observed between patients with high viral load compared to 
those with low viral load. Patients were transplanted for immunodeficiencies, hemopoietic defects 
and leukemia (Familial Hemophagocytic Lymphohistiocytosis, Severe Combined Immunodeficiency, 
Wiskott-Aldrich Syndrome, Metachromatic Leukodystrophy, β-Thalasemia, Acute Lymphoblastic 
Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Fanconi, Severe Aplastic 
Anemia). The sources of stem cells were HLA-identical matched family donors (MFD), mismatched 
family donors (MMFD) and matched unrelated donors (MUD). T cell depletion, if necessary, was 
performed by sheep erythrocyte rosetting and albumin gradient centrifugation, immuno-rosetting 
using anti-CD2 and anti-CD3 (sometimes combined with anti-CD19 and anti-CD22) monoclonal 
antibodies (34) (< 3-log T cell depletion), Campath-1G “in the bag” or CD34+ precursor cell 
enrichment on a CliniMACS (≥ 3-log T cell depletion). Of the 36 recipients, only 2 patients 
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developed a graft-versus-host disease (GvHD) grade ≥ II. For comparison, serum samples from 17 
healthy stem cell donors, 10 children and 7 adults, were screened as well.  
 
Isolation of DNA 
Serum samples had been stored at -20°C during a period of 1 to 14 years. DNA was isolated from 
200 µl of serum using QIAamp columns (QIAamp DNA blood mini kit, Qiagen, Hilden, Germany) 
according to the manufacturer’s directions. Negative controls (water) were included in each run of 
extractions. DNA was eluted in 200 µl water and stored at –20°C until further use. 
 
PCR 
Twenty µl of template DNA was added to a final volume of 50 µl containing 1x Taq PCR Master 
Mix (Qiagen, Hilden, Germany) and 0.2 µM of the primers Hex3: GACATGACTTTCGAGGTCGA-
TCCCATGGA and Hex4: CCGGCTGAGAAGGGTGTGCGCAGGTA (23,25). The primer pair 
amplified DNA from HAdV strains belonging to the serotypes 1, 2, 3, 4, 5, 7, 7A, 8, 11, 12, 16, 19, 
30, 34, 35, 37, 48, 49 (25), 31, 41 (this study) and 6, 9, 40, 50 and 51 (unpublished data).  
PCR amplification was carried out on a Perkin Elmer 2400 thermocycler. An initial denaturation of 3 
min at 94°C was followed by 40 cycles of denaturation of 15 sec 94°C, annealing of 15 sec at 52°C 
and elongation of 30 sec at 72°C. Finally, a 7 min elongation step completed the program. To obtain 
Table 1. Characteristics of adenovirus infected patients.  
 Patient group   
 I II III 
Variable  (n = 17) (n = 12) (n = )7 
Median age in years (min-max) 3.7 (0.6-15.8) 7.1 (0.9-17.0) 4.4 (0.6-11.6) 
Donor type (n)     
    Matched Family Donor  4 2 - 
    Mismatched Family Donor  6 3 5 
    (Matched) Unrelated Donor 7 7 2 
T cell depletion     
    No depletion  9 7 3 
    < 3 loga  4 3 - 
    ≥ 3 logb  4 2 4 
AGvHDc(n)     
    0  14 7 5 
    I  3 4 1 
    II-IV  - 1 1 
Adenovirus related parameters    
    Feces culture + + + 
    Clinical symptoms - + + 
    Death - - + 
a  E-Rosetting plus albumin gradient centrifugation or immuno-rosetting using anti-CD2 and anti-CD3 
(sometimes including anti-CD19 and anti-CD22) monoclonal antibodies (34). 
b  Campath-1G “in the bag” or enrichment of CD34+ precursor cells on a CliniMACS. 
c  Acute Graft-versus-Host Disease (39). 
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a semi-quantitative measure of the load of HAdV DNA in serum, the extracted template DNA was 
diluted (10-, 100- and 1000-fold) in a 10mM Tris solution prior to PCR analysis. The highest dilution 
still yielding a PCR product was considered to be the load of DNA in the serum sample.  
 
Detection and identification of PCR products 
PCR products were detected by electrophoresis of 10 µl of the amplified product on a 1.5% agarose 
gel containing ethidiumbromide. A molecular size marker (SmartladderSF, Eurogentec, Seraing, 
Belgium) and an aliquot of the HAdV positive PCR control were mounted on the gel as well. UV 
light visualized a positive PCR as a 139 bp amplified product. In addition, the results were confirmed 
by an EIA hybridization using a digoxigenin labeled probe (Hex-30, GACCCCACCCTTCTTT-
ATGTTCTGT) (25) detected with anti-digoxigenin antibody labeled with horse radish peroxidase.  
RESULTS 
Qualitative analysis of sera for the presence of adenoviral DNA 
Sera from all 36 patients were analyzed for the presence of HAdV DNA by PCR. Serum 
samples, as far as available due to the retrospective character of this study, were taken from 
time points just before transplantation (if available), around the first positive feces (or urine, 
throat or sputum) culture and just before HAdV-related disease or death.  
A total of 156 samples was investigated (group I: 62 samples, group II: 45 samples and 
group III: 49 samples) by PCR. Forty-two of these 156 serum samples were HAdV positive 
by PCR. The 42 positive serum samples were from 17 patients: 7 of 17 (41%) patients of 
group I, i.e. asymptomatic patients, 4 of 12 (33%) patients of group II with localized disease 
and 6 of 7 (86%) patients of group III with fatal disseminated disease. This indicates that the 
presence of DNA did not correlate with the presence of clinical symptoms. However, it did 
correlate with fatal outcome, when compared with all 29 non-fatal cases, but the statistical 
significance was low (P = 0.04, Fisher exact) due to the occurrence of DNA in serum of 11 
out of 29 patients with a non-fatal course.  
 
Semi-quantitative determination of viral DNA load 
To investigate whether a quantitative measure of the DNA load in serum would be more 
informative about the course of an HAdV infection in these patients than the qualitative 
detection of DNA, a semi-quantitative PCR was performed by analyzing serial dilutions of 
serum template DNA. In the serum of 7 (of 17) asymptomatic patients of group I and of 4 (of 
12) patients with localized disease of group II, HAdV DNA was detected (Figure 1). In 9 of 
these 11 patients the level of HAdV DNA was low. The two remaining patients (numbers 
168 and 286) demonstrated transiently high loads of HAdV DNA, i.e. a PCR product still 
detectable after 1000-fold dilution of template DNA. In contrast, the HAdV DNA load was 
high (100- or 1000-fold dilution) in the sera of 6 of the 7 patients with disseminated infection 
and fatal disease (group III). These high loads of HAdV DNA were first detected 18 days 
(range between 6 and 29 days) before death, remained high until death and were always 





Figure 1. Results of the semi-quantitative HAdV PCR analysis. Pediatric SCT recipients are 
grouped according to the absence or presence of clinical symptoms (Group I-III). Culture results on 
feces, throat and urine samples (if performed), HAdV PCR results on serum samples and mortality 
(HAdV related or otherwise) are indicated in relation to the time of (first) SCT (dotted vertical line). 
Data in the first column (-30/-7) represent data obtained between 30 and 7 days prior to SCT. The 
different symbols for PCR results represent the highest dilution of template DNA (up to 1000-fold) 
after which a positive result was still obtained. All feces cultures are shown, but only positive urine 
and throat cultures are indicated. UPN = Unique Patient Number.  
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The only patient with fatal outcome who remained PCR negative had serum samples 
obtained until 3 weeks before death. No further serum samples were available.  
In general, there was a poor correlation between HAdV DNA positivity in serum and HAdV 
positive feces cultures. For example, no HAdV DNA was detected in the sera of some 
patients from groups I and II despite prolonged periods of HAdV positivity in feces. 
Although a transient presence of HAdV DNA can occur in patients without clinical 
symptoms of HAdV infection, a persistently high level of HAdV DNA correlated with fatal 
outcome. A high level of HAdV DNA in serum (100-1000 fold dilution) was observed in 6 
of 7 fatal cases and in only 2 of 29 non-fatal cases (P <0.0001; Fisher exact, Table 2).  
 
HAdV DNA in healthy subjects 
To determine whether HAdV DNA is detectable in serum of healthy individuals, serum 
samples from 17 stem cell donors were tested by PCR for the presence of HAdV DNA. This 
group consisted of 10 children (between 3 and 13 years old) and 7 adults. DNA template was 
analyzed by PCR, either undiluted or after 10-fold dilution. All but one of the tested stem 
cell donors were negative when undiluted samples were tested. The positive sample 
belonged to a pediatric case (13 years old) and this was positive, but only undiluted. Thus 
HAdV DNA may be detected occasionally in serum of healthy subjects, but only at very low 
levels.  
DISCUSSION 
The data presented indicate that a high level of HAdV DNA (i.e. a PCR-product after 100-
fold or more dilution of template DNA) in sera of pediatric stem cell transplant recipients 
infected with HAdV after transplantation correlates with fatal outcome due to disseminated 
HAdV disease. In 86% of the patients who developed fatal disease, a high HAdV DNA load 
was measured, whereas only 7% of the patients without fatal outcome had similar high loads 
Table 2. Levels of HAdV DNA in serum from HAdV-infected stem cell recipients, as 
determined by semi-quantitative PCR.   
 PCR result 
Positive, according to dilutiona 
Group n Negative None 10-fold 100-fold 1000-fold 
I 17 10 3 2 0 2 
II 12 8 1 3 0 0 
III 7 1 0 0 2 4 
Relative virus load  Negative Low Low High High 
a  The highest dilution of template DNA at which a specific PCR product was obtained is indicated 
(P < 0.0001, for groups I and II versus III, threshold between 10- and 100-fold dilution).  
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of HAdV DNA (P < 0.0001). It has been recently reported that the detection of HAdV DNA 
in serum by PCR was associated with fatal outcome (33). However, in the present extended 
retrospective analysis HAdV DNA was also detected in a significant proportion of patients 
without fatal outcome albeit at low levels. Thus, quantitative determination of HAdV DNA 
in serum contributes significantly to the identification of patients with disseminated fatal 
HAdV infection.  
Only two patients without HAdV related clinical symptoms (numbers 168 and 286) had high 
levels of HAdV DNA in their sera although only transiently. Patient UPN 168 was a SCID 
patient who was infected with HAdV serotype 31. Prior to transplantation, cultures from 
feces and urine were already HAdV positive and a high load of HAdV DNA was detected in 
serum. After transplantation, the DNA load in serum remained high until day 20 and then 
declined to undetectable levels at day 34. Feces cultures became also negative two months 
after transplantation. The other patient (UPN 286) with a high level of HAdV DNA in serum 
was transplanted for acute lymphoblastic leukemia. Feces was negative before SCT but 
became HAdV positive at day 6, which was typed as serotype 2. At day 21 post-
transplantation serum was strongly PCR positive (1000-fold dilution). Serum samples from 
day 35 and 42 were positive but lower (10- and 100-fold dilution, respectively) indicating a 
decline in load. At day 70 no HAdV DNA was detected any longer in serum despite the 
continued presence of HAdV in feces. The patient died at day 107 post SCT due to a relapse 
of the leukemia. The reason why both patients transiently had high loads of HAdV DNA in 
their serum, without any accompanying clinical symptoms, is unclear at present. 
Interestingly, it appears that some of the patients who carried high loads of HAdV DNA in 
their serum were able to resolve this situation, in the absence of any anti-HAdV 
pharmacological treatment. 
The group of 36 patients whose serum was analyzed by PCR was originally identified by the 
presence of HAdV in feces cultures. Positive cultures of throat swabs, in the absence of 
positive feces cultures, were observed in another four cases in the period between 1985 and 
1999, but these cases were all asymptomatic (data not shown). Although it is difficult to be 
certain in this retrospective study, screening of feces therefore appears to include all patients 
who may develop HAdV related clinical symptoms. However, not all patients with a positive 
feces culture developed symptoms or disease and therefore there is a need for an additional 
tool to differentiate between transient asymptomatic infections and disease caused by HAdV. 
The results of this study demonstrate that semi-quantitative data on the HAdV load obtained 
from serum provide clinically relevant information in relation to the outcome of HAdV 
infection, especially to fatal outcome. The less severe clinical symptoms in group II did not 
lead to increased DNA loads in serum. However, this could be due to the lack of appropriate 
serum samples in this retrospective analysis. More precise quantitative data from frequent 
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serum samples in a prospective setting will demonstrate whether serum load of HAdV DNA 
can provide information that is relevant to predict the course of infection more accurately.   
Because quantitative data on HAdV DNA load in serum appear to be important, we have 
started to develop a real-time PCR approach to detect HAdV DNA in an automated and 
more quantitative fashion (35). Detection of viral infections by PCR also has several other 
advantages. Results are obtained faster than with conventional culture techniques. Cultures 
may require 3-4 days until results are known, while PCR detection can be performed in 1 
day. Eventually, multiplex PCR reactions may lead to simultaneous detection of multiple 
viruses in one reaction tube.  
In this study a generic PCR amplifying a conserved region of the hexon gene was used 
(23,25,33). The advantage of this strategy is that all clinically relevant HAdV strains are 
detected. An additional possibility might be, that the availability of a segment of HAdV 
DNA amplified from a clinical sample provides the opportunity to type the infecting virus by 
sequencing the PCR product without being dependent on time-consuming virus 
neutralization tests. To investigate whether virus strains could be typed based on this limited 
sequence information, PCR products of a number of serotyped clinical isolates were 
sequenced. Comparison of the sequences from the PCR fragments with published sequences 
revealed that sequence analysis, in this limited number of cases, could provide sufficient 
information to assign an unknown strain to a certain species of human HAdV, but not to a 
specific serotype (data not shown). This single primer pair, therefore, seems suitable for 
detection and, potentially, for partial typing of all clinically relevant HAdV strains.  
Although the diagnosis of HAdV infections may be improved by a quantitative PCR 
approach, treatment options to reduce the number of fatal cases are still very limited. 
Ribavirin and cidofovir have been used in recent years with variable success (9,10,36-38). 
No systematic study on the effectiveness of these drugs has been published. Pre-emptive 
treatment based on an increase in HAdV DNA load in serum, followed by careful 
quantitative monitoring of DNA loads in patients with adenoviral infection could provide 
objective information on the antiviral efficacy of these drugs in immunocompromised 
patients. The time period between high-level HAdV DNA detection and death should be 
long enough to install treatment at a stage when the disease has not yet progressed to a 
terminal course. In this retrospective study, this time period varied between 6 and 29 days. It 
is possible that more frequent sampling may have an additional benefit of detecting HAdV 
DNA in blood earlier for the rapid installation of treatment. Since quantification of HAdV 
DNA load during infection in this patient group appears to be a valuable tool both in 
diagnosis and in clinical management of this condition we have initiated a prospective study 
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Adenovirus (HAdV) infections are increasingly frequent complications after allogeneic stem 
cell transplantation (SCT), especially in children. Only few data are available on the 
correlation between immune recovery and the course of HAdV infection, and data on 
HAdV-specific responses are lacking. In a prospective study, we determined the correlation 
between the load of HAdV DNA in plasma and lymphocyte reconstitution in 48 children 
after allogeneic SCT. Additionally, HAdV-specific humoral and cellular immune responses 
were investigated. HAdV infection occurred in 21 patients (44%) and in 6 of these patients 
the infection progressed to viremia as demonstrated by the presence of HAdV DNA in 
plasma. Low lymphocyte counts at the onset of infection were predictive for HAdV viremia. 
Survival of patients with viremia was associated with a rise in lymphocyte counts during the 
first weeks after infection. In these patients, HAdV-specific CD4+ T cell responses as well as 
rises in neutralizing antibody titers were detected following clearance of the viral DNA from 
plasma. Lymphocyte reconstitution appears to play a crucial role in clearance and survival of 
HAdV viremia, warranting further development of therapeutic interventions aimed at 
improving immune recovery.  
INTRODUCTION 
In recent years, adenovirus (HAdV) infections are observed with increasing frequency after 
allogeneic SCT, especially in young children, resulting in high mortality rates when the virus 
disseminates (1-8). Currently, 51 serotypes of adenovirus have been identified, classified in 
six species (A-F) (9,10). Species A, B and C serotypes are most frequently isolated from 
pediatric immunocompromised hosts and are the major cause of HAdV-related disease 
(1,9,11). Unfortunately, HAdV infections are usually not recognized until a late stage of 
disease is reached, due to non-specific clinical symptoms of infection in an 
immunocompromised host. Diagnostic virological culture techniques are time consuming 
and moderately sensitive for progression to viremia (12,13). With the development of real-
time quantitative PCR (RQ-PCR) techniques, patients can be diagnosed at an early phase of 
viremia and the course of infection can be monitored by the quantification of the HAdV 
DNA load in plasma (14-17).  
Immunological recovery after SCT is of great importance to clear virus infections, as has 
been shown for other viral reactivations such as cytomegalovirus (CMV) and Epstein-Barr 
virus (EBV) (18-24). So far, only few data are available on the correlation between the 
recovery of lymphocytes and HAdV infection (25) and no data have been published on 
HAdV-specific cellular and humoral immune reconstitution in relation to the course of 
HAdV infection in SCT recipients. Better understanding of the role of immune recovery in 
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adenovirus infections might be relevant to improve therapeutic options as medication with 
ribavirin or cidofovir is not unequivocally effective (26-32).  
We conducted a prospective study in which all pediatric allogeneic SCT recipients 
transplanted between 2001 and 2003 were monitored weekly for HAdV infection by culture 
of feces, throat swabs and urine samples as well as by RQ-PCR of plasma samples. 
Lymphocyte recovery as well as HAdV-specific T and B cell responses were investigated in 
HAdV-infected patients at the onset and during the course of the infection.  
PATIENTS & METHODS 
Patient cohort 
In 2001 and 2002, 53 pediatric patients received an allogeneic SCT in the pediatric bone marrow 
transplant unit of the Leiden University Medical Center. The study has been approved by the local 
Institutional Review Board and all patients were included in the study following informed consent. 
Five patients died within 2 months after SCT due to transplant related mortality or relapse. 
Characteristics, donor types and graft manipulations of 48 remaining patients are summarized in 
Table 1. Pre-treatment of the graft recipient was according to disease-specific protocols of the 
relevant working parties of the European Group for Blood and Marrow Transplantation (EBMT). 
Rabbit-ATG (IMTIX, 10 mg/kg in 4 days) or Campath-1H (1 mg/kg in 5 days) was given shortly 
before the transplant date in all HLA non-identical SCT. GvHD prophylaxis consisted of cyclosporin 
A (CsA, trough level 100-200 µg/L). All patients were kept in protective isolation for at least 4 
weeks after SCT, and received total gut decontamination. Neither systemic antibacterial nor antiviral 
prophylaxis was given; pre-emptive treatment was administered for proven (i.e. RQ-PCR-based) 
CMV (ganciclovir) and EBV reactivation (rituximab® administration for depletion of B cells to 
prevent post transplant lymphoproliferative disease). For HAdV viremia, ribavirin (60 mg/kg/day, 
starting dose 30 mg/kg) or cidofovir (5 mg/kg/week) was given (32). Intravenous immunoglobulin 




Patients were screened for 6 months after SCT, with weekly sampling during the first 8-12 weeks and 
every 2-4 weeks thereafter. In this cohort, retransplantation was considered (n=3) as endpoint for 
follow-up. Feces, urine and throat swab samples were inoculated on human A549 cells and scored for 
cytopathological effect (CPE). Plasma samples were tested by RQ-PCR for the presence of 
adenoviral DNA. DNA was extracted from plasma by standard procedures and 10 µL of DNA 
containing extract was amplified by real-time PCR using the oligonucleotide primers previously 
described (33). The amplification protocol was 15 min at 95 °C followed by 50 cycles of 95°C, 55°C 
and 72°C (each 30 sec). To detect these amplified products, a molecular beacon 
(GAGCCCACCCTTCTTTATGT) with a 5' FAM label and 3' dabcyl label was applied (Biolego, 
Malden, the Netherlands) using an iCycler IQ system (Biorad laboratories, Hercules, CA). Sensitivity 
of the assay was 50-250 copies/mL (Claas, submitted). A quantitated HAdV5 stock was a kind gift of 
M. Havenga (Crucell, the Netherlands).  
HAdV infection was defined as ≥ 2 consecutive positive viral cultures. Likewise, HAdV viremia was 
defined as the presence of >1000 copies/mL HAdV DNA in ≥ 2 consecutive plasma samples. 
Serotyping of HAdV isolates was performed by virus neutralization using a panel of serotype-
specific antisera (RIVM, Bilthoven, the Netherlands).  
 
Viruses 
HAdV serotypes 1, 2, 5 and 11 (RIVM) were grown on human Hep2 cells. Virus was released from 
the cells by two freeze-thaw cycles and purified by CsCl density gradient centrifugation. Virus stocks 
were titrated using the plaque assay on 293 cells. Purified HAdV serotypes 6 and 31 were a kind gift 
of M. Havenga. For the antibody neutralization assay, crude lysates of HAdV-infected cells (Hep2 or 
A549 cells) were generated as above. The 50% tissue culture infective dose (TCID50) of each lysate 
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was determined by diluting the lysate in tenfold followed by addition of Hep2 or A549 cells. After 7 
























































Table 1. Characteristics of all patients and those with HAdV infection and 
viremia  
 Total (n = 48) 
HAdV infection 
no (n=27) / yes (n=21) 
HAdV viremia 





22 / 14 
5 / 7 
10 / 1 
2 / 5 
Age median  
     (range) 
7.8  
(0.2-17.3) 
8.5 / 7.6 
(0.2-17.3) / (1.4-14.7) 
7.5 / 7.7 
(2.7-14.7) / (1.4-13.3) 
Diagnosis: 
    Hematol malignancies 
            ALb 
            MDSc 
            other 
    Hematol disorders 









15 / 10 
9 / 5 
2 / 3 
4 / 2 
7 / 6 
5 / 5 
 
 3 / 4 
2 / 2 
1 / 2 
0 / 0 
 5 / 1 
 4 / 1 
Donor type: 
     MFDd 
     MMFD 
     MUD 
 
HLA-matching: 
     10/10 match 










11 / 6 
 4 / 3 
 12 / 12 
 
 
22 / 11 
  5 / 10 
 
 5 / 0 
 2 / 0 
 5 / 6 
 
 
 7 / 2 
 5 / 4 
Graft: 
     BM unmanipulatede 
     BM T cell depletedf 






18 / 14 
5 / 2 
4 / 5 
 
 9 / 4 
 0 / 1 
 3 / 1 
Conditioning host: 
     Myeloablativeh  
     Reduced intensity 
Immunosuppression: 
     no ATG/Campath 








21 / 19 
 6 / 2 
 
11 / 2 
  16 / 19 
 
11 / 5 
  1 / 1 
 
  2 / 0 
10 / 6 
a 3 patients excluded due to loss to follow-up shortly after culture positivity. 
b AL acute leukemia : ALL and AML. 
c MDS: myelodysplastic syndrome including JMML. 
d MFD: matched family donor, MMFD: mismatched family donor, MUD: matched unrelated donor. 
e bone marrow unmanipulated including 1 cord blood. 
f immunorosetting T ± B cell depletion or Campath in the bag. 
g peripheral blood stem cells CD34+ selected (CliniMACS). 
h either TBI ≥7 Gray or ≥16 mg/kg busulfan or ≥140 mg/kg melphalan. 
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Immunological reconstitution 
Leukocyte and lymphocyte counts were determined every one to three days during the first 2 months 
after SCT. Subset analysis of peripheral blood mononuclear cells (PBMC), i.e. CD4+ T cells, CD8+ T 
cells, NK cells and B cells, was performed every 4-8 weeks when sufficient lymphocytes were 
present (usually from 4-8 weeks after SCT onwards) using flow cytometry.  
 
HAdV-specific antibodies 
To determine neutralizing antibody (NAb) titers, sera were heat inactivated at 56°C for 30 min and 
diluted in twofold from 1:4 to 1:2048 in a 96-well plate in duplicate. HAdV lysate was diluted to 100 
× TCID50 and added to each well, followed by 1 h incubation at 37°C. Hep2 or A549 cells were 
added and wells were scored for CPE after 7 days of culture. The neutralizing titer was the highest 
serum dilution at which CPE was no longer observed. Rises in titers (>4-fold increase) against the 
serotype that infected the patient while NAb against other serotypes remained stable were considered 
specific responses.  
 
HAdV-specific proliferation 
Autologous irradiated stimulator PBMC (30 Gray) were infected at a multiplicity of infection (MOI) 
of 100 with the purified HAdV serotype infecting the patient. In uninfected patients, infection was 
performed with the common serotype HAdV5, as HAdV-specific T cells are usually cross-reactive 
(34). Infection was performed in RPMI/0.5% BSA (Sigma-Aldrich, St. Louis, MO) at 107 cells/mL 
and after 1 h PBMC concentration was adjusted to 106 cells/mL with RPMI/10% human AB serum. 
Stimulator cells (1×105, infected or uninfected as control) were co-cultured with 1×105 responder 
PBMC per well in a 96-well round-bottom plate for 4 days, after which [3H] thymidine (0.5 µCi/well, 
Amersham International, Amersham, UK) was added for 16 h. A stimulation index (SI) >3 was 
considered a specific response. As a control, PBMC (4×104/well) were stimulated for 4 days in a 96-
well flat-bottom plate with α-CD3 antibodies (Janssen-Cilag BV, the Netherlands), α-CD3 + IL-2 
(50 IU/mL, Chiron, Emeryville, CA) or 5 µg/mL phytohemagglutinin (PHA, Murex Biotech Ltd., 
Dartford, UK). 
 
HAdV-specific cytokine production 
For IFN-γ ELIspot, PBMC (2×105/well) in RPMI/10% human AB serum were stimulated with the 
HAdV serotype infecting the patient at MOI 10 in a 96-well round-bottom plate, or unstimulated as 
control. After 4 days, IFN-γ ELIspot was performed according to instructions of the manufacturer 
(Mabtech, Nacka, Sweden) (35). More than 25 specific spots (spots HAdV – spots control) were 
considered a specific response. 
For intracellular cytokine staining, cells were incubated with Brefeldin A (BFA, 5 µg/mL, Sigma-
Aldrich) for 5 h at day 5, and stained for IFN-γ or TNF-α as described previously (36). Antibodies 
were: αCD3-PerCP-Cy5.5, αCD4-FITC, αIFN-γ-PE or αTNF-α-PE (Becton Dickinson) and αCD8-
APC (Beckman Coulter, Miami, FL). Cells were analyzed on a FACS Calibur flow cytometer using 
CellQuest software (Becton Dickinson). 
 
Statistical analysis 
Transplant-related variables and immune reconstitution were evaluated in relation to HAdV infection 
and viremia by univariate analyses in binary logistic regression models using SPSS software. 
Multivariate analysis was not performed due to small patient numbers. 
RESULTS 
Incidence of HAdV infection and viremia 
HAdV infection was present in 21 of 48 patients (44%). Detailed information on the 21 
infected cases is given in Table 2. Three of the 21 patients were lost to follow-up (patients 1 
- 3 in Table 2) due to retransplantation or transplant related mortality. In 6 of the remaining 
18 patients, the infection progressed to viremia as defined by the presence of HAdV DNA in 
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Of these patients, 3 survived the infection, 2 died due to HAdV (1 after a second SCT) and 1 
patient died with HAdV as a probable cofactor in combination with GvHD.  
The Kaplan-Meier curve for infection in correlation with the type of donor shows that 
patients with grafts from matched and mismatched family donors (MFD and MMFD, 
respectively) as well as patients with grafts from matched unrelated donors (MUD) were 
infected with HAdV in similar frequencies (Figure 1). However, only in patients with 
unrelated donors the infection progressed to viremia (data not shown).  
The onset of infection in patients who remained PCR negative (median 31 days, range 13-91 
days after SCT) was not significantly different from the patients with HAdV viremia 
(median 22 days, range 12-42 days after SCT) (P = .129) (Table 2). PCR in plasma samples 
became positive at a median of 26 days (range 0-49). PCR positivity followed 1-3 weeks 
after the first positive culture in 4 patients, and preceded the first positive culture by 1-2 
weeks in 2 patients. Duration of the infection was in some cases prolonged, both in patients 
with and without viremia, indicating that sustained infection can occur without progression 
to viremia (Table 2).  
At the time of first detection of HAdV DNA in plasma of patients, clinical symptoms that 
could exclusively be attributed to HAdV were not observed; in patients who died due to 
infection, severe symptoms as liver failure were evident only at the endstage of the disease. 
All 21 infected patients were HAdV positive in feces; in 11 patients no other site became 
culture positive. Four of the 5 patients who were positive at multiple sites including urine 
also had HAdV viremia as defined by the presence of HAdV DNA in plasma (Table 2). 
 









































Figure 1. HAdV infection occurs in recipients of grafts from all donor types. Kaplan-Meier 
curves for HAdV infection in recipients of matched family donors (MFD), mismatched family 





Risk factors for HAdV infection and viremia 
Risk factors for HAdV infection were HLA mismatched donors (≥ 1 mismatch, P = .017), 
serotherapy with ATG or Campath in vivo (P = .026) and melphalan in the conditioning 
regimen (P = .018). To determine the risk factors for viremia (PCR positivity), patients with 
HAdV viremia were compared with HAdV-infected patients without viremia. A MUD donor 
was a risk factor for viremia (P = .005), as well as the female gender of the recipient (P = 
.016). All other variables tested in univariate analyses, such as ex vivo manipulation of the 
graft, either by T cell depletion or CD34+ enrichment, underlying disease, use of cyclosporin 
A, occurrence of GvHD and age of the recipient were not significantly correlated with 
HAdV infection or viremia. 
 
Immune reconstitution and course of HAdV infection 
As delayed recovery of the immune system might be of importance for the occurrence and 
progression of HAdV infection, absolute leukocyte and lymphocyte counts were compared 
between uninfected patients, HAdV-infected patients and patients with HAdV viremia. The 
time period to leukocyte reconstitution (set at 1×109/L) was identical in all groups (data not 
shown), whereas lymphocyte reconstitution (set at 0.2×109/L) was significantly delayed in 
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Figure 2. Lymphocyte recove-
ry is correlated with develop-
ment and outcome of HAdV 
viremia. A) The time to 
lymphocyte recovery (set at 
0.2×109/L) is shown for 
uninfected patients (solid line), 
HAdV-infected patients (dotted 
line) and patients with HAdV 
viremia (combined line). B) 
Lymphocyte counts are shown 
at the onset of infection and 
within the first 30 days after 
onset of infection for HAdV-
infected patients (■), patients 
surviving HAdV viremia (●, 
solid line) and patients 
succumbing to HAdV viremia 
(●, dotted line). At t=0, patients 
with viremia had significantly 
lower lymphocyte counts than 
HAdV-infected patients (P = 
.025), and at t=30 patients 
surviving HAdV viremia had 
higher lymphocyte counts than 
patients succumbing to viremia 
(P = .067). 
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Furthermore, absolute lymphocyte counts were determined at the onset of infection and 
during the first 30 days thereafter. Patients with HAdV viremia had lower lymphocyte 
numbers (geometrical mean 62 per µl) at the onset of infection (t=0) than those without 
viremia (geometrical mean 310 per µl) (P = .025) (Figure 2B). Furthermore, in the six 
patients with HAdV viremia an increase in lymphocyte counts during the next 30 days 
correlated with clearance of the infection and survival (t=30, geometrical mean 926 
lymphocytes per ul in patients surviving viremia versus 28 lymphocytes per µl in patients 
succumbing to viremia, P = .067). Patients succumbing to viremia had continuously 
increasing HAdV DNA loads in their plasma without lymphocyte recovery (Figure 3A and 
(32)), whereas in patients surviving viremia, lymphocyte recovery coincided with the 


























All lymphocyte subsets, e.g. T cells, B cells and NK cells, were reconstituting in patients 
surviving viremia, whereas only few lymphocytes recovered in patients succumbing to 
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Figure 3. Patients succumbing to HAdV viremia have no cellular immune recovery and no 
increase in HAdV-specific NAb. Patients with HAdV viremia who succumbed to the infection are 
shown for viral and immunological parameters pre- and post-SCT. A) Viral parameters are shown as 
follows: HAdV culture on feces (F), throat (T) and urine (U) (○: culture negative, ●: culture 
positive); HAdV DNA load by RQ-PCR on plasma (solid line). Lymphocyte recovery is depicted as 
a dotted line. Treatment with ribavirin (▲) and cidofovir (▼) are indicated. The time point of 
second transplantation is indicated by an arrow. Patient 20 had grade IV acute GvHD and an EBV 
infection, and patient 21 had grade II acute GvHD and a CMV infection (not shown). B) Absolute 
CD4+ and CD8+ T cell counts, as well as NK and B cell numbers per µl blood are shown at several 
time points pre- and post-SCT. C) HAdV-specific NAb against the serotype infecting the patient are 
shown. Treatment with α-CD20 antibodies (rituximab) for EBV reactivation is indicated (►). The 




HAdV viremia (Figure 4B and 3B, respectively). Viral infections other than HAdV occurred 
in patients from both groups and were successfully treated with ganciclovir and rituximab. 
Of the 3 patients that survived HAdV viremia, one received no antiviral medication aiming 
at HAdV, one patient received a short course of cidofovir and one patient a short treatment 
with ribavirin. However, HAdV clearance coincided with rising lympocyte counts in all 3 
patients. Moreover, inefficacy of ribavirin treatment was documented in the 3 patients who 
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Figure 4. Patients surviving HAdV viremia have cellular immune recovery, as well as an 
increase in HAdV-specific NAb and HAdV-specific T cells. Patients with HAdV viremia who 
survived the infection are shown for viral and immunological parameters pre- and post-SCT. A) 
Viral parameters are shown as follows: HAdV culture on feces (F), throat (T) and urine (U) (○: 
culture negative, ●: culture positive); HAdV DNA load by RQ-PCR on plasma (solid line). 
Lymphocyte recovery is depicted as a dotted line. Treatment with ribavirin (▲) and cidofovir (▼) 
are indicated. Patient 17 had a CMV infection and patient 18 had an EBV and CMV infection (not 
shown). B) Absolute CD4+ and CD8+ T cell counts, as well as NK and B cell numbers per µl blood 
are shown at several time points pre- and post-SCT. C) HAdV-specific NAb against the serotype 
infecting the patient are shown. The specific NAb response (>4-fold increase, see Patients and 
Methods) is indicated with an arrow. Treatment with α-CD20 antibodies (rituximab) for EBV 
reactivation is indicated (►). D) HAdV-specific T cell responses are shown in relation to the time 
after SCT. PBMC from donors and patients were stimulated with the HAdV serotype that infected 
the patient and tested for proliferation (shown as stimulation index (SI), ■) and IFN-γ production by 
ELIspot (bars: HAdV-specific spots after subtraction of background spots). The first detection of 
HAdV-specific T cell responses is indicated with an arrow.  
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HAdV-specific immune recovery 
In patients who died with HAdV viremia, serotype-specific neutralizing antibodies (NAb) 
were present in serum prior to infection, in some cases even at high titers (Figure 3C, patient 
20 and 21). Nevertheless, infection as well as progression to viremia occurred in these 
patients. During the infection, titers gradually declined to low levels.  
In patients with HAdV viremia who cleared the infection, humoral immune responses were 
observed as serotype-specific NAb increased 8- to 16-fold (indicated in Figure 4C), while 
NAb titers against other serotypes remained unchanged (data not shown). Responses were 
observed 1-9 months after clearance of HAdV from the plasma. Patient 18 received 
rituximab treatment because of EBV reactivation, which might explain the delayed humoral 
response to HAdV. The early rises in NAb shortly after SCT in patient 16 and 17 were most 
likely due to IVIG administration since NAb against other serotypes increased 
simultaneously (data not shown).  
As PBMC of patients who died from HAdV viremia were not available due to poor 
lymphocyte recovery, we were unable to test for HAdV-specific T cells in these patients. In 
patients surviving viremia, HAdV-specific responses were observed around 5-6 weeks after 
clearance of the viremia in two patients (patients 16 and 18), and 6 months after clearance in 
one patient (patient 17) (Figure 4D). Accordingly, T cell recovery was fast in patients 16 and 
18, whereas T cell recovery in patient 17 was delayed (Figure 4B). The latter observation 
was reflected by severely impaired responses to α-CD3 stimulation in this patient prior to 
detection of HAdV-specific T cells (data not shown).  
HAdV-specific T-cell responses were also investigated at 3 and 6 months after SCT in 
HAdV-infected patients without viremia and in some patients without HAdV infection 
(Figure 5). At 3 months, responses to the infecting serotype were observed in 3 out of 7 
(43%) of HAdV-infected patients and 2 out of 6 (33%) uninfected patients responded to 
HAdV5. At 6 months, the number of HAdV-infected patients with specific T cell responses 
increased to 75% (6 of 8 patients), whereas the proportion of responders in uninfected 
patients remained 33% (Figure 5). 
Intracellular cytokine stainings after in vitro stimulation of PBMC with HAdV revealed that 
most IFN-γ (and TNF-α) producing cells were CD4+ T cells, both in donors as well as in 
patients (Figure 6 and data not shown). These data suggest that the HAdV-specific T cells 









Figure 5. HAdV-specific T cell responses can be 
detected in most HAdV-infected patients 
without viremia and in some uninfected patients 
at 6 months after SCT. HAdV-infected patients 
without viremia were tested for HAdV-specific 
responses at 3 months (n = 7) and 6 months after 
SCT (n = 8), as well as some uninfected patients (n 
= 6 at both time points). The number of HAdV-
specific IFN-γ producing cells by ELIspot is shown 
(>25 spots is considered as a response). ○: HAdV-
infected patients in which infection was cleared 
from the feces before that time point, ●: HAdV-
infected patients in which feces was still HAdV 
positive at that time point, □: uninfected patients. 
 
 
Figure 6. HAdV-specific T cells are IFN-γ 
producing CD4+ T cells, both in donors as well 
as in patients surviving HAdV infection. PBMC 
from donors and patients were tested by 
intracellular cytokine stainings for production of 
IFN-γ after a 5-day stimulation with the HAdV 
serotype that infected the patient, or unstimulated 
as control. An example of donor (upper panel) and 
patient (lower panel; patient number 17 at week 60 
after SCT) CD3+ cells producing IFN-γ is shown. 
These IFN-γ producing cells are large CD3+CD4+ 
cells based on their forward and side scatter plot. 
Results are representative for 7 donors and 11 
patients of which 9 patients had HAdV infection 
with or without viremia.  
 
DISCUSSION 
In this prospective study, 48 pediatric SCT patients were monitored for the occurrence of 
adenovirus infection and viremia in relation to HAdV-specific immune reconstitution. The 
value of detection of viral DNA in plasma has been well documented for the diagnosis and 
management of virus infections, such as EBV and CMV and more recently also for HAdV 
(15-17,33,37-39). Quantification of the HAdV DNA load is essential as only persistent and 
rising loads have been shown to correlate with progressive disease and eventually death 
(12,13). In this study, infection occurred in 44% of patients, of whom 33% developed 
viremia as documented by the presence of viral DNA in plasma. The risk factors identified in 
this study, HLA mismatched transplants and immunosuppression with ATG or Campath in 
vivo are likely to have an impact on lymphocyte recovery (5,6,25,40). A low lymphocyte 
count at the time of the first virus isolation was a strong predictor of HAdV viremia. 
Furthermore, increasing lymphocyte counts during the first weeks of HAdV viremia were 
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lymphocyte numbers could be due to a variety of factors such as the occurrence and 
treatment of GvHD or retransplantation. This strong correlation between lymphocyte 
recovery and clearance of HAdV confirms and extends a previous report (25) and is in 
accordance with results obtained with respect to CMV infection (23,24,41).  
This is, to our knowledge, the first report in which HAdV-specific immunity is investigated 
longitudinally in SCT recipients with documented infection. Serotype-specific humoral 
immune responses were detected in patients recovering from HAdV viremia several weeks 
to months after clearance of the viral DNA from the circulation. In comparison, peak titers of 
HAdV-specific antibodies in healthy individuals were observed 2-4 weeks after adenoviral 
vector administration for gene therapy purposes (42). This difference in kinetics is probably 
due to the slowly recovering immune system in allogeneic SCT recipients. Interestingly, the 
presence of pre-existing high HAdV-specific NAb titers in serum of 2 out of 6 patients did 
not prevent progression to viremia. Viremia did not occur in 9 HAdV-infected patients, 
despite the fact that 5 patients had only low NAb titers (≤ 32) and 3 patients had intermediate 
titers (between 32 and 256) at the time of infection. Together, these results suggest that the 
role of pre-existing NAb (as measured in vitro) in protection against progression to viremia 
may be limited. As the number of patients is small, more patients should be evaluated to 
confirm these findings. 
In patients who had cleared the HAdV viremia, predominantly CD4+ HAdV-specific T cells 
producing IFN-γ were detected weeks to months after clearance of viremia. In healthy blood 
bank donors, HAdV-specific CD4+ T cells producing IFN-γ upon HAdV stimulation in vitro 
have also been detected (34,43). In individual patients, the increase in total lymphocyte 
numbers coincided with a decrease of viral DNA from plasma. As this result suggests a 
causal relationship, the question remains why specific humoral or cellular responses were 
only detected at later time-points. At this stage, we can only speculate about the reasons for 
this observation. The decrease in viral DNA load strongly suggests that a specific immune 
response has been initiated at the site of infection, but it might be that responses are 
undetectable in the circulation because the frequency of specific cells is below detection 
limit. In CMV and varicella zoster virus infections, specific CD4+ cells were also observed 
only after clearance of the virus in patients with symptomatic disease (44) (RAW van Lier, 
personal communication), possibly reflecting the redistribution characteristics of CD4+ T 
cells after viral infection. In other viral infections such as EBV, the presence of specific 
CD8+ cells at the time of clearance of the virus has recently been demonstrated using MHC-
antigen tetramers, making detection independent of in vitro functionality (45,46). Defining 
HAdV-specific immunodominant epitopes, as has been described by Olive at al (47), may be 
instrumental in the detection of HAdV-specific T cells at earlier time points using tetramer 
technology. Another possibility is that the initial control of infection is established by other 
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(innate) immune mechanisms, for instance NK cells, while the adaptive immune response is 
initiated at a later time point. Further research is needed to address these questions. 
Taken together, weekly RQ-PCR based screening of plasma for HAdV during the first 
months following allogeneic SCT, especially in recipients of grafts from MMFD or MUD 
donors, identifies high-risk patients at an early stage of viremia. If viremia is accompanied 
by a rise in lymphocyte counts, the viral infection will most likely be controlled. When 
lymphocyte counts remain low, alternative measures should be taken. As the antiviral effect 
of ribavirin appears limited and cidofovir is not proven to be unequivocally effective 
(26,27,29-32), other interventions aimed at improving immune reconstitution should be 
considered. Tapering of the immunosuppression post-SCT has been suggested to improve 
the outcome of the infection (25). However, this strategy bears a high risk of concurrent 
severe GvHD, especially in a non-HLA-identical transplant. Adoptive immunotherapy with 
HAdV-specific T cells, as has been performed for EBV and CMV (48-50), or infusion of 
donor cells that are depleted of alloreactive T cells (51,52) might be options for treatment in 
immunocompromised graft recipients at early signs of HAdV viremia in the near future. 
ACKNOWLEDGEMENTS 
We would like to thank Drs. Jan de Jong and Menzo Havenga for providing virus strains and Martijn 
Rabelink for virus purification and titration; Erik de Klerk for technical advice; Els Jol and Hanny 
Bakker for database support; Ronald Geskus for statistical advice; Prof. René van Lier, Dr. René 
Toes and Dr. Nicola Annels for critical reading of the manuscript.  
REFERENCES 
1.  Flomenberg P, Babbitt J, Drobyski WR et al. 1994. Increasing incidence of adenovirus disease in bone 
marrow transplant recipients. J.Infect.Dis. 169:775. 
2.  Childs R, Sanchez C, Engler H et al. 1998. High incidence of adeno- and polyomavirus-induced 
hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell 
depletion and cyclosporine. Bone Marrow Transplant. 22:889. 
3.  Hale GA, Heslop HE, Krance RA et al. 1999. Adenovirus infection after pediatric bone marrow 
transplantation. Bone Marrow Transplant. 23:277. 
4.  Howard DS, Phillips II GL, Reece DE et al. 1999. Adenovirus infections in hematopoietic stem cell 
transplant recipients. Clin.Infect.Dis. 29:1494. 
5.  Baldwin A, Kingman H, Darville M et al. 2000. Outcome and clinical course of 100 patients with 
adenovirus infection following bone marrow transplantation. Bone Marrow Transplant. 26:1333. 
6.  Runde V, Ross S, Trenschel R et al. 2001. Adenoviral infection after allogeneic stem cell transplantation 
(SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance 
study. Bone Marrow Transplant. 28:51. 
7.  Bruno B, Gooley T, Hackman RC, Davis C, Corey L, and Boeckh M. 2003. Adenovirus infection in 
hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol.Blood Marrow 
Transplant. 9:341. 
8.  Walls T, Shankar AG, and Shingadia D. 2003. Adenovirus: an increasingly important pathogen in 
paediatric bone marrow transplant patients. Lancet Infect.Dis. 3:79. 
9.  Hierholzer J. 1992. Adenoviruses in the immunocompromised host. Clin.Microbiol.Rev. 5:262. 
Immune reconstitution and HAdV infection 
 61
10.  De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW et al. 1999. Adenoviruses from human 
immunodeficiency virus-infected individuals, including two strains that represent new candidate 
serotypes Ad50 and Ad51 of species B1 and D, respectively. J.Clin.Microbiol. 37:3940. 
11.  Carrigan DR. 1997. Adenovirus infections in immunocompromised patients. Am.J.Med. 102:71. 
12.  Schilham MW, Claas EC, van Zaane W et al. 2002. High levels of adenovirus DNA in serum correlate 
with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. 
Clin.Infect.Dis. 35:526. 
13.  Lankester AC, van Tol MJ, Claas EC, Vossen JM, and Kroes AC. 2002. Quantification of adenovirus 
DNA in plasma for management of infection in stem cell graft recipients. Clin.Infect.Dis. 34:864. 
14.  Echavarria M, Forman M, van Tol MJ, Vossen JM, Charache P, and Kroes AC. 2001. Prediction of 
severe disseminated adenovirus infection by serum PCR. Lancet 358:384. 
15.  Lion T, Baumgartinger R, Watzinger F et al. 2003. Molecular monitoring of adenovirus in peripheral 
blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. 
Blood 102:1114. 
16.  Leruez-Ville M, Minard V, Lacaille F et al. 2004. Real-time blood plasma polymerase chain reaction for 
management of disseminated adenovirus infection. Clin.Infect.Dis. 38:45. 
7.  Gu Z, Belzer SW, Gibson CS, Bankowski MJ, and Hayden RT. 2003. Multiplexed, real-time PCR for 
quantitative detection of human adenovirus. J.Clin.Microbiol. 41:4636. 
18.  Hromas R, Cornetta K, Srour E, Blanke C, and Broun ER. 1994. Donor leukocyte infusion as therapy of 
life-threatening adenoviral infections after T cell depleted bone marrow transplantation. Blood 84:1689. 
19.  Chakrabarti S, Collingham KE, Fegan CD, Pillay D, and Milligan DW. 2000. Adenovirus infections 
following haematopoietic cell transplantation: is there a role for adoptive immunotherapy? Bone Marrow 
Transplant. 26:305. 
20.  Gratama JW, van Esser JW, Lamers CH et al. 2001. Tetramer-based quantification of cytomegalovirus 
(CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may 
identify patients at risk for progressive CMV infection. Blood 98:1358. 
21.  Chakrabarti S, Milligan DW, Pillay D et al. 2003. Reconstitution of the Epstein-Barr virus-specific 
cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative 
allogeneic stem cell transplantation. Blood 102:839. 
22.  Meij P, van Esser JW, Niesters HG et al. 2003. Impaired recovery of Epstein-Barr virus (EBV)--specific 
CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients 
at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 101:4290. 
23.  Hakki M, Riddell SR, Storek J et al. 2003. Immune reconstitution to cytomegalovirus after allogeneic 
hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. 
Blood 102:3060. 
24.  Boeckh M, Leisenring W, Riddell SR et al. 2003. Late cytomegalovirus disease and mortality in 
recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell 
immunity. Blood 101:407. 
25.  Chakrabarti S, Mautner V, Osman H et al. 2002. Adenovirus infections following allogeneic stem cell 
transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and 
immune recovery. Blood 100:1619. 
26.  Chakrabarti S, Collingham KE, Fegan CD, and Milligan DW. 1999. Fulminant adenovirus hepatitis 
following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy. Bone Marrow 
Transplant. 23:1209. 
27.  Gavin PJ and Katz BZ. 2002. Intravenous ribavirin treatment for severe adenovirus disease in 
immunocompromised children. Pediatrics 110:e9. 
28.  Ribaud P, Scieux C, Freymuth F, Morinet F, and Gluckman E. 1999. Successful treatment of adenovirus 
disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin.Infect.Dis. 28:690. 
29.  Bordigoni P, Carret AS, Venard V, Witz F, and Le Faou A. Treatment of adenovirus infections in 
patients undergoing allogeneic hematopoietic stem cell transplantation. Clin.Infect.Dis. 2001; 32:1290. 
30.  Legrand F, Berrebi D, Houhou N et al. 2001. Early diagnosis of adenovirus infection and treatment with 
cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 27:621. 
31.  Ljungman P, Ribaud P, Eyrich M et al. 2003. Cidofovir for adenovirus infections after allogeneic 
hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the 
European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 31:481. 
32.  Lankester AC, Heemskerk B, Claas ECJ et al. 2004. Effect of ribavirin on plasma viral DNA load in 
disseminating adenovirus infection. Clin.Infect.Dis. 38:1521. 
33.  Echavarria M, Forman M, Ticehurst J, Dumler JS, and Charache P. 1998. PCR method for detection of 




34.  Heemskerk B, Veltrop-Duits LA, van Vreeswijk T et al. 2003. Extensive cross-reactivity of CD4+ 
adenovirus-specific T cells: implications for immunotherapy and gene therapy. J.Virol. 77:6562. 
35.  van der Burg SH, Ressing ME, Kwappenberg KM et al. 2001. Natural T-helper immunity against human 
papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical 
lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int.J.Cancer. 91:612. 
36.  de Jong A, van der Burg SH, Kwappenberg KM et al. 2002. Frequent detection of human papillomavirus 
16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 62:472. 
37.  Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, and Osterhaus AD. 2000. Development 
of a real-time quantitative assay for detection of Epstein-Barr virus. J.Clin.Microbiol. 38:712. 
38.  Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, and Griffiths PD. 2000. Application of 
viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 
355:2032. 
39.  Niesters HG. 2002. Clinical virology in real time. J.Clin.Virol. 25 Suppl 3:S3. 
40.  Hoffman JA, Shah AJ, Ross LA, and Kapoor N. 2001. Adenoviral infections and a prospective trial of 
cidofovir in pediatric hematopoietic stem cell transplantation. Biol.Blood Marrow Transplant. 7:388. 
41.  Gutierrez A, Munoz I, Solano C et al. 2003. Reconstitution of lymphocyte populations and 
cytomegalovirus viremia or disease after allogeneic peripheral blood stem cell transplantation. 
J.Med.Virol. 70:399. 
42.  Harvey BG, Hackett NR, El Sawy T et al. 1999. Variability of human systemic humoral immune 
responses to adenovirus gene transfer vectors administered to different organs. J.Virol. 73:6729. 
43.  Olive M, Eisenlohr LC, and Flomenberg P. 2001. Quantitative analysis of adenovirus-specific CD4+ T-
cell responses from healthy adults. Viral Immunol. 14:403. 
44.  Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, Van Lier RA, and ten Berge IJ. 2003. Primary 
immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection 
against CMV disease. Blood 101:2686. 
45.  Marshall NA, Howe JG, Formica R et al. 2000. Rapid reconstitution of Epstein-Barr virus-specific T 
lymphocytes following allogeneic stem cell transplantation. Blood 96:2814. 
46.  Smets F, Latinne D, Bazin H et al. 2002. Ratio between Epstein-Barr viral load and anti-Epstein-Barr 
virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. 
Transplantation 73:1603. 
47.  Olive M, Eisenlohr L, Flomenberg N, Hsu S, and Flomenberg P. 2002. The adenovirus capsid protein 
hexon contains a highly conserved human CD4+ T-cell epitope. Hum.Gene.Ther. 13:1167. 
48.  Walter EA, Greenberg PD, Gilbert MJ et al. 1995. Reconstitution of cellular immunity against 
cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. 
N.Engl.J.Med. 333:1038. 
49.  Heslop HE and Rooney CM. 1997. Adoptive cellular immunotherapy for EBV lymphoproliferative 
disease. Immunol.Rev. 157:217. 
50.  Einsele H, Roosnek E, Rufer N et al. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the 
treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916. 
51.  Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S et al. 2002. Immune reconstitution without graft-
versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 360:130. 
52.  Amrolia PJ, Muccioli-Casadei G, Yvon E et al. 2003. Selective depletion of donor alloreactive T cells 






Effect of ribavirin on the plasma viral DNA 

























Arjan C. Lankester1, Bianca Heemskerk1, Eric C.J. 
Claas2, Marco W. Schilham1, Matthias F.C. Beersma2, 
Robbert G.M. Bredius1, Maarten J.D. van Tol1, Aloys 
C.M. Kroes2 
 
Departments of 1Pediatrics and 2Medical Microbiology, 
Leiden University Medical Center (LUMC), Leiden, the 
Netherlands 
 




Adenovirus infections are an increasingly frequent and potentially fatal complication in 
allogeneic stem cell recipients. To determine the antiviral potential of ribavirin in an 
unbiased way, four cases without immune recovery were prospectively analyzed by 
quantitative measurement of HAdV DNA in plasma. Administration of ribavirin at the first 
signs of HAdV dissemination was not accompanied by a reduction of viral DNA load in 
plasma in any of these cases, and even a further increase of the viral load was documented in 
three of them. These observations question the potential of ribavirin to improve outcome in 
disseminating HAdV infections, and support a critical evaluation of antiviral therapies in 
HAdV infections by using kinetics of viral DNA load as an objective parameter of viral 
replication. 
INTRODUCTION 
Adenovirus (HAdV) infections are increasingly recognized and frequently result in a fatal 
complication in allogeneic stem cell transplant (SCT) and solid organ transplant recipients 
(1). At present, 51 HAdV serotypes have been identified, which are classified into six 
species (A-F). In pediatric immunocompromised patients, HAdV species A-C are most 
frequently isolated. In the majority of cases HAdV infections are restricted to one anatomical 
site, mostly the intestinal or urinary tract (2,3). In these cases the localized HAdV infections 
may present with clinical symptoms e.g. diarrhea or hemorrhagic cystitis, but frequently an 
asymptomatic course is seen. Progression to disseminated HAdV infection may initially 
occur in the absence of typical clinical symptoms, but it usually results in clinical disease 
which is fatal in the majority of the patients. In pediatric patients disseminated HAdV 
infections are largely restricted to SCT recipients using other than HLA-identical family 
donors. Similar to what has been reported for Epstein-Barr virus (EBV) (4) and 
cytomegalovirus (CMV) (5,6), absent or inadequate immune recovery in the early 
posttransplant period is probably a major determinant for the occurrence, dynamics and 
outcome of the HAdV infection (7). Until recently, monitoring of HAdV infections was 
hampered by the lack of a reliable parameter of viral dissemination. Recently, HAdV DNA 
load measurements in plasma have become available for monitoring infections (8-11). In 
these studies, evidence has been provided that viral DNA detection and quantification in 
plasma is an informative and objective parameter to identify HAdV-infected patients at high 
risk of disseminating disease.  
Treatment of HAdV infections has been hindered by the lack of antiviral medication, whose 
efficacy has been demonstrated unequivocally. Ribavirin and cidofovir are the two antiviral 
drugs that are being used in most transplant centers. Conflicting results on the presumed 
efficacy of these drugs have been reported in several studies (12-17). The relatively small 
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number of systematically analyzed cases of ribavirin treatment has not provided convincing 
evidence for a beneficial effect of this antiviral drug compared to the natural course of the 
infection in these patients. It should be noted that the presumed therapeutic success in some 
cases might well be biased by a concomitant immune recovery. 
Viral DNA load assays have been found to be extremely valuable not only to study the 
natural dynamics of infection but also to assess the therapeutic benefits of antiviral regimens. 
This has been convincingly shown in the field of HIV and hepatitis B virus (18-19) and more 
recently also for CMV (reviewed in (20)) and EBV (21). In the current prospective setting, 
we have applied the quantitative measurement of HAdV DNA in plasma by real-time 
quantitative PCR (RQ-PCR) to study the antiviral potential of ribavirin in SCT recipients at 
the first signs of dissemination of the infection. 
PATIENTS & METHODS 
From 2001 onwards, all pediatric SCT recipients in the pediatric transplant unit of the Leiden 
University Medical Center have been prospectively analysed for the occurrence of HAdV infection 
(Heemskerk et al. manuscript in preparation). Viral screening for HAdV infection included weekly 
cultures of feces, throat swabs and urine. HAdV isolates were serotyped by classical viral 
neutralization assays on A549 cells using type-specific antisera (10). Real-time quantitative PCR for 
HAdV DNA was performed on weekly plasma samples as recently described (9). In summary, DNA 
was extracted from plasma samples by standard procedures and 10 µL of DNA containing extract 
was amplified by real-time PCR using the oligonucleotide primers described by Echavarria et al. 
(22). To detect these amplified products, a molecular beacon with a 5' FAM label and 3' dabcyl label 
was used (Biolegio, Malden, The Netherlands). A quantitated adenovirus type 5 stock was obtained 
as a kind gift from dr. M. Havenga (Crucell, Leiden, The Netherlands). Using an iCycler IQ system 
(BioRad laboratories, Hercules, CA), real-time amplification of a dilution series of this stock resulted 
in an external standard line based on the threshold cycles (Ct). This standard was used to quantitate 
HAdV DNA in the plasma samples by its Ct value. 
Four recipients of an HLA non-identical SCT who presented with HAdV infection received treatment 
with ribavirin. Clinical characteristics are summarized in Table 1. These patients fulfilled the 
following criteria: 1) HAdV DNA load in plasma > 1000 copies (cp)/mL as measured by RQ-PCR at 
two consecutive time points within a period of one week at the start of treatment. Clinical and 
additional laboratory parameters that might be related to HAdV infection were not considered for 
decision making about ribavirin treatment. 2) Intravenous ribavirin was administered as first line 
treatment during the period of positive HAdV DNA load in plasma. 3) Follow-up of HAdV DNA 
load was performed weekly. 4) Signs of immune recovery, defined as lymphocyte counts exceeding 
100 cells/µL, were absent during the entire treatment period. Stable engraftment finally occurred in 
all cases. Engraftment (> 500 neutrophils/µl) occurred on day + 19 (patient 1), day + 19 (patient 2), 
day +18 (patient 3, following 3rd SCT), and day + 14 (patient 4, following 2nd SCT), respectively. 
Graft-versus-host disease (GvHD) grade II was documented in patient 1 and 2, starting on day +14 
and +20 respectively, requiring prolonged steroid treatment. None of the patients received any form 
of antiviral prophylaxis. Ribavirin (ICN Pharmaceuticals, Zoetermeer, The Netherlands) was 
administered as a loading dose of 30 mg/kg, followed by a maintenance dose of 60 mg/kg q.i.d.. 
Cidofovir (Gilead Sciences Int. Ltd, Cambridge, UK) was administered at a dose of 5 mg/kg once a 
week, combined with Probenecid and hyperhydration to prevent nephrotoxicity.  
RESULTS 
Ribavirin was administered as first line therapy for 1-4 weeks in all four patients (Figure 1). 
In none of the patients a decrease in viral DNA load was documented during ribavirin 
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treatment. A continuously increasing level of HAdV DNA load was measured in three of the 
four cases. In two patients (patient 3 and 4) symptoms that could be attributed to HAdV 
infection were absent at the initiation of treatment. In the other two cases (patient 1 and 2) 
symptoms possibly related to HAdV infection (i.e. fever, diarrhea and slightly elevated 
transaminases and bilirubin) were documented at the initiation of treatment. However, in 
both cases concurrent, histologically confirmed, intestinal GvHD was probably mainly 
responsible for these symptoms. HAdV was cultured from stool prior to the detection of 
HAdV DNA in plasma in all cases except for patient 4. HAdV was also isolated from urine 
and/or throat swabs in all cases during the infection episode. In three cases, the positive 
HAdV plasma PCR preceded or coincided with HAdV isolation by culture from extra-
intestinal sites. HAdV serotypes 1, 2, 5 (all species C), and 18 (species A) were isolated in 
these four cases. Because of clinical deterioration, sampling of culture specimens was 
discontinued in the final stages of clinical disease. 
 
Due to the apparent lack of antiviral effect of ribavirin in these patients, a switch was made 
to cidofovir in two cases (patient 2 and 4). Some stabilization of HAdV DNA levels in 
plasma was subsequently observed, although cidofovir was only initiated at very high viral 
load levels > 106 cp/mL and > 1010 cp/mL, respectively). However, follow-up was too 
limited in these cases to draw firm conclusions about the antiviral effect of cidofovir, as both 
patients succumbed from their disease. Disseminated HAdV infection was the major 
determinant of mortality in two of the patients (patient 2 and 4). In the other two cases 





Table 1. Patient characteristics  
Patient Age (yr) Diseasea Donor Conditioning Graft manipulation Serotype 
1 14 MDS MUD B/C/M/ATG None 2 
2 8 MDS MUD B/C/M/ATG None 5 
3 6 CML MUDb T/F/ATG CD34+ selectionc 1 
4 3 Schwachman  MUDb B/F/C/ATG CD34+ selectionc 18 
a MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; MUD, matched unrelated donor; B, 
Busulfex; C, Cyclophosphamide; M, Melphalan; T, Thiotepa; ATG, anti-thymocyte globulins. 
b 3rd transplant following two previous rejections of haplo-identical SCTs in patient 3; 2nd transplant 
following non-engraftment of the first SCT from the same donor in patient 4. 
c CD34+-selection of peripheral blood stem cells performed using Clinimacs®. 
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In contrast to HAdV infection, in 3 out of 4 patients concurrent infections with other DNA 
viruses responded well to specific antiviral treatment (data not shown). In patient 1 CMV 
reactivation was first documented on day +19 upon which viral DNA load further increased 
to a maximum of 106 copies/mL on day +35. A firm and persisting decrease in CMV DNA 
load (1000-fold) was observed within 3 weeks following treatment with ganciclovir (5 
mg/kg b.i.d.) and subsequently foscarnet (60 mg/kg t.i.d.). In patient 2 EBV reactivation was 
diagnosed based on an increase in EBV DNA load that responded rapidly upon a single 
infusion of Rituximab (375 mg/m2) on day +30. Finally, patient 3 was treated with 
intravenous aciclovir (10 mg/kg t.i.d.) and topical cidofovir emulsion (1% w/w) (23) because 




































































Figure 1. Culture results and viral DNA loads in 4 patients treated with ribavirin. Patient 1-4 
are depicted in Figure 1A-D, respectively. HAdV was cultured in feces (F), urine (U) and throat 
swabs (T) and results are shown as positive (closed symbols) or negative (open symbols). Viral DNA 
load is shown in logarithmic values of copies/mL. The period of ribavirin and cidofovir 
administration is indicated by (▼) and (□), respectively. The arrow at week 15 in Figure 1C indicates 
the third SCT, the arrow at week 7 in Figure 1D indicates the second SCT. The results of feces 
cultures of patient 1 (Figure 1A) at week 9 and 10 were inconclusive (‘?’) because of the presence of 




We have previously reported that HAdV DNA measurement and quantification in plasma of 
HAdV-infected SCT recipients are instrumental in defining individuals at risk for fatal 
disseminated infections (8,10). These observations have provided the rationale for pre-
emptive treatment of HAdV infections guided by viral DNA levels in plasma. Recently, 
HAdV DNA load quantification by RQ-PCR has become available and this approach has 
now been introduced in the clinical management of pediatric SCT recipients in our center. 
As has been suggested before, this diagnostic tool might also be of great value to document 
any changes in viral replication upon the administration of proposed antiviral therapies (9-
11). 
So far, ribavirin and cidofovir are the drugs most often used to treat HAdV infections. 
Ribavirin is a synthetic guanosine analogue with in vitro inhibitory activity against a broad 
range of DNA and RNA viruses. In vivo efficacy has been demonstrated mainly in infections 
with respiratory syncytial virus and chronic hepatitis C, both RNA viruses (24-26). The 
mechanism of action is still unclear, but a potentiating effect on treatment with type I IFN 
has been reported in chronic hepatitis C infections. 
It is commonly accepted that effective antiviral therapy by a certain therapeutic 
concentration of a drug in a certain period of time should result in a consistent and 
proportional reduction in the level of viral replication. This means that a drug should result 
in a reduction in viral replication by a constant factor, which in a steady state situation would 
be measurable by a reduction in the plasma load of the viral nucleic acid, if a systemic and 
disseminated infection is present. 
In the present study the efficacy of ribavirin to inhibit HAdV replication and progressive 
disease was analyzed using a pre-emptive treatment strategy in four patients without evident 
immune reconstitution at the first signs of disseminating HAdV infection and during the 
period of treatment. In none of the cases a reduction in viral DNA load was observed during 
the period in which ribavirin was administered. Strikingly, even an apparently unaffected 
rise in viral DNA load was documented in three of the cases. 
From our present study, it may be concluded that ribavirin lacks significant antiviral activity 
in vivo against at least various HAdV strains. Our data provide evidence that ribavirin is not 
the drug of choice to treat HAdV infection in these severely immunocompromised patients. 
Within the framework of an international collaborative study, investigations on the 
pharmacokinetics of ribavirin and in vitro susceptibility of clinical HAdV isolates towards 
ribavirin are currently being performed in order to further document these findings. Studies 
along this line will bear relevance also to the question whether ribavirin could have a role in 
approaches of prophylactic treatment. 
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Because an apparent effect on viral DNA load kinetics following ribavirin therapy was 
lacking, therapy was switched to cidofovir in two cases. Cidofovir is a nucleotide analogue 
with potent reactivity against several DNA viruses and therapeutic efficacy in vivo has been 
reported in CMV infection (27). It should be noted that in our patients cidofovir therapy was 
initiated at a very high viral DNA load, which is compatible with serious disseminated 
infection. Although a further increase of the viral DNA load was tempered, it is not justified 
to draw firm conclusions with respect to antiviral efficacy of cidofovir based on the 
observations in these end-stage patients. However, together with several recently published 
studies in which the anti-HAdV efficacy of cidofovir was reported in patients without 
significant T-cell reconstitution (12,13,16), our observations support that further study of 
this drug as first line pre-emptive treatment in less deteriorated patients in earlier stages of 
infection is warranted.  
In accordance to what is already regarded common practice in most other systemic viral 
infections, like EBV and CMV, this case series does emphasize the value of HAdV DNA 
load as an objective endpoint, also in the assessment of the therapeutic efficacy of antiviral 
therapies in cases of disseminated HAdV infections. 
 
Note added in proof: 
Upon revision of the manuscript, the report by Leruez-Ville et al. (CID, 2004, 38:45) was published, 
which essentially confirmed the need for adenoviral DNA load determination in the evaluation of the 
treatment responses and in this way found evidence for the potential use of cidofovir in the treatment 
of this condition. 
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Adenovirus (HAdV)-specific T cell responses in healthy adult donors were investigated. 
HAdV5, inactivated by Methylene Blue plus visible light, induced proliferation and IFN-γ 
production in PBMC of the majority of donors. Responding T cells were CD4+ and produced 
IFN-γ upon restimulation with infectious HAdV5 and HAdV of different species. T cell 
clones showed distinct cross-reactivity patterns recognizing HAdV serotypes from either one 
species (C), two species (B and C) or three species (A, B, and C). This cross-reactivity of 
HAdV-specific T cells has relevance both for adenovirus-based gene therapy protocols as 
well as for the feasibility of T-cell mediated adoptive immunotherapy in recipients of an 
allogeneic stem cell transplantation. 
INTRODUCTION 
Adenoviruses (HAdV) rarely cause severe clinical symptoms in healthy children and adults 
as infections in immunocompetent individuals are usually self-limited. For this reason, 
adenovirus has been considered to be a safe vector for gene delivery and vaccination 
strategies, although pre-existing immunity is a major limitation when vectors are being 
administered repeatedly (16,47). However, HAdV may cause life-threatening complications 
in immunocompromised children (20,29). In recent years, the incidence of HAdV infections 
in pediatric recipients of an allogeneic stem cell transplant (SCT) has increased remarkably 
(2,8,14,17,22,39) (and van Tol et al., manuscript in preparation). Recipients of a T-cell 
depleted allogeneic graft, i.e. patients with a non-HLA-identical donor, have a higher risk of 
developing HAdV infection, probably due to the delayed immune reconstitution in these 
children after SCT (17) (and van Tol et al., manuscript in preparation). Dissemination of the 
infection often leads to a fatal outcome (14,17,20,21,32).  
Currently, 51 serotypes of adenovirus have been identified, distributed among six species 
(A-F) (11,20). Species A, B and C serotypes are most frequently isolated from pediatric 
immunocompromised hosts and are the major cause of disease (4,14,20). Treatment of 
adenoviral infections with antiviral medication using drugs such as cidofovir and ribavirin 
has not been unequivocally effective (3,5,23,25,28,31,38). A novel therapeutic approach 
may be immunotherapy by means of HAdV-specific lymphocytes as case reports have 
suggested that donor lymphocyte infusions (DLI) may contribute to clearance of an HAdV 
infection (6,24). This study focuses on the feasibility of generating HAdV-specific T cells 
from graft donor origin with the final goal of infusing these cells into the infected SCT 
patient. This strategy has already successfully been pursued for other viral infections or 
reactivations such as CMV or EBV (13,19,46). 
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RESULTS & DISCUSSION 
Inactivation of adenovirus 
Stimulation of HAdV-specific T cells using wild-type or E1-E3- recombinant HAdV-vectors 
has been reported previously (9,14,43,44). In clinical practice, however, biosafety constraints 
require a validated inactivation procedure of the HAdV used for T cell stimulation in order 
to circumvent infusion of infectious or genetically modified virus into the patient. Our 
strategy has therefore focused on complete inactivation of purified wild-type virus using the 
photosensitizer Methylene Blue (MB) and visible light (40). MB is already in use for routine 
treatment of fresh frozen plasma prior to infusion to inactivate viruses such as hepatitis C 
virus (33,35,42).  
MB inactivation of HAdV was previously shown to reduce viral infectivity by at least 4 log 
after illumination for 10 min (40). Prolonging the illumination period revealed that infectious 
particles could no longer be detected after 30 minutes of inactivation as determined by the 
lack of cytopathological effect in human epithelial cells (Hep-2) cells, indicating that MB 
can inactivate HAdV5 at least 7 log (data not shown).  
 
Frequency of T cell responses to MB-inactivated HAdV5 
As the use of MB-inactivated HAdV5 as antigen has not been reported previously, the 
frequency of donors reacting against MB-inactivated HAdV5 was determined in a panel of 
healthy adults by proliferation and IFN-γ ELIspot assays. In total, 19 out of 25 (76%) donors 
responded to MB-inactivated HAdV5 by proliferation, with stimulation indices (SI) ranging 
from 4.5 to 234 (Figure 1A). Analyzing this panel of healthy adults simultaneously for IFN-γ 
producing cells by ELIspot revealed that 80% of donors responded after 4 days of 
stimulation with MB-inactivated HAdV5 (Figure 1B). Calculated SI for the ELIspot results 
(in responding donors ranging from 4.1 to 109) correlated significantly with the SI from the 
proliferation assay (Pearson correlation coefficient 0.757, P <0.001) (Figure 1C). Donors not 
reacting against MB-inactivated virus were also tested by proliferation against UV- or heat-
inactivated HAdV5 as well as non-inactivated wild-type HAdV5 to determine whether the 
non-responsiveness was due to the nature of the viral antigen. However, these donors were 
unresponsive to any type of adenoviral stimulation, indicating that the MB inactivation of the 
virus was not responsible for the lack of response (data not shown). Unfortunately, sera from 
these donors were unavailable to test for previous HAdV infections by serology. As MB-
inactivated HAdV induced good proliferative responses of PBMC, our results confirm 
previous data which suggested that T cell responses are directed to structural proteins 
(14,34,43,45). The frequency of responders obtained with MB-inactivated HAdV5 was 
comparable to frequencies that have been described using purified E1-E3- HAdV5 (64%) (9) 
or using HAdV2-lysate from Hep-2 cells (>90%) (14), indicating that MB-inactivated HAdV 
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is a valid source for antigenic stimulation (36). This high response rate in adult donors 
indicates that the generation of HAdV-specific T cells would be a feasible option for the 
majority of transplant recipients at risk for developing a disseminated HAdV infection.  
Increased HAdV-specific IFN-γ production and reduced alloreactivity after 
restimulation 
If HAdV-specific T cell cultures are to be infused in patients, alloreactive, potentially 
GvHD-causing T cells should be eliminated. One way to reach this goal is a prolonged 
period of repetitive stimulation with specific antigen in culture. Furthermore, cells generated 
against MB-inactivated virus should be reactive against cells infected with infectious virus to 
be able to combat an ongoing infection in a patient. To this end, bulk cultures were initiated 
with PBMC from donors responding against MB-inactivated HAdV5 and restimulated at day 
12; IL-2 was added from day 15. At day 28, T cells proliferated specifically against 
autologous PBMC with MB-inactivated HAdV5 as well as with active HAdV5 (Figure 2A) 






































































































Figure 1. Proliferation and IFN-γ responses against MB-inactivated HAdV5 in healthy adults. 
PBMC from 25 healthy adult donors were stimulated with MB-inactivated HAdV5 or not stimulated 
as control. A) Proliferation against MB-inactivated HAdV5 is shown as the stimulation index (SI) for 
each donor. The SI is defined as proliferation (cpm of [3H] thymidine incorporation) against MB-
inactivated HAdV5 divided by the proliferation against PBMC without virus. Donors with SI >3 and 
meanHAdV > (meancontrol +3×SD) were considered responding donors (19 out of 25). All donors 
responded to PHA stimulation (not shown). B) IFN-γ production was determined by ELIspot in the 
same donors. Specific spots (background spots are substracted) are shown for each donor. Donors 
with at least 25 specific spots/100,000 PBMC and mean spotsHAdV > (mean spotscontrol +3×SD) were 
considered responding donors (20 out of 25). C) SI were calculated for both assays for comparison. 
The Pearson correlation coefficient is 0.757 (P <0.001); the orthogonal regression line is shown (y = 
0.04 + 1.14x). 
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Intracellular cytokine staining combined with immunophenotyping revealed a strong 
enrichment of CD4+ T cells producing IFN-γ upon restimulation with HAdV5 (median 5% 
IFN-γ+ cells in the CD3+CD4+ subset, range 1.2% – 30.1%, n=8) (Figure 2B). CD8+ cells 
specifically producing IFN-γ were not detected using intracellular stainings, neither using 
MB-inactivated HAdV nor infectious HAdV for stimulation (data not shown). Accordingly, 
other groups have demonstrated CD4+ T cell responses against HAdV, either in proliferation 
assays (9,14,18) or in IFN-γ ELIspot assays (36). In the same cultures alloreactive responses 
tested after 28 days of culture were strongly reduced when compared with the alloreactive 




Figure 2. Proliferation of T cells, 
frequency of IFN-γ producing CD4+ 
T cells and alloreactivity after 28 
days of culture. PBMC of healthy 
adult donors were stimulated with MB-
inactivated HAdV5 (MOI 10) at day 0 
and restimulated at day 12. At day 28, 
specificity of cultures was assessed and 
compared to the response at initiation 
of culture. A) Proliferation against 
irradiated autologous PBMC with MB-
inactivated HAdV5 (MB HAdV5) and 
active HAdV5 (A HAdV5) at MOI 100 
or without virus was measured in a 6-
day proliferation assay. The mean and 
SEM of triplicate wells are shown (ND 
= not done). B) The percentage of IFN-
γ producing T cells at day 28 was 
assessed by intracellular FACS staining 
following an 18 h stimulation with 
irradiated autologous PBMC with MB-
inactivated HAdV5 and active HAdV5 
at MOI 100 or without virus. Brefeldin 
A was added after 1 h of co-culture. 
The percentages IFN-γ+ cells within the 
CD3+CD4+ subset prior to culture (day 
0) and following 28 days of culture are 
shown. IFN-γ+ cells were not detected 
in the CD3+CD8+ subset (data not 
shown). C) Alloreactivity was tested in 
a 6-day proliferation assay against 
irradiated allogeneic PBMC of 3 
donors. The mean and SEM of 
triplicate wells are shown. All data are 
representative for experiments with 6 













































































































Cross-reactivity of HAdV5-specific bulk cultures and T cell clones 
A complicating factor in generating T cells for immunotherapy of HAdV infection is that 51 
serotypes of HAdV are described to date. It is currently not possible to predict which 
serotype will lead to infection in individual patients. Therefore, it is of interest to know 
whether T cells generated by stimulation with HAdV5 are also able to recognize other 
serotypes of HAdV, since HAdV strains belonging to species A, B and C have been reported 
to cause severe infections in immunocompromised hosts (4,14,20). 
Cells from 28-day T cell cultures generated against MB-inactivated HAdV5 were tested 
against a panel of HAdV serotypes, including strains belonging to species C (HAdV1, 
HAdV5 and HAdV6), species B (HAdV3, HAdV7, HAdV11, HAdV34 and HAdV35) and 
species A (HAdV12, HAdV18 and HAdV31). Cells proliferated against HAdV5 as well as 
against other serotypes belonging to the same species (C), which have extensive homology 
with HAdV5. However, proliferation was also observed against the less homologous 
serotypes from species B and species A in several bulk cultures (example shown in Figure 
3A). These results suggest that HAdV serotypes belonging to different species share T cell 
epitopes.  
The recognition pattern of different HAdV serotypes was further investigated at the clonal 
level. To this end, T cell clones were generated by limiting dilution from 28-day bulk 
cultures and resulting clones were tested for specificity using uninfected and HAdV5-
infected autologous EBV-transformed B cells (B-LCL). FACS analysis showed that HAdV-
specific T cell clones were CD4+, IFN-γ producing cells which is in agreement with the 
phenotype of the responding cells from bulk cultures (data not shown).  
In total, 11 independent T cell clones from 4 different donors were tested for cross-reactivity 
against HAdV belonging to species C (HAdV1, HAdV5 and HAdV6), species B (HAdV3, 
HAdV7, HAdV11, HAdV34 and HAdV35) and species A (HAdV12, HAdV18 and 
HAdV31). Proliferation assays showed three different recognition patterns. Two clones were 
reactive against species C viruses only (Figure 3B). Four clones recognized both species C 
and species B viruses (Figure 3C). Finally, five clones recognized HAdV from all three 
species tested, showing the broadest reactivity profile (Figure 3D). HAdV5-specific clones 
used either HLA-DR or HLA-DP as restriction element for antigen recognition, as assessed 
by addition of blocking antibodies to HLA-DR and HLA-DP (Figure 3B-D). There was no 
correlation between the restriction element (HLA-DR or -DP) and the cross-reactivity 
pattern. Although reactivity of HAdV-specific T cell cultures to other serotypes has been 
reported previously (14,44), this is the first report in which extensive cross-reactivity of 
HAdV-specific CD4+ T cells is described at the clonal level indicating that different HAdV 
strains harbour shared antigenic epitopes.  
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In general, human T cell recognition of epitopes that are conserved between different but 
related subtypes of viruses has been described for enteroviruses, herpes viruses, flaviviruses 




Figure 3. Cross-reactivity of 
T cells from HAdV5-
induced bulk cultures and 
CD4+ T cell clones. A) 
Twenty-eight day T cell 
cultures were tested in a 6-day 
proliferation assay for 
reactivity against irradiated 
autologous PBMC without 
virus (-) or infected with 
HAdV strains from species C 
(HAdV1, 5, 6), B (HAdV3, 7, 
11, 34, 35) and A (HAdV12, 
18, 31). The response pattern 
of a representative donor out 
of 4 donors tested is shown. 
B-D) CD4+ T cell clones, 
obtained by limiting dilution, 
were stimulated with 
irradiated autologous B-LCL 
without virus (-) or infected 
with HAdV strains from 
species C (HAdV1, 5, 6), B 
(HAdV3, 7, 11, 34, 35) and A 
(HAdV12, 18, 31) and tested 
in a 4-day proliferation assay. 
B) represents a clone with 
restricted recognition (only 
species C). C) represents a 
clone with a broader reactivity 
against both species C and B 
serotypes. D) depicts a clone 
which recognizes HAdV from 
all species tested (species A, B 
and C). Blocking antibodies to 
HLA-DR and HLA-DP were 
added to B-LCL infected with 
HAdV5 (hatched bars) to 
determine the restriction 
element (separate experiment, 
dashed line; anti-HLA-DQ 
and anti-class I was also 
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Recently, it has been proposed that exposure of individuals to consecutive infections with 
different strains of a virus will result in repeated cycles of stimulation and expansion of those 
T cells that recognize shared epitopes (15). In this way, consecutive infections with different 
strains of HAdV could explain the observed cross-reactivity. Such cross-reactivity implies 
the presence of sequence homology in structural proteins between the HAdV serotypes from 
different species. For instance, the hexon protein which is the major structural protein and 
comprises about 95% of the capsid, is approximately 80% homologous between species A, B 
and C (10). Further characterization of the cross-reactive T cell epitopes will demonstrate 
whether these shared epitopes are completely identical between HAdV strains or whether 
amino acid differences exist that have no crucial effect on HLA-binding or T cell receptor 
recognition.  
Pre-existing immunity limits the application of HAdV5 both in gene therapy protocols as 
well as in vaccine delivery. The neutralizing antibody response to the HAdV-based vector 
may be circumvented efficaciously by subsequent use of vectors containing hexons from 
different serotypes (37,48). Pre-existing cellular immunity, however, may not be as easily 
circumvented by this hexon gene switch strategy due to the extensive cross-reactivity of T 
cells described in this study. 
In conclusion, our results show that HAdV-reactive T cells can be cultured after stimulation 
with MB-inactivated HAdV5. In order to control HAdV infections in patients, these T cells 
should probably be infused pre-emptively when HAdV DNA is detected for the first time in 
plasma by PCR, indicating dissemination of the infection (12,27,41). The high degree of 
cross-reactivity enables the use of these cells in immunocompromised patients irrespective 
of the serotype of the HAdV-strain that infects a particular patient and may thus be a 
valuable tool to decrease the mortality rate in this pediatric patient group.  
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The immune response against human adenovirus (HAdV) has gained interest because of the 
high incidence of infections in pediatric recipients of an allogeneic stem cell graft and 
because of gene therapy with HAdV-based vectors. Since antiviral medication is frequently 
ineffective, the option of adoptive transfer of HAdV-specific donor-derived T cells receives 
much attention. Responses against HAdV5 in PBMC of healthy adults are primarily found in 
CD4+ T cells suggesting that a large proportion of the response is directed against structural 
viral proteins. Here we compare T cell recognition of HAdV5 hexon and penton capsid 
proteins with that of E1A, one of the early proteins. Most donors responded to the conserved 
C-terminal part of the hexon protein. By screening a panel of overlapping peptides of the 
hexon protein, five peptides were identified, that were recognized by the majority of donors. 
CD4+ T cells from long-term cultures of PBMC stimulated with this panel of five peptides 
recognized not only HAdV5, but also other HAdV serotypes belonging to different species. 
These data demonstrate that conserved peptides are present in HAdV, which have 
consequences for gene therapy, but also may represent a useful tool for the generation of 
HAdV-specific T cells for adoptive immunotherapy. 
INTRODUCTION 
Human adenovirus (HAdV) infections are usually mild and self-limiting in the 
immunocompetent host. However, recently it has been recognized that HAdV may cause 
life-threatening complications in severely immunocompromised patients, such as pediatric 
recipients of allogeneic stem cell transplants (1-5). In recent years, the incidence of HAdV 
infection increased in these recipients (6-8) (and van Tol, submitted). Risk factors for HAdV 
infection included HLA-mismatched transplants, the use of immunosuppression with ATG 
and Campath and delayed immune reconstitution (8), indicating a role for the adaptive 
immune system. Treatment of HAdV infection in immunocompromised patients with 
ribavirin and cidofovir are being administered, but these two drugs have not been shown to 
be unequivocally efficacious and closely monitoring of patients indicates that immune 
recovery is essential to eliminate the virus (9-14). Therefore, immunotherapy by infusion of 
HAdV-specific donor-derived T cells might be an option for treatment. Case reports have 
already reported that infusion of donor lymphocytes contributes to the clearance of HAdV 
infection (15,16). Since infusion of unselected donor lymphocytes bears the risk of inducing 
graft-versus-host disease (15), it would be more attractive to infuse only HAdV-specific 
donor cells. In peripheral blood mononuclear cells (PBMC) of healthy donors the response to 
HAdV is dominated by CD4+ T cells recognizing structural viral proteins (17-21).  
To date, 51 serotypes of HAdV have been described, which are classified into 6 species (A 
to F). Species A, B and C are responsible for most of the infections in pediatric recipients 
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(8,13,22). The protein capsid of the virion is composed of seven polypeptides. Polypeptide II 
is the most abundant virion component forming the hexon protein. The penton base protein, 
present at each vertex of the icosahedral particle, is formed by five polypeptides III 
(reviewed by (23)). Since HAdV-specific T cells show cross-reactivity between the different 
serotypes and species, the epitopes recognized by the HAdV-specific T cells are probably 
derived from conserved parts of the structural proteins (17,19,20). Until now, only one 
epitope for CD4+ T cells has been reported, which is restricted by HLA-DP4 (24,25). For 
CD8+ T cells, 5 epitopes have been identified that are restricted by HLA-A1, -A2, -A24 and 
-B7 (26). For both studies, peptides were selected by a predictive algorithm. Although 50% 
or more of the population has an HLA-A1, -A2, -B7 or -DP4 allele, these data do not 
guarantee that the selected peptides are widely recognized in the population. To perform a 
comprehensive unbiased study of T cell epitopes of HAdV, we investigated the recognition 
of several HAdV5 proteins, i.e. the structural polypeptide II, and polypeptide III and the 
early protein E1A. Since polypeptide II was recognized more frequently, this protein was 
synthesized as a set of overlapping peptides. Screening of PBMC from a panel of healthy 
donors revealed that a relatively limited set of peptides was able to evoke responses in 
almost all donors, apparently independently of HLA-typing. CD4+ T cells specific for these 
peptides recognized target cells pulsed with HAdV of different serotypes, thus avoiding the 
use of complete virus or recombinant virus for the production of T cells for clinical 
application in immunotherapy. 
MATERIALS & METHODS 
PBMC 
PBMC were isolated from blood of anonymous healthy blood bank donors; these donors were typed 
for HLA-A, B, C and HLA-DR. The HLA-types of the selected donors represented the normal 
distribution of HLA-alleles in the Dutch population.  
 
Antigens 
The HAdV5 polypeptide II gene in plasmid pJM17 (kindly provided by Prof. R. Hoeben, Department 
of Molecular Cell Biology, Leiden) was amplified by PCR in four overlapping parts (Table 1). The 
PCR products were cloned by Gateway technology (Invitrogen, San Diego, CA) in a bacterial 
expression vector containing an N-terminal histidine tag. The proteins were overexpressed in 
Escherichia coli BL21 (DE3), purified, dissolved in DMSO and diluted in PBS (27). The four 
overlapping parts are indicated by the numbers of the first and last amino acid in the polypeptide 
(IIA1-273, IIB245-509, IIC479-743, IID720-952). Recombinant HAdV5 polypeptide III and E1A protein were 
gifts from A. den Boer and Dr. S.H. van den Burg (Department of Immunohematology and 
Bloodtransfusion, Leiden). 
Peptides spanning the HAdV5 polypeptide II consisted of 63 peptides of 30 amino acids with an 
overlap of 15 amino acids and are indicated as II4 to II66. They were synthesized by solid-phase 
strategies on an automated multiple peptide synthesizer (Abimed AMS22, Langenfeld, Germany). 
Peptides were analyzed by reverse phase HPLC, dissolved in DMSO and diluted in PBS. The 63 
peptides were grouped in 12 pools; each pool containing 5-6 adjacent peptides (e.g. peptide pool P1 









Wildtype HAdV2, HAdV5, HAdV6, HAdV12, and HAdV35 (RIVM, Bilthoven, the Netherlands) 
were grown on Hep2 cells and purified (8). Methylene blue (MB) inactivation of virus was 
performed as previously described (28).  
 
T cell stimulation 
PBMC were cultured in RPMI 1640 (GibcoBRL, Grand Island, NY) supplemented with 10% human 
AB serum (AB) at 2×106 cells/mL. Cells were stimulated with 5 µg/mL recombinant protein or 
peptide, HAdV5 at a multiplicity of infection (MOI) of 10, or with medium alone as negative control. 
Cells were cultured for 4 or 5 days either in a round-bottom 96-wells plate (Corning Incorporated, 
Life Sciences, Acton, MA) in order to measure the amount of secreted IFN-γ by ELISA or in a 48-
wells plate (Corning Incorporated) to determine the IFN-γ spot forming units (SFU) by ELIspot or by 
intracellular cytokine staining and flow cytometry.  
 
IFN-γ levels in culture supernatant 
To determine which peptide pools were recognized by PBMC of healthy donors, we measured the 
level of IFN-γ secreted by PBMC in culture supernatants after 4 days. Secreted IFN-γ was 
determined using an ELISA kit (Sanquin, Amsterdam, the Netherlands). The response to a distinct 
peptide pool was considered positive if the IFN-γ production to this pool was at least 10% of the sum 
of IFN-γ production in response to all 12 peptide pools. 
 
IFN-γ ELIspot 
Recognition of the recombinant proteins or polypeptide II peptides by T cells was analyzed by 
ELIspot as described (29). After 4 days of culture the cells were transferred to an αIFN-γ IgG 
antibody (MabTech, Nacha, Sweden) coated Multiscreen 96-wells plate (Millipore, Etten-Leur, the 
Netherlands), which was blocked for aspecific binding by 10% FCS (GibcoBRL) in RPMI at a 
concentration of 1×105 cells per well. After 16 h of incubation the spot forming units (SFU) were 
visualized using αIFN-γ IgG antibody MAb 7-B6-1-biotin (Mabtech), Avidin-AP (Sigma-Aldrich, 
St. Louis, MO), followed by the substrate NBT-BCIP (NitroBlue tetrazolium and 5-Bromo-4-Chloro-
3-indolyl phosphate (Sigma-Aldrich) in 0.1 M Tris-HCl pH 9.5 and 5 mM MgCl2. In between each 
detection step the plate was washed with PBS/0.05%Tween-20. Spots with a diameter > 35 µm were 
counted by computer-assisted video image analysis using KS ELIspot software release 4.1 (Carl 
Zeiss Vision GmbH, Hallbergmoos, Germany). The response was considered as positive if the mean 
of the number of spots was > 25 spots and exceeded the mean of the negative control + 3 times SD. 
 
Intracellular cytokine staining 
To determine the phenotype of the IFN-γ-producing cells, cells were incubated at day 5 for 5 h with 5 
µg/mL Brefeldin A (BFA, Sigma-Aldrich) for intracellular IFN-γ staining. The procedure was 
performed as described (30). In short, cells were washed with PBS containing 0.2% w/v NaN3 and 
fixed with freshly made 4% paraformaldehyde (Sigma Aldrich). Cells were permeabilized with 
PBS/NaN3 containing 0.1% saponin and 0.5% BSA, and non-specific binding was blocked by 
incubating with PBS/NaN3/saponin/BSA/10% FCS. Cells were stained with αCD3-PerCP-Cy5.5, 
Table 1. Primers for recombinant polypeptide II proteins  
Recomb. 
protein 
Primer Nucleotide of 
polypepide II 
gene 





IIA1-273 IIA-sense 225 - 244 5'-ggggacaagtttgtacaaaaaagcaggctta- atggctaccccttcgat 
 IIA-antisense 1043 - 1026 5'-ggggaccactttgtacaagaaagctgggtca- ggtcgcctcagtagttg 
IIB245-509 IIB-sense 960 - 977 5'-ggggacaagtttgtacaaaaaagcaggctta- gggcaaggcattcttgt 
 IIB-antisense 1751 - 1732 5'-ggggaccactttgtacaagaaagctgggtca- caccactcgcttgttca 
IIC479-743 IIC-sense 1659 - 1676 5'-ggggacaagtttgtacaaaaaagcaggctta- ctgtatttgcccgacaag 
 IIC-antisense 2453 - 2436 5'-ggggaccactttgtacaagaaagctgggtca- aaactcgttgggggtaag 
IID720-952 IID-sense 2382 - 2400 5'-ggggacaagtttgtacaaaaaagcaggctta- aaggtggccattaccttt 
 IID-antisense 3083 - 3066 5'-ggggaccactttgtacaagaaagctgggtca- ttatgttgtggcgttgcc 
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αCD4-FITC, αIFN-γ-PE (Becton Dickinson Biosciences, San Jose, CA) and αCD8-APC (Beckman 
Coulter, Miami, FL). Cells were analyzed on a FACS Calibur flow cytometer using CellQuest 
software (Becton Dickinson). 
 
DC generation 
PBMC were cultured at a concentration of 2-3×106 cells/mL in a T75 flask in RPMI enriched with 
10% FCS. After 2 h the cells were washed and the non-adherent fraction (peripheral blood 
lymphocytes, PBL) was removed. The adherent fraction was cultured in RPMI with 10% FCS 
supplemented with 800 U/mL recombinant GM-CSF (rGM-CSF, Leucomax, Novartis Pharma AG, 
Basel, Switzerland) and 40 ng/mL recombinant IL-4 (Peprotech, Rocky Hill, NJ) for 5 days. These 
cells were referred to as immature DC (iDC) and were CD14 negative and CD1a positive as 
measured by FACS analysis. The iDC were transferred to a round-bottom 96-wells plate at a 
concentration of 1×104 DC/well in RPMI enriched with 10% AB supplemented with 800 U/mL rGM-
CSF and 40 ng/mL IL-4. After 24 h, the iDC were matured by adding 0.25 µg/mL αCD40 (Mab89, 
Immunotech, Beckman-Coulter, Miami, FL) and 500 U/mL IFN-γ for an additional 24 h. Mature DC 
were typically CD14 negative and CD83 positive, as assessed by FACS analysis (31). 
 
T cell culture 
Mature DC were loaded with peptides in a volume of 25 µl/well of RPMI containing 1 mM of 
Ca2+/Mg2+ at 37°C. After 2 h of incubation, autologous PBL were added at a DC:PBL ratio of 1:20 in 
200 µl RPMI/10% AB supplemented with 10 IU/mL of IL-2 (Proleukin, Chiron, Emeryville, CA) 
and 2 ng/mL of IL-7 (Peprotech).  
At day 12, responding cells were restimulated using autologous irradiated PBMC (30 Gray) loaded 
with the same concentration of peptides as used for loading the DC at the initiation of the culture in 
RPMI/0.5% BSA at 1×107 cells/mL for 2 h. The T cells were co-cultured with the stimulator cells in 
a T cell: stimulator ratio of 1:5 in a 24-wells plate in RPMI/10% AB in the presence of 0.1 µg/mL 
anti-CD40 and 5 ng/mL IL-7. At day 19, 10 U/mL IL-2 and 5 ng/mL IL-7 were added. At day 12 and 
26 cells were tested for specificity. 
 
Proliferation and IFN-γ production by peptide-specific T cells 
To test T cell specificity, autologous irradiated stimulator PBMC were infected at day -1 with 
HAdV5 at a MOI of 100 or loaded with 10 µg/mL peptide, or medium alone as a negative control in 
RPMI/0.5% BSA at 1×107 cells/mL for two h and left overnight at 1×106 cells/mL in RPMI/10% AB. 
For intracellular IFN-γ production, 2×105 responder cells were co-cultured with 2×105 stimulator 
cells in 400 µl in a polystyrene round-bottom tube (5 mL Falcon, Becton Dickinson, Franklin Lakes, 
NJ). After 1 h, 5 µg/mL BFA was added, and 16 h later intracellular staining was performed as 
described above. 
To determine the specific proliferative response, 2×104 responder cells were co-cultured with 1×105 
stimulator cells in triplicate in a 96-well round-bottom plate. At day 5, [3H]-thymidine (0.5 µCi/well, 
Amersham International, Amersham, UK) was added for 16 h. 
RESULTS 
Selecting HAdV5 peptides 
We have shown that MB-inactivated HAdV induces CD4+ T cells that can recognize cells 
with infectious HAdV, suggesting that epitopes for these T cells are derived from structural 
polypeptides (19). Because of the abundance of polypeptide II in the virion capsid, we 
compared the recognition of the recombinant proteins IIA1-273, IIB245-509, IIC479-743, IID720-952, 
III and, for comparison, E1A in cultures of PBMC from healthy donors and measured the 
IFN-γ SFU. A representative reaction profile is shown in Figure 1A, where PBMC of donor 
A responded to recombinant protein IIC479-743, IID720-952 and III (Figure 1A). The responses 
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Figure 1. Recognition of HAdV5 
recombinant polypeptides II 
and III. (A) PBMC of healthy 
donor A were cultured for 4 days 
with HAdV5 or recombinant 
polypeptides, after which IFN-γ 
SFU per 1×105 PBMC was 
measured. Dotted line represents 
threshold (25 spots) above which 
the response is considered 
positive. Results are representative 
for the results obtained from 33 
donors. (B) Overview of healthy 
donors tested for their recognition 
of the recombinant proteins IIA-
IID, III and E1A. White bar 
represents the number of donors 
tested, black bar the number of 
donors responding to the 
recombinant protein. 
Figure 2. Recognition of 
HAdV5 polypeptide II 
peptides. PBMC of 
healthy donor B were 
cultured for 4 days (A) 
with peptide pools (P1-
P12), after which the 
amount of IFN-γ secreted 
in culture supernatant 
was determined or (B) 
with the single peptides 
of the selected peptide 
pools, after which the 
IFN-γ SFU per 1x105 
PBMC was measured. 
Dotted line represents 
threshold above which 
the response is 
considered positive. 
Results are from one 
donor and representative 
for the results obtained 
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In total, PBMC from 33 healthy donors, recognizing HAdV5, were tested. The C-terminal 
part of polypeptide II, which includes recombinant proteins IIC479-743 (82%) and IID720-952 
(82%), was recognized by more donors than the N-terminal part of polypeptide II, IIA1-273 
(27%), IIB245-509 (55%), or recombinant polypeptide III (67%) (Figure 1B). The recognition 
of the early gene product E1A (20%) was low. These data indicate that the conserved part of 
polypeptide II contains widely recognized T cell epitopes. 
To further elucidate recognition of the hexon protein, overlapping peptides of 30 amino acids 
with an overlap of 15 amino acids of the complete polypeptide II (peptide II4 to II66) were 
synthesized and tested. PBMC of donor B contained T cells that recognized peptide pools 
P7, P9 and P11 (Figure 2A). Next, PBMC of donor B were cultured with the single peptides 
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Figure 3. Overview of recognition of HAdV5 polypeptide II peptides. (A) PBMC of 21 donors 
were tested for their recognition of polypeptide II peptide pools (P1-P12) (IFN-γ secretion in culture 
supernatant). (B) Donors with a positive response to the peptide pool were tested for their recognition 
of the single peptides from that pool (IFN-γ SFU). White bar represents the number of donors tested, 
black bar the number of donors recognizing the indicated (A) peptide pool or (B) the indicated single 




II51 of peptide pool P9 and peptides II57-II61 of peptide pool P11, and the response was 
measured by ELIspot assay. Responses against HAdV5 or medium alone were used as 
positive and negative control, respectively. Positive responses were observed against 
peptides II37, II41, II51, II57, II60 and II61 (Figure 2B).  
A total of 21 donors was tested accordingly. Most responses were observed against peptides 
from peptide pools at the C-terminal part of polypeptide II, which is in agreement with the 
results obtained using the recombinant polypeptides (Figure 3A). Peptides from pools P8 (13 
donors), P9 (11 donors) and P11 (10 donors) were recognized most frequently. At the level 
of single peptides most donors responded to peptide II42 (11 out of the 13 peptide pool P8 
positive donors), peptide II61, peptide II50 and peptide II57 (Figure 3B). Peptide II64 of 
peptide pool P12, containing epitope II910-924 was recognized by 5 of the 6 peptide pool 
positive donors (24). This screening resulted in 5 peptides of polypeptide II, which are 
frequently recognized by PBMC of healthy donors. 
Since it would be attractive for adoptive immunotherapy to culture PBMC with HAdV 
peptides instead of complete virus, these five most recognized peptides (peptides II42, 50, 57 
61 and 64 (Figure 3B)) were selected and combined to a HAdV peptide culture pool (PCP). 
To test whether these five single peptides and the PCP were able to induce responses in the 
majority of donors, 14 different healthy blood bank donors, responding to HAdV5, were 
tested. Thirteen (92%) of these donors recognized one or more of the 5 peptides as well as 

















The differences in percentages of responders during screening for the identification of the 
reactive peptide (Figure 3B) and during testing the selected peptides (Table 2) can be 
Table 2. Recognition of 5 selected HAdV5 hexon 
peptides by 14 donors 
  peptides of HAdV PCP   
donor  II42 II50 II57 II61 II64  PCP 
1  + + + + +  + 
2  + - + + +  + 
3  + + - - -  + 
4  - - + + +  + 
5  - - - - -  - 
6  - - - + -  + 
7  - + - - +  + 
8  + - + + +  + 
9  + - - - -  + 
10  - - + + +  + 
11  + - + + +  + 
12  - - - + -  + 
13  + + - - -  + 
14  + + + + +  + 
positive  8 5 7 9 8  14 
IFN-γ SFU / 105 PBMC: +: ≥ 25 spots and exceeding the mean of 
the negative control + 3 times SD 
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explained by the use of different techniques. The IFN-γ ELISA used to determine the 
positive peptide pools in a first screening is not as sensitive as the ELIspot technique used 
for identification and recognition of the single peptides.  
 
HAdV5 PCP almost exclusively induced IFN-γ production in the CD4+ T cell population, 
which was also observed after culture with wild type HAdV5 (data not shown). Thus, with 
the set of these 5 peptides, we are able to stimulate T cells of most donors, and these reactive 
T cells show the same phenotype as T cells cultured with intact virus.  
 
Peptide-generated T cells recognize HAdV 
To investigate whether PCP reactive T cells also recognize cells infected with HAdV, PBL 
of healthy donors were cultured for 28 days with HAdV5 PCP in different concentrations 
(range 1 µg/mL to 0.08 ng/mL). T cells stimulated with low concentrations of PCP (optimal 
concentration 0.4 ng/mL) recognized MB-inactivated HAdV5 better than T-cells stimulated 
with high concentrations of PCP, although at all concentrations T cells were peptide specific 
(data not shown). At day 12, 3.0% of the CD4+ T cells recognized autologous PBMC loaded 
with MB-inactivated HAdV5, which increased to 8.6% at day 26 (Figure 4A). The 
recognition of HAdV PCP itself increased from 7.4% of the CD4+ T cells at day 12 to 21.9% 
at day 26 (Figure 4A). Besides IFN-γ production, these peptide reactive T cells also showed 
proliferative capacity specifically to cells pulsed with MB-inactivated HAdV5 at day 12 and 
26 (Figure 4B). These data show that T cells cultured with HAdV peptides are able to 
recognize MB-inactivated HAdV5. 
To investigate whether peptide-cultured T cells also recognize other HAdV serotypes, PBL 
cultured with 0.4 ng/mL HAdV5 PCP were tested at day 26 against autologous PBMC 
pulsed with one of 8 different MB-inactivated HAdV serotypes from 4 different species. The 
CD4+ T cells from this culture responded to all 8 MB-inactivated HAdV from species A, B, 
C and D in IFN-γ production and proliferation (Figure 5A and B), indicating that these 
peptide-cultured T cells are indeed broadly reactive against different HAdV species.  
Furthermore, it is important for adoptive immunotherapy that the cultured cells also 
recognize autologous PBMC infected with infectious HAdV. Ten percent of the CD4+ T 
cells produced IFN-γ in response to infectious HAdV5 stimulation, confirming that these T 
cells not only recognized MB-inactivated virus but also infectious HAdV (Figure 6). In 
addition, these peptide-cultured T cells also recognized infectious HAdV35 infected 
stimulator cells, but did not show reactivity towards allogeneic PBMC (data not shown). 
Because the peptide generated T cells recognized infectious HAdV but not allogeneic 




























The main conclusion from this study is that HAdV polypeptide II, forming the hexon 
protein, contains multiple long peptides, that a) are recognized by CD4+ T cells of a majority 
of the population, b) are conserved between HAdV serotypes, and c) induce T cells that 
recognize HAdV-infected target cells. Thereby, these peptides are good candidates for 
culture of HAdV-specific T cells for adoptive immunotherapy. It has already been reported 
that the responses of human peripheral blood (CD4+) T cells to HAdV were directed (at least 
partly) against structural proteins (17,32). So far, no comparison in recognition of different 
HAdV proteins has been performed in the healthy human population. Comparison of T cell 
responses against the two structural proteins II (hexon) and III (penton) and one early gene 
product, E1A, of HAdV5 in the present study revealed that most T cell responses were 
directed against the structural polypeptides and the C-terminal part of polypeptide II in 
particular. This part represents the section that is most conserved between different serotypes 
(33,34), offering an explanation for the cross-reactivity found in cultured HAdV-specific T 
cells (17,19,20). In contrast, the epitopes recognized by serotype-specific neutralizing 
Figure 4. T cells cultured with HAdV5 PCP recognize MB-inactivated HAdV5. PBL were 
cultured for 26 days with 0.4 ng/mL PCP and tested at day 12 and 26 for recognition of 
autologous PBMC pulsed with MB-inactivated HAdV5 (MOI 100) (gray bars) in (A) IFN-γ 
production and (B) proliferation. Medium alone (white bars), referred to as no stimulus, and 
PBMC pulsed with HAdV5 PCP (black bars) were used as negative and positive control. Results 
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antibodies are mainly located in the N-terminal part of the hexon protein (35,36). The 
phenomenon of recognition by T cells of epitopes conserved between different but related 
viral subtypes is also described for other viruses (37-40). An explanation for this observation 
could be that consecutive exposure of individuals to multiple infections with different viral 











































Figure 6. T cells cultured with HAdV5 PCP 
recognized active HAdV5. PBL were 
cultured for 26 days with 0.4 ng/mL HAdV5 
PCP and tested for their recognition of 
autologous PBMC infected with HAdV5 (MOI 
100) by measuring IFN-γ producing cells after 
intracellular staining. Medium alone, referred 
to as no stimulus, was used as negative 
control. Results are from one donor and 
representative for the results obtained from 
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Figure 5. T cells cultured with HAdV5 PCP recognize HAdV from different species. PBL were 
cultured for 26 days with 0.4 ng/mL PCP and tested for recognition of autologous PBMC pulsed with 
MB-inactivated HAdV from different species (MOI 100) in (A) IFN-γ production (intracellular 
staining and flow cytometry) and (B) proliferation. Medium alone, referred to as no stimulus, was 
used as negative control. Results shown are of one donor and representative for the results obtained 
from two different donors tested. 
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This is the first comprehensive study comparing T cell responses to HAdV hexon peptides in 
the healthy population. The five most frequently recognized peptides identified in this study 
are derived from the conserved part of polypeptide II. The amino acid sequences of these 
peptides were compared between different HAdV serotypes from various species. Peptide 
II42, 50, 61 and 64 show minimal differences between species (Table 3). Peptide II64 
contains the described HLA-DP restricted, epitope II910-924, which is conserved between 
many human and other mammalian adenoviruses (24). Peptides II42, 57 and 61 have not 
been described before as containing major T cell epitopes but are recognized at a high 
frequency (57%, 50% and 64%, respectively). Peptide 50 is recognized at slightly lower 
frequency (36%). No correlation between recognition of peptides and expression of HLA-
DR alleles could be observed. It might be possible that, because 30-mers were used, the 
peptides contain two or more T cell epitopes (42). Another reason for this lack of correlation 
may be due to the fact that the hexon peptides are presented by certain HLA-DP alleles that 
occur very frequently in the population, as described for the II910-924 peptide presented by 
HLA-DP4 (25). Establishment of correlations between HLA class II alleles and peptide 
recognition would require a much larger cohort of donors. However, for this study it was not 
our aim to determine the exact T cell epitopes of polypeptide II, but to select peptides in 
HAdV with broad recognition for culturing HAdV-specific T cell applicable in adoptive 
immunotherapy. 
The results from this study might also have important implications for the use of 
recombinant adenoviral vectors for gene therapy and vaccination. It has been well 
established that pre-existing immunity, especially humoral, against the adenoviral vector can 
limit the application of HAdV5 for both gene therapy protocols and vaccine delivery. To 
circumvent the neutralizing antibody response to the HAdV-based vector different strategies 
are being pursued including the use of other human serotypes (43) and non-human 
adenoviruses (44). Recent studies suggest that T cells may also have a role in limiting the 
potency of HAdV5 gene transfer and vaccine potency (45). Our results indicate that human 
HAdV-specific T cells recognize conserved peptides of the hexon protein and therefore will 
also recognize vectors derived from other serotypes. In a C57/BL6 mouse model, no 
evidence for T cells cross-reactive between HAdV serotypes 5 and 35 was found using 
artificial induction of immunity against HAdV (46). Nevertheless, detailed studies on the 
interaction of HAdV and the human immune system are warranted to better understand the 
influence of cross-reactive T cells on gene therapy procedures and vaccination potency. 










































In allogeneic stem cell graft recipients, HAdV infection or reactivation can be a serious 
clinical problem (1-5). Since medication for HAdV infection is usually not effective, the 
option of transferring HAdV-specific T cells to the infected immunocompromised recipient 
is an attractive option for treatment. A number of studies suggested that it might be possible 
to generate HAdV-specific T cells for adoptive immunotherapy (19,20,47). The 
disadvantage of generating HAdV-specific T cells using infectious wild type HAdV might 
be the transfer of the virus strain to the patient. Introduction of replication-deficient virus 
harbors the risk of recombination with the wild-type virus in the patient. For these various 
reasons, it is very attractive to culture HAdV-specific T cells with HAdV peptides. In the 
present study we demonstrated that HAdV-specific T cells, recognizing wild-type HAdV-
infected cells, can be generated using a panel of only 5 HAdV5 hexon peptides. Thirteen out 
of 14 (93%) healthy adult donors responded to this panel. Since 4 out of 5 selected peptides 
are conserved between HAdV species, the peptide-cultured CD4+ T cells recognized HAdV 
of various species. This is of utmost importance because it is usually unknown in advance 
which serotype will infect a certain patient.  
HAdV peptide-cultured T cells of healthy adults and pediatric patients are CD4+ T cells, as is 
also mainly found for HAdV-stimulated T cells (8,19). The function of these CD4+ T cells 
might be indirect, by cytokine (i.e. IFN-γ) secretion, providing help to B cells or inducing 
maturation of dendritic cells, or direct, by lysis of infected target cells (Heemskerk, in 
preparation). 
In conclusion, a set of five HAdV5 peptides derived from the conserved region of the hexon 
forming protein polypeptide II were recognized by T cells of most adult donors. With this 
peptide pool, HAdV-specific T cells were generated that not only respond to HAdV5 but 
also to other HAdV serotypes belonging to various species. These data suggest that these 
peptides are promising candidates for generating HAdV-specific T cells for adoptive 
immunotherapy, as peptides can easily be generated under GMP conditions. Infusion of 
these HAdV-specific T cells may be a valuable tool to decrease the high mortality rate due to 
HAdV viremia in immunocompromised pediatric patients after allogeneic stem cell 
transplantation. 
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Adenovirus (HAdV) infection is a frequent and potentially severe complication following 
allogeneic stem cell transplantation in children. Since treatment with the antiviral drugs 
ribavirin or cidofovir is often ineffective, adoptive transfer of donor-derived HAdV-specific 
T cells may be an option for therapy of HAdV viremic immunocompromised patients. In 
healthy donors, predominantly CD4+ HAdV-specific T cells are detected. In this study, a 
pre-clinical in vitro model was used to analyze whether HAdV-specific human CD4+ T cells 
have an antiviral effect. CD4+ HAdV-specific T cell clones from 5 different donors were 
generated. These clones all produced IFN-γ and most clones recognized peptides that were 
derived from the conserved part of the hexon protein. HAdV-specific T cell clones were able 
to control viral replication as viral titers in HAdV-infected EBV transformed B cells (B-
LCL) were reduced 100- to 1000-fold in the presence of HAdV-specific T cells. In a co-
culture of T cells with peptide-loaded autologous B-LCL as well as HAdV-infected HLA-
mismatched B-LCL no inhibition of viral outgrowth was observed, suggesting that cognate 
interaction between T cells and target cells was necessary to control viral replication. The 
HAdV-specific CD4+ T cell clones expressed perforin and granzyme B and were able to 
specifically lyse infected target cells using a perforin-dependent mechanism. Together, these 
results show that HAdV-specific CD4+ T cells can control replication of HAdV in vitro and 
provide a rationale for the use of HAdV-specific T cells in adoptive immunotherapy 
protocols for control of life-threatening HAdV-infections in immunocompromised patients. 
INTRODUCTION 
Adenoviruses (HAdV) rarely cause severe clinical symptoms in healthy children and adults 
as infections in immunocompetent individuals are usually self-limiting. However, HAdV 
may cause life-threatening complications in immunocompromised patients (1,2). In recent 
years, the incidence of HAdV infections in pediatric stem cell transplant (SCT) recipients 
has increased remarkably (3-7). Recipients of a T-cell depleted or CD34+ enriched 
allogeneic stem cell graft, i.e. patients with a non-HLA-identical donor, have a higher risk of 
developing HAdV infection and dissemination, due to the delayed immune reconstitution in 
these children after SCT (7,8), and van Tol, manuscript in preparation). Clinical symptoms 
include gastroenteritis, hemorrhagic cystitis, hepatitis, pneumonia, encephalitis and multi-
organ failure. Dissemination of the infection, documented by a rise of HAdV DNA loads in 
plasma, is associated with a fatal outcome (7,9-13).  
Currently, 51 serotypes of adenovirus have been identified, distributed among six species 
(A-F) based on their differential hemagglutination with erythrocytes and their DNA 
homology (14,15). Species A, B and C serotypes are most frequently isolated from pediatric 
immunocompromised hosts and are the major cause of disease (1,7,16-18).  
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Treatment of adenoviral infections with antiviral medication such as cidofovir and ribavirin 
has not been unequivocally effective (reviewed in (19)). Therefore, new strategies to treat 
HAdV infections are needed. A potential approach is adoptive immunotherapy by infusion 
of HAdV-specific lymphocytes. This strategy has already been successfully pursued for 
other viral infections or reactivations such as CMV or EBV (20-22). Furthermore, case 
reports have suggested that donor lymphocyte infusions (DLI) or tapering of 
immunosuppression may contribute to clearance of an HAdV infection, illustrating the 
potential role of T cells in the immune response to HAdV (8,23,24).  
Few reports on HAdV-specific immune responses in healthy donors have been published 
until recently (18,25,26). Current reports on the occurrence and frequency of HAdV-specific 
T cells have shown that predominantly HAdV-specific CD4+ T cells are detected, although 
HAdV-specific CD8+ T cells have been described (27-31). Furthermore, in a previous report 
we have shown the presence of CD4+ HAdV-specific T cells in the blood of patients 
recovering from HAdV infection or viremia (7), suggesting that these cells may be 
functionally involved in clearance of the virus. 
As mainly CD4+ HAdV-specific T cells can be detected in healthy donors and patients after 
SCT, the question arises whether these CD4+ T cells can exert direct antiviral functions and 
if so, by which mechanisms. To study this, we generated HAdV-specific CD4+ T cell clones 
as described previously (30), and determined the HLA restriction, protein and peptide 
specificity of these clones. To investigate the antiviral activity of these T cells, inhibition of 
viral replication in HAdV-infected EBV transformed B cells (B-LCL) or melanoma cells 
was determined in a newly developed in vitro inhibition assay. In this assay, the viral titer 
was determined in cell lysates of HAdV-infected B-LCL after 3 days of culture in the 
presence or absence of an HAdV-specific CD4+ T cell clone. These CD4+ T cells were able 
to inhibit viral replication, which required cognate MHC-peptide interaction. T cell clones 
lysed target cells in a perforin-mediated manner, which could be the mechanism of 
inhibition. Together, these results imply that HAdV-specific CD4+ T cells are a promising 
tool for immunotherapy in immunocompromised patients at risk of developing severe HAdV 
infection. On the other hand, HAdV-specific CD4+ T cells might hamper the efficacy or 
longevity of gene transfer with HAdV-based vectors in gene therapy trials. 
MATERIALS & METHODS 
Cells and viruses 
The human epithelial cell line Hep2 was used to propagate HAdV. Cells were maintained in RPMI 
1640 with glutamax (GIBCO-BRL, Paisley, Scotland, UK) supplemented with 10% heat-inactivated 
fetal calf serum (FCS; GIBCO-BRL), 100 U/mL penicillin and 100 µg/mL streptomycin. HAdV 
strains of serotypes 2 and 5 (species C), 12 (species A) and 35 (species B) (RIVM, Bilthoven, the 
Netherlands) were grown on Hep2 cells and harvested when cytopathological effect (CPE) was 
present. Virus was released from the cells by two freeze-thaw cycles and purified by CsCl density 
gradient centrifugation. Virus stocks were titrated using the plaque assay on 293 cells at the 
Department of Molecular Cell Biology, Leiden, the Netherlands.  
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HAdV-specific T cell clones 
PBMC from healthy blood bank donors (Sanquin, Leiden, the Netherlands) were isolated using Ficoll 
gradient centrifugation. Monocytes were depleted by adherence to plastic for 2 h, after which the 
non-adherent peripheral blood lymphocytes (PBL) were collected and used as responder cells. PBL 
(2×106/well) were added in a 24-well plate (Corning Incorporated, Acton, MA) and stimulated with 
1×105 irradiated (30 Gy) autologous PBMC pre-incubated with methylene blue (MB)-inactivated 
HAdV5 at a multiplicity of infection (MOI) of 10. Cells were cultured for 12 days in RPMI/10% 
human AB medium, harvested, seeded at 2.5×105 cells per well and restimulated with 1×105 HAdV5-
infected stimulator PBMC as before. IL-2 (50 IU/mL, Chiron, Emeryville, CA) was added at day 15 
and replenished twice or three times a week thereafter.  
At day 28, a limiting dilution assay was performed in which cells were plated at a density of 10, 1 or 
0.3 cells/well in 96-well round-bottomed plates (Corning) and stimulated with 1 µg/mL PHA (Murex 
Biotech Ltd., Dartford, UK), 150 IU/mL IL-2 and 1×106/mL irradiated allogeneic PBMC. After two 
weeks, wells with expanding cells were restimulated as before with PHA, IL-2 and allogeneic 
PBMC. Specificity of clones was determined by proliferation as described below, and the phenotype 
of the clones was assessed by flow cytometry (see below). 
 
HAdV-specific proliferation 
T cells (2×104 per well) were plated in 96-well round-bottomed plates in triplicate. As stimulator 
cells, autologous EBV transformed B cells (B-LCL) were resuspended in RPMI with 0.5% BSA at 
5×106 B-LCL/mL, irradiated at 40 Gy and infected for 1 hour (h) at 37°C with HAdV5 at an MOI 
100, or uninfected as control. Hereafter, 5×104 stimulator cells were added per well in RPMI/10% 
AB medium. After 3 days at 37°C and 5% CO2, cultures were pulsed with 0.5 µCi [3H]-thymidine 
(Amersham International, Amersham, UK) per well for 18 h. Plates were harvested (Skatron, 
Sterling, VA) and filters were subsequently counted in a betaplate counter (Wallac, Turku, Finland).  
To determine which protein was recognized by a T cell clone, B-LCL were loaded with recombinant 
hexon protein (protein II, generated in 4 parts as IIA (amino acids (aa) 1-273), IIB (aa 245-509), IIC 
(aa 479-743) and IID (aa 720-952)) (Veltrop-Duits, manuscript in preparation), the penton protein or 
an early protein, E1A, at a final concentration of 5 ug/mL. For peptide recognition, the hexon protein 
was synthesized in overlapping peptides of 30 aa with a 15-aa overlap (Veltrop-Duits, manuscript in 
preparation). Proliferation was determined against B-LCL loaded with pools of 5-6 peptides (5 
ug/mL), and specific peptides were determined from positive peptide pools by loading single 
peptides on B-LCL. 
The HLA restriction element was determined by addition of blocking monoclonal antibodies against 
HLA class I (W6/32), HLA-DR (B811.2), HLA-DQ (SPVL3), and HLA-DP (B7.21) in the 
proliferation assay (antibodies were a kind gift of Dr. A. Mulder, Dept. of Immunohematology and 
Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands) and using partially 
HLA-matched B-LCL as stimulators. 
 
Detection of cytokine production and mediators of apoptosis 
HAdV-specific T cell clones were tested for cytokine production by intracellular staining and flow 
cytometry. T cells (2×105) were stimulated with 1×105 irradiated autologous B-LCL either 
uninfected, infected with HAdV5 at MOI 100, or loaded with the specific peptide in round-bottomed 
polystyrene 5 mL tubes in a total volume of 400 µl. After 1 h, brefeldin A (Sigma-Aldrich, St. Louis, 
MI, USA) was added for 18 h to block exocytosis. Cells were stained on ice and analyzed using flow 
cytometry. Cells were washed with PBS containing 0.2% w/v NaN3, fixed with freshly made 4% 
paraformaldehyde (PFA, Sigma-Aldrich) in PBS for 4 min, and washed twice with PBS/NaN3. Cells 
were permeabilized by washing with PBS/NaN3 containing 0.1% saponin and 0.5% BSA, and non-
specific binding was blocked with PBS/NaN3/saponin/BSA/10% FCS for 10 min. After washing with 
PBS/NaN3/saponin/BSA, antibodies were added: αCD3-PerCP-Cy5.5, αCD4-FITC, αIFN-γ-PE / 
αTNF-α-PE / α-IL-10-PE / αIL-4-PE (Becton Dickinson, Mountainview, CA, USA) and αCD8-
APC (Immunotech, Prague, Czech Republic) and incubated for 30 min. For detection of perforin and 
granzyme B intracellularly, cells were stained with α-perforin-FITC (Hölzel Diagnostika, Köln, 
Germany) or with α-granzyme B-PE (Sanquin, Amsterdam, the Netherlands) in combination with 
αCD3-PerCP-Cy5.5 and αCD4-APC as above. After washing, cells were either fixed in 0.5% PFA or 
analyzed immediately on a FACSCalibur flow cytometer using the CellQuest software (Becton 
Dickinson). 
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The level of secreted IFN-γ in culture supernatant was measured with an ELISA kit (Sanquin, 
Amsterdam, the Netherlands) according to manufacturer’s guidelines.  
 
Chemokine receptor expression on HAdV-specific T cell clones 
Primary antibodies used for chemokine receptor stainings were PE-labeled αCCR3 and unlabeled 
αCXCR6 (R&D Systems, Minneapolis, MN), and unlabeled αCXCR3 (BD Pharmingen, San Diego, 
CA). For detection of the unlabeled primary antibodies, cells were stained with the relevant PE-
conjugated isotype-specific secondary antibody (Southern Biotechnology Associates Inc., 
Birmingham, Alabama), followed by αCD3-PerCP-Cy5.5 and αCD4-APC staining. Cells were 
analyzed on a FACSCalibur flow cytometer using the CellQuest software.  
 
HAdV replication inhibition assay 
To test whether HAdV-specific T cell clones were able to inhibit viral replication, we developed an 
in vitro inhibition assay. B-LCL or a melanoma cell line expressing HLA-DR17, mel juso (MJS, a 
kind gift from Dr. M. Ressing, Dept. of Virology, Leiden University Medical Center, Leiden, the 
Netherlands), were infected with HAdV5 at MOI 100 for B-LCL (5×106/mL) or MOI 10 for MJS as 
described above. MJS cells (1×105) were plated one day prior to infection in the wells of a 24-well 
plate. Infected B-LCL were washed three times with 10 mL RPMI/10% FCS, and MJS three times 
with 1 mL per well to remove free virus. For B-LCL, cells were plated at 1×105 in 500 µl RPMI/10% 
FCS per well of a 24-well plate (Corning). HAdV-specific T cell clone (at an effector to target (E:T) 
ratio of 10:1 unless indicated otherwise) was added in 500 µl RPMI/10% FCS, or medium alone as a 
control for viral replication. In preliminary experiments, cells were harvested daily from day 0 till 
day 6 to determine the kinetics of viral replication in the B-LCL. In later experiments, cells were 
harvested at day 3 after infection. Cells were washed three times with RPMI/10% FCS to remove 
free virus, and virus was released from the cells by two freeze-thaw cycles. The virus titers of cell 
lysates were determined with the tissue culture infective dose of 50% (TCID50 assay). For this, 
lysates were diluted 100 till 108-fold and each dilution was plated in tenfold in 96-well flat-bottomed 
plates. Hep2 cells were added to the wells at 5×103 cells/well. After 7 days of incubation at 37°C and 
5% CO2, wells were scored for the presence of CPE, which indicates infectious virus in those wells. 
The viral titer of each lysate was calculated via the method of Reed and Munch, which determines 
the dilution at which 50% of wells are infected as described elsewhere (30). For detection of 
HAdV12 and HAdV35 viral replication, A549 cells were used to determine the viral titer as these 
viruses do not grow optimally on Hep2 cells. 
In some experiments, a co-culture of autologous B-LCL and HLA-DR mismatched B-LCL was 
performed. To stimulate the HAdV-specific T cell clone, autologous B-LCL were loaded with the 
specific peptide, while the mismatched B-LCL were infected with HAdV5. Viral titers were 
determined in cell lysates to investigate the bystander effect of soluble factors or non-HLA restricted 
recognition on inhibition of viral replication. 
 
Chromium release assay (CRA) 
To determine HAdV-specific cytotoxicity, 51Cr release assays were performed on B-LCL or MJS 
cells. Target cells were infected with HAdV5 at MOI 100 or 10 as described before or loaded with 
peptide at 5 µg/mL and cultured for 16 h. Target cells were labeled with 51Cr for 1.5 h at 37°C and 
washed 3 times with RPMI. Various numbers of effector cells were co-cultured with 2.5×103 B-LCL 
or 1.25×103 MJS/well for 4 h at 37°C and 5% CO2 and 51Cr release was determined in the 
supernatant. Maximal release was determined by addition of 2 N HCl to target cells, and spontaneous 
release was obtained by addition of medium alone. Counts were measured in an automatic gamma 
counter (Wallac). Percentage of specific release was calculated as: [(cpm experimental release – cpm 
spontaneous) / (cpm maximal – cpm spontaneous)] × 100.  
In some experiments, inhibitors of the perforin-mediated lysis were added. Concanamycin A (CMA 
at 50 nM, a kind gift from Dr. J.P. Medema, Dept. of Clinical Oncology, Leiden University Medical 
Center, Leiden, the Netherlands) or EGTA (at 2 mM, Boehringer Mannheim GmbH, Mannheim, 
Germany) were added to the effector cells 1 h prior to co-culture with target cells and CMA or EGTA 




Most HAdV-specific CD4+ T cell clones recognize peptides derived from the hexon 
protein 
HAdV-specific CD4+ T cell clones, generated against HAdV5 (species C), have been 
obtained from several healthy donors as recently described (30). These clones exhibited a 
restricted to broad cross-reactivity pattern against serotypes from different species, most 
clones recognizing serotypes from species A, B and C. To further characterize these clones, 
we investigated which protein of HAdV was recognized using proliferation assays with 
recombinant hexon protein (generated in 4 parts, IIA-D), recombinant penton, and an early 
gene product E1A (Veltrop-Duits, in preparation). Three out of 8 HAdV-specific T cell 
clones were unresponsive to any of these proteins, but the majority of clones (n=5) 
recognized the C-terminal part of the hexon protein (IIC or IID) (Table I and example in 
Figure 1A), which is highly conserved between different species (32,33) and might explain 
the broad cross-reactivity that we observed previously (30).  
 
To further investigate which peptides of the hexon protein were recognized, 64 overlapping 
peptides of 30 aa with 15 aa overlap of the hexon protein (peptides II4-II68) were 
synthesized and tested in proliferation assays. An example is shown in Figure 1B, and results 
Table I. HAdV-specific CD4+ T cell clones with hexon peptides 
and HLA restriction  
T cell clone Donor Hexon protein Hexon peptide HLA restriction 
A1.1 1 -a - DR7 
D1.23 1 - - DR7 
C30.4 2 - - DR7 
A4 0.3-4 3 IIC II44(43)b DR17 
A5 1.32 3 IID II64, 910-924c DP4 
M2.11 4 IID II57 DR17 
K1.2 5 IID II64, 910-924 DP4 
K3.1 5 IID II61 DR17 
a  indicates none of the hexon, penton or E1A proteins were recognized. 
b  indicates that peptide II44 induced the highest poliferation; proliferation to II43 
was observed to a lesser extent suggesting that the minimal epitope resides in 
the N-terminal part of peptide II44. 
c  peptide II64 was recognized as well as the minimal epitope which is present in 
II64, the II910-924 epitope (described in (28)). 
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are summarized in Table I. Two clones recognized II64, which contains a conserved epitope 
II910-924 that has recently been described by Olive et al (28,34). Proliferation was also 
observed against this minimal epitope, indicating that these two HAdV-specific clones 
specifically recognized this II910-924 epitope in peptide II64. HLA restriction of these clones 
was determined by stimulation with HLA-DR or -DP matched B-LCLs or addition of 
blocking antibodies. The T cell clones of which the peptide specificity could not be 
determined were all HLA-DR7 restricted, while the other 5 clones which recognized various 


























Cytokine production and chemokine receptor expression of HAdV-specific CD4+ T cell 
clones 
When the clones were stimulated with HAdV5-infected B-LCL, ~40% of the T cells 
produced IFN-γ and TNF-α as determined by intracellular cytokine staining (Figure 2A). IL-
2 was produced in few cells (Figure 2A), whereas IL-5 and IL-10 was not detected (data not 
shown). Upon stimulation with HAdV5-infected B-LCL, no increase in IL-4 production was 
detectable compared to uninfected BLCL (Figure 2A). When T cell clones were stimulated 
with peptide-loaded B-LCL, >90% of T cells co-expressed IFN-γ and TNF-α. IL-2 
production was strongly increased, while IL-5 and IL-10 remained undetectable (Figure 2B 


























































































) Figure 1. Most HAdV-specific CD4+ T cell clones recognize 
peptides in hexon protein 
(protein II). A) T cells from clone 
A5 1.32 were tested in a three-day 
proliferation assay against 
autologous B-LCL infected with 
HAdV5 or loaded with 
recombinant proteins from hexon 
(IIA-D), the penton protein (III), 
or the early E1A protein. 
Proliferation, as measured by [3H]-
thymidine incorporation, was only 
observed against HAdV and the 
recombinant IID protein. B) Clone 
A5 1.32 was further tested for 
proliferation against autologous B-
LCL loaded with 30 aa peptides 
from the IID protein, and was 
found to proliferate exclusively 
against peptide II64. This peptide 
contains a minimal epitope 910-
924 as recently described (28), 
which was found to be the epitope 
for this clone. Results are 
representative for 5 clones. 
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In agreement with the cytokine production pattern, HAdV-specific T cell clones expressed 
the chemokine receptors CXCR3 and CXCR6 on their surface, while the chemokine receptor 
CCR3 was expressed on <10% of cells (Figure 2C and data not shown). CXCR3 is reported 
to be expressed on CD4+ T cells early after commitment to a Th1 phenotype, and the 
presence of CXCR6 has also been correlated with CD4+ T cells with a Th1 phenotype, 
predominantly in the liver (35-37). The other chemokine receptor, CCR3, has been reported 
on Th2 cells (38,39). Together, the phenotype and cytokine profile of the HAdV-specific T 




























Inhibition of HAdV replication in vitro 
If HAdV-specific CD4+ T cells will be administered to patients as adoptive immunotherapy, 
these T cells are required to have antiviral functions in order to combat the infection in vivo. 
Figure 2. HAdV-specific CD4+ T cell clones secrete IFN-γ and TNF-α and express the 
chemokine receptors CXCR3 and CXCR6. A) Autologous B-LCL were infected with HAdV5 at 
MOI 100 or uninfected as control. T cells from clone M2.11 were added for 16 hr, and cytokine 
production was determined with intracellular cytokine staining using α-IFN-γ-PE, α-TNF-α-PE, α-
IL-2-PE or α-IL-4-PE in combination with α-CD4-FITC. The percentage of CD4+ T cells producing 
a specific cytokine is shown in the upper right quadrant. B) T cells were stimulated with B-LCL 
loaded with the specific peptide II57. Intracellular cytokine staining was performed with α-IFN-γ-
FITC in combination with α-TNF-α-PE, and α-IL-2-PE in combination with α-CD4-FITC. C) 
Chemokine receptor expression was determined on HAdV-specific T cell clones. Shown are CXCR3 
and CXCR6 expression (filled histogram). As a control, secondary antibodies were added to 
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To investigate whether HAdV-specific CD4+ T cell clones can exert antiviral activity, an in 
vitro inhibition assay was developed which determines the effect of these T cell clones on 
HAdV replication. HAdV replication in B-LCL was determined by measuring the virus titers 
in cell lysates daily from day 0 till day 3 after infection. HAdV virus titers increased 100- to 
1000-fold in 3 days. When an HAdV-specific T cell clone, A1.1, was added to autologous 
infected B-LCL at an E:T ratio of 10:1, viral titers were more than 1000-fold reduced (Figure 
3A). Prolonging the experiment till 6 days resulted in a similar reduction in titer when T 
cells were added (data not shown). Therefore, in further experiments cells were harvested at 
day 3 and viral titers were compared between infected B-LCL cultured alone or in the 
presence of T cells. The inhibitory effect of the CD4+ T cell clones was dependent on the 
number of T cells present, as shown with different E:T ratios. At an E:T ratio of 1 T cell per 
B-LCL, viral replication was inhibited significantly, whereas inhibition could no longer be 
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Figure 3. Inhibition of viral replication in B-LCL by HAdV-specific CD4+ T cell clones is HLA-
restricted. The antiviral activity of T cell clones was tested in a three-day in vitro assay in which 
viral replication was assessed. A) Autologous B-LCL were infected with HAdV5 at MOI 100 and 
cultured for three days in the presence (■) or absence (♦) of T cell clone A1.1 at an E:T ratio of 10:1. 
Cell lysates were obtained on day 0, 1, 2 and 3 and the titer of infectious virus on Hep2 cells was 
determined with the TCID50 assay. B) Autologous B-LCL were infected with HAdV5 at MOI 100 
and cultured for three days in the presence of the T cell clone K3.1 at different E:T ratios of 10:1, 1:1 
and 0.1:1. At day 3, cell lysates were harvested and viral titers were determined. C) Autologous B-
LCL, HLA-DR matched B-LCL or HLA-mismatched B-LCL were infected with HAdV5 at an MOI 
100 and used in the in vitro assay at an E:T ratio of 10:1. At day 3, cell lysates were harvested and 
viral titers were determined. Two representative examples are shown out of 4 clones (A1.1, M2.11, 
K3.1, A5 1.32) tested. 
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Strong reduction in viral titers was not only observed when autologous B-LCL were used, 
but also when HLA-DR or -DP matched B-LCL (depending on the clone) were used (Figure 
3C). However, viral titers were not reduced when mismatched B-LCL were applied as target, 
indicating that inhibition of viral replication is HLA-restricted (Figure 3C). 
 
Cognate interaction required for inhibition of viral replication 
To elucidate potential mechanisms by which these HAdV-specific CD4+ T cell clones exert 
their antiviral effect, we investigated whether cognate interaction between T cells and target 
cells was required or whether the inhibition of viral replication could be achieved by soluble 
factors produced by the T cells or via non-specific cell-cell contact. Therefore, a co-culture 
experiment was performed with autologous B-LCL loaded with the specific peptide together 
with HLA-mismatched B-LCL infected with HAdV5. In this setting, T cell clones were 
stimulated by the peptide-loaded autologous B-LCL, while the viral replication was assessed 
in the HLA-mismatched B-LCL. Any factor secreted by the peptide-stimulated T cells 
should then directly exert the potential effect on the virus production in HAdV-infected 
HLA-mismatched B-LCL. As a control, the virally infected B-LCL was, like the peptide-
loaded B-LCL, of autologous origin. As expected, a >1000-fold reduction in titer was seen in 
the control experiment in which T cells were co-cultured with peptide-loaded as well as 
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Figure 4. Inhibition of viral replication is not mediated via soluble factors. In a co-culture 
experiment, autologous B-LCL were loaded with the specific peptide (+P) in order to stimulate the 
HAdV-specific T cell clone K3.1. In the same well, HLA-DR mismatched B-LCL were added which 
were infected with HAdV5 at MOI 100. In control wells, HAdV-infected autologous B-LCL were 
added which could directly be recognized by the T cell clone. T cells were added at an E:T ratio of 
10:1. Viral titers were determined in cell lysates at day 3. Similar results were obtained with clone 
M2.11. 
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When the virus was present in the mismatched B-LCL, however, only a slight reduction in 
viral titer was observed (Figure 4), even though T cells were strongly stimulated with the 
peptide presented by autologous B-LCL as measured by IFN-γ production in the supernatant 
(~50 ng/mL IFN-γ). Together, these results indicate that the antiviral effect of HAdV-
specific CD4+ T cell clones does not seem to be mediated by soluble factors (such as IFN-γ) 
or non-HLA-restricted cell-cell contact. Thus, cognate interaction between the T cell and the 
target cell appears to be required to achieve an antiviral effect.  
 
Lysis of HAdV-infected target cells 
As HLA-restricted recognition of target cells as well as cell-cell contact appeared to be 
essential for the antiviral function of the T cell clones, we investigated whether these HAdV-
specific CD4+ T cell clones had cytolytic activity against infected target cells. Maximal lysis 
of HAdV5 infected B-LCL was usually low (<30%) (Figure 5A), but this observation is 
probably due to the fact that HAdV infection of B-LCL is inefficient and results in ~5-10% 
infected cells as visualized by immunohistochemistry (40) (and data not shown). However, 
when B-LCL were loaded with the specific 30-aa peptide, lysis increased to ~80% or more 
(Figure 5B). A melanoma cell line, mel juso (MJS), that is more easily infected (>90% 
infected cells, data not shown) and expresses HLA-DR17, was used to further investigate 
lysis of HAdV-infected cells. Using these targets, lysis of HAdV5-infected MJS by the CD4+ 
HAdV-specific T cell clones was as efficient as lysis obtained with the peptide-loaded B-
LCL (Figure 5C).  
Mechanisms of contact-dependent T cell induced death of target cells include release of 
preformed vacuolar perforin and granzymes into the intercellular space and up-regulation of 
cell surface molecules such as Fas ligand and TRAIL (41-43). The perforin effector pathway 
can be inhibited by the action of concanamycin A (CMA), which raises the pH in 
intracellular vacuoles and inactivates perforin, as well as by EGTA which binds intracellular 
calcium that is required for release of perforin (44). Lysis was almost completely abrogated 
by either of these inhibitors, indicating that these CD4+ T cells lyse predominantly using the 
perforin pathway (Figure 5D and data not shown). The presence of both perforin and 
granzyme B in the cytoplasm of HAdV-specific T cell clones was confirmed by intracellular 
staining, supporting their role in HAdV-specific lysis (Figure 6).  
 
Inhibition of viral replication of different serotypes by HAdV-specific T cell clones 
Most HAdV-specific T cell clones raised against HAdV5 were highly cross-reactive towards 
many serotypes in proliferation assays as described recently (30). The peptide specificity 
found in the present study supports these results since most peptides are located within the 








































To analyze whether the T cell clones are not only cross-reactive in proliferation assays, but 
are also able to inhibit viral replication of different serotypes, viral replication inhibition 
perforin granzyme B
Figure 6. HAdV-specific T cell 
clones express perforin and 
granzyme B. Intracellular FACS 
staining was performed on T cell 
clones. Cells were stained with 
α-perforin-FITC or α-granzyme 
B-PE (filled histograms) or 
unstained as control (open 
histograms). Shown is one 
example out of 3 T cell clones 
(A1.1, M2.11 and K3.1) tested. 
Figure 5. HAdV-specific T cell clones lyse HAdV-infected or peptide-loaded targets using the 
perforin-pathway. A) HLA-DR matched (DR7/DR17 positive) B-LCL were infected with HAdV5 
at MOI 100 (●), loaded with peptides II61 (▼) and II64 (▲) or uninfected (♦) as controls since this 
clone does not recognize any peptide in the hexon protein, and used these targets in a 4 h 51Cr-
release assay (CRA). T cells from clone A1.1 were added at different E:T ratios and the percentage 
of specific lysis is shown. B) The same targets as in A were used in a CRA with T cells from clone 
K3.1 at different E:T ratios. C) MJS cells (HLA-DR17) were infected with HAdV5 at MOI 10 (●), 
loaded with specific peptide II57 (■), or uninfected as control (♦) and used as targets in a CRA with 
T cells from clone M2.11 as effectors. D) T cells from clone M2.11 were pre-incubated with 50 nM 
CMA for 1 h prior to addition of T cells to MJS target cells in medium containing CMA. Lysis 
results in (A) are representative of 8 T cell clones tested against HAdV5, and in (B) of 5 clones that 
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assays with multiple serotypes from different HAdV species were performed. As not all 
serotypes tested were able to replicate in B-LCL, the MJS melanoma cell line was used in 
these experiments. A broadly cross-reactive HAdV-specific T cell clone, K3.1, was able to 
inhibit viral replication of HAdV5 as well as HAdV2 (belonging to the same species C), 
HAdV12 (species A) and HAdV35 (species B) (all >1000-fold reduction of titer), 
confirming that T cell clones showing cross-reactivity in proliferation assays can exert cross-
reactive antiviral activity as well (Figure 7). These results are promising for adoptive 
immunotherapy, as T cells generated against HAdV5 could also be effective in patients 

















In this study, human HAdV-specific CD4+ T cell clones have been extensively characterized 
for their effector functions and antiviral activity. HAdV infection in immunocompromised 
patients is a severe complication, especially in pediatric patients following SCT (3-7). As 
medication with ribavirin or cidofovir is frequently ineffective (reviewed in (19)), 
immunotherapy might be a promising option for treatment. In healthy donors as well as in 
patients that cleared HAdV infection, mainly CD4+ HAdV-specific T cells are detected 
(7,27,30,31). To date, however, it has not been investigated whether and by which 
mechanism CD4+ HAdV-specific T cells are capable of mediating antiviral activity, which 
would be required for optimal immunotherapy. Therefore, HAdV-specific CD4+ T cell 
clones from healthy donors were generated against HAdV5 and characterized for their 
recognition of specific peptides from HAdV, their phenotype and their antiviral function. 
Most of our T cell clones reacted against peptides that are in the C terminal part of the hexon 
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Figure 7. Inhibition of viral replication of serotypes from different HAdV species. MJS were 
infected at MOI 10 with HAdV5 and HAdV2 (both species C), HAdV12 (species A) and HAdV35 
(species B). Inhibition of viral replication of these serotypes was tested using the T cell clone K3.1 at 
an E:T ratio of 10:1. Viral titers were determined in cell lysates at day 3. 
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protein, which is in accordance with other reports showing that the hexon protein is 
recognized by CD4+ T cells (28,45) (Veltrop-Duits, manuscript in preparation). 
The cytokine profile of the HAdV-specific CD4+ T cell clones suggested that these T cells 
have a Th1 phenotype as they produced large amounts of IFN-γ and TNF-α, as well as IL-2 
upon peptide stimulation. Furthermore, detailed analysis of chemokine receptor expression 
indicated a Th1 phenotype as the T cell clones cells expressed CXCR3 and CXCR6 (35,37).  
To determine whether CD4+ HAdV-specific T cells were capable of mediating antiviral 
activity, we developed an in vitro assay in which the effect of T cells on viral replication was 
investigated. Viral titers were determined in cell lysates of infected B-LCLs, which have the 
advantage that they can be obtained with almost all HLA alleles and have previously been 
shown to be able to facilitate a productive infection (46). Addition of a T cell clone at a 10:1 
or 1:1 ratio had a strong impact on viral replication by reducing replication >1000-fold 
(99.9% inhibition of viral outgrowth). This antiviral activity by the CD4+ T cell clone was 
HLA-restricted as viral replication in infected mismatched B-LCL was not inhibited. In the 
co-culture experiments, peptide-stimulated T cells were in close proximity to HAdV5-
infected B-LCL without the proper HLA-restriction element, allowing detection of a possible 
effect of all short-range factors and/or non-specific cell-cell contact. As viral titers were not 
reduced in this setting, cognate interaction between the CD4+ T cell clone and the HAdV-
infected B-LCL appeared to be required for the antiviral effect. Furthermore, these CD4+ T 
cell clones were able to lyse infected targets (B-LCL or MJS), which could completely be 
inhibited by obstructing the perforin pathway, suggesting that lysis of target cells appeared to 
be the mechanism of the observed in vitro inhibition of viral replication. 
In other viral infections such as CMV and EBV infection, many reports on virus-specific 
CD8+ T cells have been published (reviewed in (47)). Nevertheless, in recent years a 
growing number of reports on virus-specific CD4+ T cells with lytic activity have been 
published for EBV, CMV, and HSV (48,49), which in some reports have been shown to 
inhibit viral outgrowth in vitro (50,51). The cytolytic pathway used by human CD4+ T cells 
is less well defined than in mice, where the FAS pathway is most important for CD4+ T cell-
induced lysis (42). Most reports indicate that perforin-mediated lysis is the main mechanism 
of human cytotoxic CD4+ T cells, either directly ex vivo (52) or in cell lines or clones 
(48,49,53), while some CD4+ T cell clones have been shown to utilize the FAS pathway 
(50). In this respect, it is noteworthy that HAdV has developed immune evading 
mechanisms. The early protein E3-gp19K has been reported to downregulate MHC class I 
expression by retention of MHC molecules in the endoplasmic reticulum, which might result 
in reduced recognition of the infected cell by CD8+ T cells and, conversely, in increased NK 
cell recognition (reviewed in (54)). Another early E3 protein complex, the RIDα/β (receptor 
internalization and degradation) complex, has been reported to internalize FAS, TNF-RI and 
TRAIL-R and induce their degradation, thereby circumventing FAS or TRAIL mediated 
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lysis of infected cells (55). In view of these immune evasion strategies of HAdV, it is not 
surprising that HAdV-specific CD4+ T cells are present that have antiviral activity against 
HAdV by mediating lysis of infected cells using the perforin-pathway. Nevertheless, HAdV-
specific CD8+ T cells have been described (31), indicating that these viral evasion 
mechanisms may not be absolute. In vivo, the CD4+ T cells described here may provide help 
to these HAdV-specific CD8+ T cells indirectly by maturing DC via CD40-CD40L 
interactions (56,57). 
As HAdV infects primarily epithelial cells, which under normal conditions do not express 
HLA class II molecules, the question arises how HAdV-specific CD4+ T cells would be able 
to recognize their infected targets. Several mechanisms might be induced which result in 
class II expression on these cells. First, the HAdV infection itself induces the cell to produce 
IFN-α or -β and other stress proteins, which might also induce the upregulation of class II 
expression. Preliminary data from our group obtained in post-mortum biopsies from patients 
which succumbed to HAdV infection showed in some cases that HAdV-infected cells were 
also HLA class II positive (Heemskerk, unpublished data); however, these findings will need 
to be confirmed and require further investigation. Second, when CD4+ T cells have been 
activated by antigen-presenting cells in the draining lymph node and return to the site of 
infection, the IFN-γ produced by these T cells is able to induce class II upregulation in 
infected and uninfected epithelial cells (58).  
In conclusion, HAdV-specific CD4+ T cell clones have antiviral activity as they were able to 
inhibit viral replication in vitro, which required cognate HLA-peptide interactions and is 
most likely dependent on perforin-mediated lysis. The cross-reactive inhibition of viral 
replication with serotypes from different species by the CD4+ T cell clones generated against 
HAdV5 is encouraging for the clinical application of these cells in immunocompromised 
patients. The observed cytolytic activity and cross-reactivity of HAdV-specific CD4+ T cell 
clones have implications for gene therapy trials with HAdV-based vectors as well, as the 
longevity of gene expression might be reduced when HAdV-specific CD4+ T cells are 
present that could eliminate the transduced cells. For monitoring HAdV-specific responses 
ex vivo in the future, it might be useful to determine the minimal epitopes present in the 30 
aa peptides and to generate HLA class II tetramers. These investigations are currently being 
addressed in our laboratory so that infusion of HAdV-specific T cell lines with antiviral 
activity in immunocompromised patients suffering from disseminated HAdV infection post-
transplant is a feasible option for immunotherapy in the near future.  
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Stem cell transplantation is the preferable curative therapy for a great number of disorders of 
the hematopoietic system in children. More diseases may be eligible for SCT in the future, 
and most likely more transplants will be performed with alternative donors than MFD as 
these donors are frequently not available. This large number of non-MFD transplantations 
requiring manipulation of the graft implies that infections will remain a major problem in 
these prolonged immunocompromised graft recipients. HAdV infections will probably 
account for a substantial part of morbidity and mortality within the infections or 
reactivations with viruses post-SCT in the future. Interestingly, HAdV has only recently 
emerged as an important pathogen, whereas other viruses such as EBV and CMV have been 
known for many years to cause complications after transplantation (van Tol et al., 
submitted). Several explanations for this apparent increase in HAdV infections can be given. 
Improved therapy for EBV and CMV infections in recent years might have opened a window 
for other viruses to cause severe infections (1-3). Also, in recent years more high-risk 
transplants with other than MFD donors have been performed, resulting in a prolonged 
immunocompromised state of the recipient, which might be responsible for the increased 
incidence of HAdV infection. Another possibility could be a change in policy with regard to 
removing the adenoids and tonsils in children, as T cells in tonsils and adenoids have been 
reported to contain DNA from HAdV species C in 79% of specimens (4). Therefore, these 
organs might represent a reservoir of HAdV from which the virus can reactivate. Before the 
mid-nineties, these lymphoid organs were surgically removed in almost all children with 
upper respiratory tract problems, while in recent years a more restricted policy of surgical 
removal has been applied. As a result, many children are being transplanted nowadays with 
their adenoids and tonsils still present. Unfortunately, we were not able to investigate this 
hypothesis in our retrospectively or prospectively studied patients, nor have others reported 
on a possible relationship between the presence of tonsils/adenoids and HAdV infection. In 
this respect, the question where the virus originates from is relevant. The virus might 
reactivate in the recipient, be introduced via the graft from the donor, or be introduced from 
the environment inducing a de novo infection. If the virus reactivates from the host, this 
reactivation may originate from the HAdV reservoir in adenoids and tonsils. However, even 
though viral DNA was detected in T cells derived from tonsils, the presence of infectious 
virus was rare (4). The authors hypothesized therefore that these cells might contain HAdV 
in a quiescent or perhaps latent form. Whether latency exists and by which mechanism the 
virus might reactivate is not known yet, but the use of TBI and chemotherapy in the 
conditioning for SCT might possibly damage the lymphoid tissues of tonsils and adenoids 
and release virus particles. Alternatively, the conditioning - especially melphalan (Chapter 3) 
- may damage gut tissues which might harbour persistent HAdV particles that are 
responsible for intermittent secretion of HAdV in the feces in healthy individuals (5). If the 
virus is derived from the host, this would implicate that the virus is present in the inoculum 
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of the SCT graft, most likely the lymphocytes. In an international collaborative EU study 
from 2003 onwards, prospective follow-up of HAdV infection in children is being performed 
in our center as well as investigation of the presence of HAdV in grafts by quantitative PCR. 
The presence of viral DNA (in low titers) has been observed in 2 grafts from 41 donors 
tested. However, these patients did not develop HAdV infections (unpublished data). 
Therefore, it seems unlikely that the viral DNA is present in the graft or that it is responsible 
for reactivations in the recipient. The third hypothesis, i.e. that the virus is a de novo 
infection from the environment, seems unlikely in the case of an HAdV infection early post-
SCT. During this period, patients are kept in strict isolation to prevent infections. As we have 
observed in almost all patients in whom the virus disseminated, the virus was already 
detected within the first 4 weeks after SCT (Chapter 3), suggesting that early reactivation of 
HAdV was present instead of a de novo infection. To further differentiate between donor 
versus recipient origin, results of serological studies may be helpful. A reactivation of HAdV 
from the recipient is likely if the donor does not possess NAb against the particular serotype 
causing the infection early post-SCT, indicating that the donor has not been in contact with 
that serotype recently. Conversely, if the recipient has no NAb to the infecting virus but the 
donor does, these serological data might suggest that the virus was present in the graft and 
proceeded to initiate a new infection in the patient. In one study, a correlation was found 
between the presence of antibodies against HAdV in the donor (measured by ELISA) and the 
occurrence of HAdV infections in the recipient (6). However, we were not able to confirm 
this correlation using the same ELISA which detects all antibodies against HAdV 
(unpublished observations). Furthermore, our data on the presence of NAb in patients and 
donors have so far not been conclusive as most donors and patients had NAb against the 
infecting serotype (as well as other serotypes) in their serum pre-SCT (Chapter 3 and 
unpublished observations). More patients are currently being investigated in the prospective 
EU study mentioned above. 
It is also remarkable that HAdV infection poses such a threat in children after SCT, but 
appears to be of limited impact in adult recipients of an SCT (7-9). If the hypothesis about 
the reactivation of HAdV from adenoids is true, then this could also explain why adult 
patients do not suffer from HAdV reactivations, as these lymphoid organs were probably 
removed in their youth, or at least reduced in size due to atrophy. An alternative explanation 
could be that adults have less HAdV present in their lymphoid organs, as Garnett et al. 
observed a lower amount of viral DNA in lymphocytes from older children. This is most 
likely due to the fact that young children are infected with different serotypes of HAdV more 
frequently and more recently (5), as attending day care centers has been reported to be a 
source of HAdV outbreaks among children (10). If the virus is transferred from donor to 
recipient, it is likely that an adult recipient will have been infected with that serotype at some 
point during life, in which case the adult recipient has immunity against that serotype, 
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whereas a pediatric recipient may not, which results in a primary infection with an HAdV 
serotype and a greater challenge to the immune system. The question is whether any residual 
immunity against HAdV remains after conditioning treatment of a patient prior to SCT, 
which will also depend on the type of conditioning (myeloablative or reduced intensity) that 
is given. In a young child with mixed chimerism after SCT for acute lymphoblastic 
leukemia, we observed an HAdV-specific T cell response at 12 weeks after SCT. 
Surprisingly, HAdV-specific T cell clones generated from this time point were derived from 
T cells originating from the patient instead of the donor (Chapter 3, Figure 4, patient 16 and 
unpublished data). Immune responses to CMV and Candida albicans from recipient origin 
have also been observed in children after an UCB-SCT, in which mainly naive T cells from 
donor origin are transferred to the recipient (11). In addition, plasma cells, residing in the 
bone marrow, may remain present for years after SCT and could be a source of ongoing 
NAb production after SCT. However, consumption of such antibodies by the infecting virus 
appeared to occur in the absence of an immune response post-SCT (Chapter 3, Figure 3, 
patient 20).  
 
The increasing frequency of HAdV infections and the high mortality of disseminated 
infection, reflected by an increase in viral DNA load in the blood of patients, warrant 
investigations to improve HAdV-specific antiviral therapies. Several possibilities for 
treatment will be discussed in the section below. 
HAdV infection might be treated with antiviral drugs. So far, two drugs, ribavirin and 
cidofovir have been tested in relatively large cohorts of patients. Some reports suggested that 
ribavirin might have an antiviral effect against HAdV (12,13). However, results obtained in 
this thesis showed that lymphocyte recovery was associated with clearance of the virus 
(Chapter 3), and data on lymphocyte recovery were lacking in studies on ribavirin efficacy. 
Using sensitive RQ-PCR techniques to determine viral DNA loads, the use of ribavirin as an 
antiviral drug turned out to be ineffective as administration of this drug did not result in a 
decrease of the viral load in the absence of lymphocyte recovery (Chapter 4). In addition, a 
report on the in vitro susceptibility of HAdV serotypes to ribavirin treatment showed that 
serotypes belonging to species C were more sensitive to ribavirin than other species (14). 
This might explain the somewhat controversial findings on efficacy of ribavirin in vivo, for 
example in a report that showed inefficacy of ribavirin in patients infected with HAdV11 
(species B) or HAdV12 (species A) (15). In the collaborative EU study, additional data on 
ribavirin efficacy will be obtained via the in vitro testing of susceptibility of clinical HAdV 
isolates to ribavirin, as well as by studying the pharmacokinetics of ribavirin administration 
in vivo. Similar tests are being performed for cidofovir, which has been shown to have 
antiviral activity in vitro and in vivo in animal models (16,17). Several studies have recently 
been published in which an antiviral effect of cidofovir was reported in patients without 
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significant T cell reconstitution (18,19). So far, only one report on cidofovir treatment has 
been published in the context of HAdV viral load monitoring during treatment, which 
reported a success rate of 63% (20). Unfortunately, as data on immune recovery were 
lacking in this report, the possibility of viral clearance by the immune system cannot yet be 
ruled out. Therefore, further investigation of this drug as a first-line pre-emptive treatment 
for patients at risk for HAdV dissemination is needed in which the efficacy of cidofovir is 
evaluated by monitoring HAdV viral loads in plasma together with the recurrence of 
lymphocyte counts and subsets. These studies also need to address the occurrence and 
severity of renal toxicity that has been described for cidofovir treatment (overall renal 
toxicity of ~26% in pediatric SCT recipients) (19). In our clinic, patients have been 
prospectively monitored from 2003 onwards in the context of the EU collaborative study of 
HAdV infections. When patients develop viremia exceeding 1000 copies/mL in two 
consecutive plasma samples, treatment with cidofovir is initiated. At the time of writing, 6 
patients have been treated with cidofovir (until November 2004). Preliminary data show that 
in 5 HAdV viremic patients with lymphocyte recovery, cidofovir treatment resulted in a 
decrease of the viral load. However, cidofovir treatment in one patient without any 
lymphocyte recovery (<0.1×109/L) was unsuccessful, suggesting that lymphocyte recovery 
might be more important for clearance of the disseminated infection than cidofovir treatment 
(unpublished observations).  
The encouraging results with DLI infusions indicate that transfer of immunity from donor to 
host can be effective as a treatment for disseminated HAdV infection (21,22). However, the 
risk of inducing GvHD is high in the case of an HLA-mismatched donor-recipient 
combination ((23) and unpublished observations). To circumvent the transfer of alloreactive 
T cells, most studies focus on transfer of HAdV-specific T cells (24-26), but passive transfer 
with NAb specific for the serotype infecting the patient might also be an option for treatment 
as has been suggested in a case report (27). Our data indicate that high titers of pre-existing 
NAb are not sufficient to prevent HAdV infection, dissemination or death post-SCT 
(Chapter 3 and unpublished data), but these NAb will most likely be consumed by the HAdV 
in the absence of an active humoral immune response of the host. However, it is not yet clear 
whether high-titered NAb can be obtained, either from serum of healthy donors or generated 
in vitro by the use of, for example, phage libraries. Administration of pooled 
immunoglobulins from healthy donors (IVIG) was not effective for the prevention of 
infection and death, but these concentrated stocks of IVIG batches usually contain NAb with 
a titer of ~256-512 against the common serotypes HAdV1, 2 and 5 (unpublished data). After 
administration, these IVIG will be diluted in vivo. Nevertheless, if it were feasible to 
generate stocks with very high NAb titers, infusion of these stocks might be effective in 
preventing spreading of the infection in the patient. An additional problem that arises if this 
approach would be pursued is the great variability in HAdV serotypes. Currently, 51 
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serotypes are known, many of which can cause severe infections after SCT, especially 
serotypes from species A, B and C. Most commonly HAdV1, 2, 5, 6, and 31 are detected, 
and to a lesser extent HAdV3, 11, and 12. In studies performed in the US, HAdV35 has been 
reported as a frequently detected pathogen (9), while this pathogen is largely absent in 
European studies. Furthermore, serotyping of HAdV strains cultured from frequently 
obtained feces samples of individual HAdV-infected patients has in some cases resulted in 
the detection of several serotypes within one patient (up to 5 different HAdV serotypes; 
unpublished observations). Interestingly, patients with sequential infections with multiple 
serotypes usually survive the infection. Since NAb are only specific for one serotype, it 
would be very laborious and expensive to have high-titered NAb stocks available for each 
serotype. 
These problems are less pronounced when HAdV-specific T cells will be used for adoptive 
immunotherapy. CD4+ HAdV-specific T cells, generated against HAdV5, were able to cross-
react against HAdV from species A, B, C and D (Chapter 5, 6 and 7), which is in agreement 
with other reports (26,28). It has been proposed that exposure of individuals to consecutive 
infections with different strains of a virus will result in repeated cycles of stimulation and 
expansion of those T cells that recognize epitopes shared between different serotypes (29). 
On the other hand, T cells recognizing strain-specific epitopes will only be stimulated by 
infections with that particular strain. This mechanism provides a relative survival and/or 
growth advantage for T cells that are specific for shared epitopes. In this way, consecutive 
infections with different strains of HAdV could explain the observed cross-reactivity. This is 
of great importance as it is not yet possible to predict which HAdV serotype will infect a 
patient, and serotyping of an infecting strain as well as generation of HAdV-specific T cells 
requires time. A possibility would be to perform a serotype- or species-specific PCR on 
feces of the patient pre-SCT in order to investigate which serotypes are present in the feces 
and thus to predict which serotype might reactivate post-SCT. However, in a report by Lion 
et al., PCR was performed on feces but HAdV DNA could only be detected in feces prior to 
SCT in 10 out of 132 patients tested (30). The observed cross-reactivity of the HAdV-
specific CD4+ T cells might also have important implications for the use of recombinant 
adenoviral vectors for gene therapy and vaccination. Pre-existing humoral immunity against 
the adenoviral vector can limit the application of HAdV5 for both gene therapy protocols 
and vaccine delivery. To circumvent the neutralizing antibody response to the HAdV-based 
vector, vector backbones of other human serotypes (31-33) and non-human adenovirus 
serotypes (34) are being developed for gene therapy. As the HAdV-specific T cells recognize 
conserved peptides of the hexon protein, these cells could limit the potency of HAdV gene 
transfer and vaccine delivery, irrespective of the serotype of the vector backbone (Veltrop-
Duits, unpublished observations). Detailed studies on the interaction of HAdV and the 
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human immune system are warranted to better understand the influence of cross-reactive T-
cells on gene therapy procedures and vaccination potency. 
 
Since a major part of this thesis focuses on adoptive immunotherapy for patients that 
otherwise succumb to the infection, what can be learned from the patients that survived a 
disseminated infection? In other words, which immunological factors may have been 
important in patients that cleared the HAdV infection? In the 5 patients who were included 
in the current cidofovir study and survived the infection, 8 episodes of viral dissemination 
were documented. Interestingly, subset analysis of the lymphocytes present during these 8 
episodes revealed that T cells were absent in 6 episodes, whereas NK cells were present in 
all episodes (unpublished observations). In the cases where only NK cells were present, viral 
DNA was detected for prolonged periods in the plasma, but the viral DNA titers remained 
either stable or decreased. Likewise, in the patient group described in Chapter 3, one patient 
cleared disseminated HAdV infection at week 10 after SCT. In this patient, only 2-3% T 
cells were detected in the blood until week ~30 after transplant, whereas NK cells were 
rapidly reconstituted (Chapter 3, Figure 4, patient 17). In another patient, the absence of a 
humoral response until week ~50 after SCT (due to αCD20 treatment for an EBV 
reactivation) did not hamper the clearance of the virus from the blood at 10 weeks after SCT, 
although prolonged viral shedding from the feces was observed (Chapter 3, Figure 4, patient 
18). Which population of lymphocytes (T cells, NK cells) is required for the initial reduction 
of a viral titer in plasma, or whether the presence of antibodies is required for the clearance 
of the virus from the gut remains to be studied in further detail. No data on NK cell reactivity 
against HAdV in humans has been published yet, although it can be envisaged that the MHC 
class I reduction induced by the virus will result in an increased recognition by NK cells 
(35); T cell reactivity could only be detected several weeks after viral clearance from the 
plasma (Chapter 3). An explanation for the delayed detection of the CD4+ T cell responses 
could be that CD4+ T cell responses were initiated earlier, but that the detection of these cells 
ex vivo was not optimal, possibly because the frequency of HAdV-specific T cells in the 
circulation was too low or that cells were unresponsive in vitro. This unresponsiveness might 
be due to the fact that patients received immunosuppressive medication (e.g. CsA to prevent 
GvHD), which could explain the severely impaired proliferative responses to polyclonal 
stimuli such as PHA or αCD3 in the first months after SCT. Alternatively, it could be that 
the HAdV-specific CD4+ T cells were present in the infected tissues at the time of viral 
clearance, and only redistributed in the circulation after the infection was cleared. The 
kinetics of the redistribution of virus-specific CD4+ T cells could be different from that of 
virus-specific CD8+ T cells which have been observed in the blood of patients with CMV 
and EBV infection at the time of viral clearance (36,37). Another possibility could be that 
NK cells prove to be essential in the initial control of the viremia shortly after SCT, while 
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the development of specific T cell immunity only develops in a later phase after SCT. An 
important role for NK cells in containing viral infections has already been observed for other 
viruses such as herpesviruses, and is best illustrated by a case-report of a patient with a 
complete absence of NK cells who succumbed to severe herpesvirus infections at an early 
age (38-40). 
Nevertheless, it remains surprising that the majority of HAdV-specific T cells that were 
detected consisted of CD4+ T cells, both in patients and in healthy donors. Even the use of 
different culture protocols, including different cells for presentation such as DCs or 
monocytes, addition of cytokines or ligands such as low-dose IL-2 and IL-7 or CD40L, or 
stimulation with an E1-E3- recombinant virus in which the MHC class I evasion has been 
abolished, did not result in significant increases of HAdV-specific CD8+ T cells (Heemskerk 
and Veltrop-Duits, unpublished observations). Of course, the possibility remains that some 
factors required for proper stimulation of CD8+ T cells were absent in the cultures and that, 
therefore, these T cells could not be detected. In agreement with our results, though, many 
reports have described HAdV-specific CD4+ T cells (25,26,41-44), whereas reports on 
HAdV-specific CD8+ T cells are scarce (45,46).  
The results described in this thesis indicate that HAdV-specific CD4+ T cell clones have 
antiviral activity in vitro (Chapter 7). Cytotoxicity exerted by CD4+ T cell lines and clones 
has been observed previously (47-49), but much scepticism has been raised whether these 
findings represent in vitro artefacts without having a physiological function in vivo. In recent 
years, reports on ex vivo cytotoxic CD4+ T cells have emerged indicating that these effector 
cells are not merely an artefact but rather a cell type with an advanced stage of cellular 
differentiation as shown by a loss of CD27 and CCR7 surface expression (50,51). However, 
whether the antiviral effect of HAdV-specific CD4+ T cells is also present in short-term 
cultured cells in addition to T cell clones remains to be further investigated. Studies using 
such short-term cultures in vitro require application of HAdV-infected targets other than 
EBV-transformed B cells since EBV reactivity might still be present in these cultures, 
confounding the anti-adenoviral effect. Furthermore, the fact that an antiviral effect is 
observed in vitro does not automatically imply relevance for the situation in vivo. Whether 
these CD4+ T cells have effect in vivo can only be determined by infusing HAdV-specific 
CD4+ T cells in patients, and even in that case it might be difficult to determine by which 
mechanism this effect is induced (either direct lysis, production of IFN-γ, stimulating 
immune recovery by providing help to CD8+ T cells or B cells, etc.) 
 
What would be the optimal strategy for diagnosis of life threatening HAdV infections in the 
near future? According to the results described in this thesis, recipients from HLA-identical 
grafts (MFD) have a similar frequency of HAdV infection as other graft recipients. 
However, recipients from HLA-identical grafts are not at risk of developing disseminated 
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and fatal HAdV infection (Chapter 3, van Tol et al., submitted, and (7,52)). Therefore, 
screening of these patients is not required. Recipients of a MUD, MMUD or MMFD graft 
should be monitored weekly for HAdV infection pre-SCT and during the first 3-4 months 
post-SCT. An optimal screening program would be to perform RQ-PCR on plasma samples 
to detect early dissemination of an HAdV infection. Additional weekly culture of feces and 
urine could be abandoned, as it is labor-intensive and only results in a diagnosis of a higher 
proportion of HAdV-infected patients without virus-associated complications. In patients 
with a positive RQ-PCR signal in plasma, feces, throat swab and urine should be obtained 
for culture. When an HAdV strain is cultured, this clinical isolate can then be used for 
serotyping and tested for drug susceptibility. Alternatively, a multiplex RQ-PCR could be 
used that distinguishes the different species or perhaps even the different serotypes when the 
PCR product is sequenced. In this respect, it should be noted that the RQ-PCR that was used 
in this study was able to detect all HAdV serotypes, but quantification was optimized for 
species C and A. More recently, we were able to improve this RQ-PCR technique allowing 
quantification of species A, B, C and D using species-specific primers and/or probes (Claas 
et al., submitted). More reports on multiplex RQ-PCR have been published in recent years, 
confirming the need for rapid detection and geno- or serotyping of infecting HAdV strains 
(20,30,53).  
Similarly, when would be the best time to initiate (which) treatment? As has been performed 
in the ribavirin study (Chapter 4), treatment should be initiated when the presence of viral 
DNA has been confirmed in a consecutive plasma sample, and reaches levels above 1000 
copies/mL (as lower levels have been observed in occasional plasma samples from patients 
who did not develop disseminated infection, unpublished observations). As cidofovir 
treatment has in vitro activity against all HAdV species, but has not yet been properly 
investigated in relation to viral load and lymphocyte recovery, this would be the first choice 
of pharmacological treatment. However, if at the time of initiation of treatment lymphocyte 
numbers are already increasing, one could speculate that treatment may not even be required 
as was observed in a few patients that cleared infection without any treatment (Chapter 3). 
Nevertheless, this referral or withdrawal of treatment would be a high-risk procedure that 
requires careful retrospective analyses of additional patients before it can be implemented in 
the clinic. Boosting the immune recovery has also been suggested as treatment for (HAdV) 
infections in some reports (54). This could be achieved either by tapering the immune 
suppression (55), or by infusion of DLI cells which have been depleted of the alloreactive T 
cells (56). In the latter case, donor lymphocytes were mixed with patient lymphocytes for 3-5 
days and T cells that had upregulated their IL-2 receptor, i.e. CD25+ T cells, were depleted 
via MACS sorting. Besides antiviral drug treatment, or perhaps even instead of cidofovir 
treatment as this was unsuccessful in one patient without lymphocyte recovery, we would 
favor the application of adoptive immunotherapy with HAdV-specific T cells, which has 
Chapter 8 
 126
already been performed for other viral infections such as CMV and EBV post-SCT (57-59). 
If these T cells were to be infused at the second positive RQ-PCR result, the T cells need to 
be generated before the patient has actually been diagnosed with HAdV dissemination as it 
requires several weeks to expand these cells. This would imply that HAdV-specific T cells 
should be generated for all patients at risk of HAdV dissemination. The main risk factor for 
dissemination of HAdV is to receive a graft from an other than MFD donor; possible other 
risk factors are T cell depletion/CD34+ enrichment of the graft and ATG/Campath treatment 
of the patient in vivo, although these risk factors need to be confirmed in larger studies. 
Generating T cells for all these patients is very costly and labor-intensive, and adoptive 
therapy will probably only be necessary for a small proportion of this group of patients. 
Alternatively, with the improvement of techniques such as tetramers or artificial liposomal 
APC for identification or stimulation (60-62), and MACS or FACS sorting of HAdV-
specific T cells (44) followed by a short, aspecific expansion period, these T cells might be 
obtained within 1 to 2 weeks in the future. Another way to obtain more HAdV-specific T 
cells from the donor could be to vaccinate this donor prior to SCT donation, for example 
with the 5 peptides selected in Chapter 6. This has two potential benefits which will need to 
be investigated: the graft may contain more HAdV-specific memory T and B cells, thus 
conferring immunity to the host, and more HAdV-specific T cells may be isolated from the 
DLI, which could circumvent the need for prolonged culture to expand these cells when the 
patient develops a disseminated HAdV infection.  
 
In conclusion, the results described in this thesis have substantially contributed to the 
knowledge on the occurrence of HAdV infection and dissemination in children after SCT as 
well as to the unraveling of the human immune response against HAdV. The major goals for 
the future remain to optimize adoptive immunotherapy, in which short stimulation periods 
are sufficient. Infusion of these HAdV-specific T cells may then prove to be a valuable tool 
to decrease the mortality rate due to HAdV infection or reactivation in immunocompromised 
pediatric patients after allogeneic stem cell transplantation. 
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Allogeneic stem cell transplantation (SCT) is a curative treatment for many disorders of the 
hematopoietic system, including primary immune deficiencies such as SCID and inborn 
errors such as β-thalassemia, as well as for high-risk leukemia patients in whom 
chemotherapy treatment failed to induce a long-lasting remission. The SCT-procedure is, 
however, associated with many complications as a result of toxicity of the drugs used and of 
the severely suppressed hematopoiesis. Notably, infusing stem cells - often depleted of T 
cells in the case of HLA mismatched transplants – after myeloablative conditioning renders 
the patients immunocompromised for a prolonged period post-SCT. Infectious complications 
frequently occur and are a major cause of morbidity and mortality. In recent years, HAdV 
infections have become increasingly prominent in this respect, especially in pediatric graft 
recipients (Chapter 1). This thesis focuses on the occurrence and treatment of HAdV 
infections as well as humoral and cellular immune responses against the virus in 
immunocompromised pediatric recipients of SCT. 
Surveillance of patients for HAdV infection with a detection method that allows early 
recognition of progressive infection with a high sensitivity and specificity is a first 
requirement to determine whether a patient is at risk of developing HAdV related disease or 
death. For a long time, culturing of feces or other specimens obtained from the patient has 
been the standard method for virus detection. However, results obtained with this technique 
are only available after 1-2 weeks of culture, during which period the infection might 
progress unnoticed if clinical symptoms are absent. Furthermore, some HAdV strains may 
grow out (too) slowly in this system, and no information is obtained on the severity of the 
infection. As for other viruses, a rapid detection method that determines the viral DNA load 
in serum or plasma was considered useful to detect early dissemination of the virus in order 
to allow timely initiation of treatment. Therefore, we have set out to develop a semi-
quantitative PCR based on a primer set described by Echavarria et al, in which a conserved 
part of the hexon gene was amplified in order to detect all HAdV serotypes (1). DNA was 
extracted from serum and amplified by PCR at several dilutions of the template ranging from 
undiluted to 1000-fold diluted. A high load of viral DNA would result in a positive signal in 
the 1000-fold diluted template. Chapter 2 describes the results that have been obtained 
using this semi-quantitative PCR retrospectively on a group of 36 HAdV-infected pediatric 
SCT patients. A high level of HAdV DNA (i.e., detection of a PCR product after 100-fold or 
greater dilution of template DNA) in serum samples correlated with fatal disseminated 
HAdV disease. A high HAdV DNA load was detected in 86% of the patients who developed 
fatal disease, whereas only 7% of the patients who survived had similar high loads of HAdV 
DNA (P < .0001), indicating a high sensitivity and specificity of the detection method. 
Previously, it was reported that the detection of HAdV DNA by PCR in serum as such was 
associated with fatal HAdV disease (2). However, in the present extended retrospective 
analysis, HAdV DNA - albeit mostly at low levels - was also detected in a significant 
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proportion of patients who survived. Interestingly, in some patients, it appeared that high 
loads of HAdV DNA in serum resolved in the absence of any treatment. Together, the results 
of this retrospective study demonstrated that semi-quantitative data on HAdV DNA load in 
serum provide clinically relevant information about the outcome of HAdV infection, which 
warranted more precise quantitative data based on the analysis of serum/plasma samples 
obtained more frequently in a prospective study. Therefore, we have developed a real-time 
quantitative (RQ)-PCR to detect HAdV DNA in an automated and more quantitative fashion. 
Using this RQ-PCR in a pilot study of two patients with a different outcome of the infection, 
the importance of quantification of viral loads was confirmed as this was the only parameter 
discriminating between the two patients (i.e., clinical symptoms and culture results were 
comparable) (3). Thus, we initiated a prospective study to address the presence and course of 
the plasma DNA load in relation to immune reconstitution more systematically (Chapter 3). 
In this prospective study, 48 pediatric SCT patients were monitored for the occurrence of 
adenovirus infection and viremia by culture and RQ-PCR, respectively. Infection occurred in 
44% of patients, of whom 33% developed HAdV viremia as documented by the presence of 
viral DNA in plasma. A low lymphocyte count at the time of the first virus isolation was a 
strong predictor of HAdV viremia, and survival of the viremic infection was correlated with 
increasing lymphocyte counts during the first weeks of HAdV infection. This strong 
correlation between lymphocyte recovery and clearance of HAdV infection confirms and 
extends a previous report (4) and data from a retrospective study of another cohort of 
pediatric SCT recipients (van Tol et al., submitted). In addition, HAdV-specific immune 
responses were investigated longitudinally in patients post-SCT. Serotype-specific humoral 
immune responses as well as CD4+ HAdV-specific T cell responses were detected in patients 
surviving HAdV viremia several weeks to months after clearance of the viral DNA from the 
circulation. Interestingly, the presence of pre-existing high HAdV-specific NAb titers in 
serum of 2 out of 6 patients did not prevent progression to viremia. These results suggest that 
the role of pre-existing NAb (as measured in vitro) in protection against progression to 
viremia may be limited.  
Ribavirin and cidofovir treatment have been used in recent years with variable success, but 
information on viral load or immune reconstitution was usually lacking in these studies (5-
8). Data on immune reconstitution in combination with antiviral therapy is essential as we 
observed that lymphocyte recovery correlated with clearance of disseminated HAdV in the 
absence of treatment (Chapter 3). With the development of RQ-PCR techniques, quantitative 
monitoring of DNA loads in patients treated with antiviral drugs is feasible and may result in 
objective information on the therapeutic efficacy of these antiviral drugs in 
immunocompromised patients with disseminated HAdV infection. In Chapter 4, we 
investigated the efficacy of ribavirin treatment to inhibit HAdV replication in 4 patients 
without lymphocyte recovery, implicating that any observed effect would be due to the 
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ribavirin treatment. Treatment was initiated at an HAdV DNA load exceeding 1000 
copies/mL in two consecutive plasma samples. No reduction in the viral DNA load was 
observed in any of the patients during the period in which ribavirin was administered. 
Strikingly, even an apparently unaffected increase in viral DNA load was documented in 3 
of the cases, suggesting that ribavirin lacks significant antiviral activity in vivo against 
various HAdV strains. These results provide evidence that ribavirin is not the drug of choice 
to treat HAdV infection in severely immunocompromised patients.  
The lack of effective antiviral drugs for the treatment of severe HAdV infections in pediatric 
SCT recipients and case reports on the positive effects of DLI on HAdV clearance (9,10) 
have prompted us to investigate the possibility of adoptively transferring immunity from the 
donor to the immunocompromised host. This adoptive immunotherapy with T cells from the 
donor has already been successfully pursued for EBV and CMV reactivations (11,12). 
Several requirements have to be considered: (i) the T cells need to be specific for HAdV and 
preferably recognize multiple serotypes from different species (ii) alloreactive T cells should 
not be present to circumvent GvHD, (iii) sufficient numbers of T cells should be obtained for 
infusion, (iv) infectious virus, used for stimulation, should not be present in the inoculum, 
nor E1-E3- recombinant virus as homologous recombination with the serotype infecting the 
patient might occur. To meet these requirements, we studied the possibilities of inactivating 
HAdV5 completely and to determine the frequency of healthy donors responding to this 
inactivated HAdV5 (Chapter 5). HAdV5 was very efficiently inactivated using the 
photosensitizer methylene blue (MB, >7 log reduction of infectivity), which is important for 
the biosafety requirements for adoptive immunotherapy. The proliferative response to MB-
inactivated HAdV5 was comparable to that of infectious, wild-type virus or differently 
inactivated HAdV5. Furthermore, T cells cultured against MB-inactivated HAdV5 also 
responded to infectious HAdV5, indicating that the antigenic determinants presented by 
APCs were largely unaltered by MB treatment. After 28 days of culture, alloreactivity in the 
expanding T cell lines was drastically reduced, probably due to the fact that the alloreactive 
T cells died by neglect or were diluted out by the expansion of the HAdV-specific T cells. 
Together, these data suggest that MB-inactivated HAdV5 is a safe source of antigen which 
can be used to culture T cells that recognize infectious HAdV5. HAdV5-specific T cells that 
were detected were predominantly CD4+ T cells and secreted IFN-γ upon stimulation in 
accordance with results of other groups (13,14). To characterize these HAdV-specific CD4+ 
T cells further, CD4+ T cell clones were obtained to dissect whether the HAdV-specific 
response was serotype-specific or cross-reactive. All T cell clones that were originally 
stimulated with HAdV5 recognized not exclusively HAdV5, but also other serotypes from 
the same species (C) or even serotypes from other species (A and B), indicating that the 
HAdV-specific T cellular immune response is predominantly cross-reactive (Chapter 5). 
Other reports have been published describing different methods to expand HAdV-specific T 
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cells ex vivo, which either make use of prolonged culture periods to reduce alloreactivity 
(15,16), or positive selection of the HAdV-specific, IFN-γ secreting T cells via magnetic 
bead sorting with the MACS (17).  
Another possibility to circumvent the use of (in)active virus would be to culture T cells with 
antigenic peptides derived from HAdV. To define these peptides, we generated several 
recombinant structural proteins as well as overlapping hexon peptides from HAdV5 and 
tested whether these proteins and peptides were recognized by a panel of healthy donors 
(Chapter 6). Comparison of T cell responses against the two structural proteins hexon 
(protein II) and penton (protein III) and one early gene product, E1A, of HAdV5 revealed 
that most T cell responses were directed against the structural proteins and the C-terminal 
part of the hexon protein in particular. The C-terminal part of the hexon protein is the most 
conserved region between different serotypes (18), offering an explanation for the cross-
reactivity found in cultured HAdV-specific T cells that we and others have observed 
(Chapter 5 and (19-21)). The five most frequently recognized peptides that were identified 
are derived from the conserved part of the hexon protein. The amino acid sequences of 4 of 
these peptides were highly conserved between different HAdV serotypes from various 
species, while one peptide was mainly restricted to serotypes belonging to species C. One of 
the conserved peptides, peptide II64, contains a previously described HLA-DP-restricted 
hexon-epitope II910-924, which is conserved between many human and other mammalian 
adenoviruses (22,23). The peptide pool of these 5 hexon-derived peptides was recognized by 
CD4+ T cells of a majority of the healthy adult population (93%). After culturing with this 
peptide pool, HAdV-specific CD4+ T cells were detected that recognized target cells infected 
with wildtype HAdV from different species. Therefore, these data suggest that these peptides 
are promising candidates for generating HAdV-specific T cells for adoptive immunotherapy 
as peptides can easily be generated under GMP conditions. 
At this stage, however, it remained unknown whether and by which mechanism these CD4+ 
HAdV-specific T cells are capable of mediating antiviral activity, which would be required 
for optimal immunotherapy. Therefore, the HAdV-specific CD4+ T cell clones that had been 
obtained (Chapter 5) were further characterized for their recognition of specific peptides 
from HAdV, their phenotype and their antiviral function in Chapter 7. Most of the T cell 
clones reacted against peptides that are located in the conserved C terminal part of the hexon 
protein, and all clones had a predominant Th1 phenotype as they produced IFN-γ and TNF-α 
upon stimulation with HAdV5 or specific peptide. To determine whether these CD4+ HAdV-
specific T cells were capable of mediating antiviral activity, we developed an in vitro assay 
in which the effect of T cells on viral replication was investigated. Viral titers were 
determined in cell lysates of infected B-LCLs in the presence or absence of a T cell clone. 
Addition of T cells at a 10:1 or 1:1 ratio had a strong impact on viral replication by inhibiting 
viral outgrowth more than 99%, suggesting that HAdV-specific CD4+ T cell clones do 
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indeed have antiviral activity in vitro. Cognate interaction between TCR and the MHC II-
peptide complex was required for the T cells to inhibit viral replication, which was most 
likely mediated by perforin-mediated lysis induced by these CD4+ T cells. 
Finally, in Chapter 8 these findings and their implications for future research, both for 
treatment of disseminated HAdV infection and the use of adenoviral vectors for gene 
therapy, are discussed. 
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Stamceltransplantatie (SCT) is een procedure waarbij stam cellen (= voorloper cellen), die 
afkomstig zijn van een gezonde donor en waaruit rode en witte bloedcellen kunnen ontstaan, 
worden overgebracht naar een patiënt. Deze behandeling wordt toegepast bij verschillende 
aandoeningen van de aanmaak van cellen van het immuunsysteem, primaire 
immuundeficiënties, en voor andere aangeboren afwijkingen zoals β-thalassemie. Ook wordt 
SCT uitgevoerd bij patiënten met kanker van cellen van het immuunsysteem, genaamd 
leukemieën, die niet voldoende reageren op de standaard chemotherapie. De procedure van 
SCT is echter geassocieerd met veel complicaties als gevolg van de toxiciteit van de 
behandeling en vanwege de langdurige afwezigheid van een goed functionerend 
immuunsysteem na de behandeling aangezien de stamcellen moeten uitrijpen tot nieuwe 
functionele cellen van het immuunsysteem, zoals T en B lymfocyten.  
Het zoeken van een juiste donor is erg belangrijk omdat normaliter een transplantaat van een 
donor door het afweersysteem van de patiënt wordt afgestoten doordat het transplantaat als 
lichaamsvreemd wordt herkend. Deze afstoting wordt veroorzaakt doordat de patiënt en de 
donor van elkaar verschillen voor bepaalde weefselantigenen, die gezamenlijk het “major” 
histocompatibiliteitscomplex (MHC) worden genoemd. Een donor moet dus in het ideale 
geval genetisch identiek zijn met de patiënt voor deze MHC antigenen, zoals het geval kan 
zijn bij een broer en zus. Een MHC-identieke familiedonor (MFD) is echter niet altijd 
aanwezig. In zo’n geval wordt er gezocht naar een vrijwillige beenmergdonor die qua MHC 
wel volledig overeenkomt met de patiënt, maar die niet tot de familie behoort (matched 
unrelated donor, MUD), of anders naar familiedonoren of beenmergdonoren die 
mismatch(es) hebben (mismatched family donor, MMFD of mismatched unrelated donor, 
MMUD). In het geval dat de donor en de patiënt verschillen van elkaar voor het MHC, 
worden de T cellen die verantwoordelijk zijn voor de afstoting, uit het transplantaat 
verwijderd. Dit heeft tot gevolg dat de patiënt na SCT een verminderde immunologische 
afweer heeft aangezien het meer tijd kost om voldoende nieuwe T en B cellen te genereren. 
Bij deze patiënten komen zeer frequent virale infecties voor, die normaal gesproken geen 
problemen zouden veroorzaken, maar in de context van een verlaagde afweer zeer ernstig en 
soms fataal kunnen zijn. 
In de laatste jaren zijn infecties door het adenovirus veelvuldig voorgekomen bij kinderen 
die een SCT ondergingen. Dit humane adenovirus (HAdV), waarvan 51 typen bekend zijn, 
geeft in gezonde kinderen slechts een verkoudheid, maar dit virus kan fatale infecties 
opleveren na een SCT. Dit proefschrift beschrijft het optreden van zulke HAdV infecties na 
SCT, evenals de mogelijke behandeling met medicijnen die momenteel beschikbaar zijn. 
Verder zijn in dit proefschrift de verschillende componenten van de specifieke 
immuunrespons tegen HAdV gekarakteriseerd bij gezonde personen en bij kinderen na SCT. 
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Deze componenten zijn onder andere de T cellen, die verantwoordelijk zijn voor het 
herkennen en opruimen van geïnfecteerde cellen (cellulaire immuniteit), en de B cellen, die 
verantwoordelijk zijn voor de productie van afweerstoffen genaamd antilichamen die aan het 
virus kunnen binden en zo infectie van cellen kunnen voorkomen (humorale immuniteit).  
Patiënten moeten regelmatig vervolgd worden na SCT om een HAdV infectie, die mogelijk 
fataal zou kunnen verlopen, snel op te sporen. De conventionele techniek waarmee 
vastgesteld kan worden of een patiënt een HAdV infectie heeft, is gebaseerd op het kweken 
van feces, urine of een keeluitstrijkje in aanwezigheid van cellen die gevoelig zijn voor 
HAdV infectie. Deze techniek is echter zeer tijdrovend omdat het virus eerst deze cellen 
moet infecteren, wat enkele dagen kan duren, voordat de uitslag bekend kan worden. Tevens 
geeft de kweektechniek weinig informatie over de ernst van de infectie. Om deze redenen 
hebben we een andere detectie methode opgezet, waarmee een ernstige HAdV infectie beter 
vast te stellen is. Deze detectietechniek is gebaseerd op het aantonen van het adenovirale 
DNA door middel van PCR (polymerase chain reaction). Met de PCR wordt viraal DNA 
vermenigvuldigd zodat het met grote gevoeligheid aantoonbaar wordt in het bloed van een 
patiënt. Een positief signaal met deze methode is een teken van verspreiding van HAdV via 
het bloed en dus van een zich door het lichaam verspreidende (gedissemineerde) infectie, die 
mogelijk een ernstig beloop kan hebben. In Hoofdstuk 2 hebben we deze PCR techniek 
toegepast op bloedplasma monsters die bewaard waren van 36 kinderen die in de jaren 
ervoor na SCT een HAdV infectie hadden doorgemaakt. Bij deze kinderen was de HAdV 
infectie aangetoond door middel van positieve feces kweken. Tevens werd het te testen 
materiaal verdund, om een indruk te krijgen van de aanwezige hoeveelheid viraal DNA. Met 
andere woorden, als het signaal nog steeds meetbaar was na 1000 × verdunning, betekende 
dit dat er meer viraal DNA aanwezig was in het plasma dan wanneer het alleen onverdund 
aantoonbaar was en bij hogere verdunningen negatief bleek te worden. De resultaten toonden 
aan dat een hoge virale load, dus het detecteren van viraal DNA in 100 of 1000 × verdund 
plasma, correleerde met een fataal beloop van de HAdV infectie. Bij patiënten die alleen een 
milde infectie hadden gehad werd weliswaar soms een positief PCR signaal in het plasma 
gevonden, maar dit signaal was hooguit nog aantoonbaar in 10 × verdund plasma. Uit deze 
resultaten bleek dat deze semi-kwantitatieve methode van het bepalen van de virale load van 
belang was om de uitkomst van de infectie (overlijden of niet) te kunnen voorspellen.  
De studie in hoofdstuk 2 was opgezet met monsters die retrospectief (achteraf) geanalyseerd 
werden. Daarom wilden we deze bevindingen bevestigen in een patiëntengroep die 
prospectief gevolgd werd voor HAdV infectie, waarbij mogelijkerwijs meer infecties 
aantoonbaar zouden zijn omdat in de retrospectieve studie alleen feceskweken afgenomen 
waren tijdens een verdenking op HAdV infectie. Tevens was inmiddels de techniek van de 
PCR geoptimaliseerd, zodat er nu in plaats van een verdunningswaarde een echte 
kwantitatieve virale load bepaald kon worden, die overeenkwam met het aantal kopieën van 
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het virale DNA (bijvoorbeeld 1000 kopieën, of 1 miljoen kopieën) per milliliter plasma. In 
Hoofdstuk 3 wordt deze prospectieve studie beschreven, waarin 48 patiënten die tussen 
januari 2001 en januari 2003 een SCT hadden ondergaan, gevolgd zijn voor het optreden van 
HAdV infectie na SCT, zowel door het uitvoeren van kweken op feces materiaal als van 
kwantitatieve PCR op plasma eenmaal per week. In 44% van de patiënten werd een HAdV 
infectie aangetoond door middel van feces kweek. In 33% (n=6) van de geïnfecteerde 
patiënten bleek het virus te dissemineren,wat resulteerde in een virale load in het plasma. 
Drie van deze 6 patiënten overleden uiteindelijk aan de HAdV infectie, terwijl de andere 3 
patiënten in staat waren om het virus te elimineren. Het bleek dat aanwezigheid van een laag 
aantal lymfocyten in het bloed na SCT samenhing met de verspreiding van het virus door het 
lichaam. Bij de patiënten met een gedissemineerde infectie die uiteindelijk het virus wisten 
op te ruimen was bovendien een sterke stijging van het aantal lymfocyten waarneembaar, die 
niet optrad bij patiënten die overleden aan de infectie. Kortom, herstel van het aantal 
lymfocyten was cruciaal voor het overleven van een HAdV infectie. In dit hoofdstuk werd 
tevens onderzocht welke immuunresponsen tegen het HAdV opgebouwd werden door de 
patiënten die de infectie overleefden. Het bleek dat de T cellen in staat waren om een anti-
HAdV respons te ontwikkelen, wat werd aangetoond door het vastsellen van de uitscheiding 
van antivirale stoffen (genaamd cytokinen zoals interferon gamma, IFN-γ) na stimulatie met 
HAdV. Tevens was er een B cel respons meetbaar, doordat er een toename zichtbaar was 
van de hoeveelheid antilichamen in het bloed van de patiënt, die gericht waren tegen het 
specifieke HAdV type dat de infectie had veroorzaakt. Deze T en B cel responsen waren 
over het algemeen pas te detecteren nadat het virus was verdwenen uit het bloed, dus nadat 
de disseminatie was geklaard. 
Er zijn niet veel medicijnen beschikbaar om een HAdV infectie mee te behandelen. Twee 
medicijnen, ribavarine en cidofovir, worden daarvoor gebruikt, maar de resultaten van deze 
behandelingen zijn niet erg overtuigend. Tevens waren de door andere onderzoeksgroepen 
gerapporteerde bevindingen alleen gebaseerd op de resultaten van feceskweken, terwijl we 
inmiddels wisten dat in een groot deel van deze patiënten het virus uiteindelijk niet 
dissemineert al naar gelang het herstel van het immuunsysteem bij de patiënt. Om deze 
redenen hebben we in Hoofdstuk 4 gekeken naar het effect van de behandeling met 
ribavarine van patiënten waarin het virus kort tevoren aantoonbaar werd in het bloed, dus 
aan het begin van de disseminatie van de infectie. Aangezien deze patiënten geen 
lymfocytenherstel hadden, moest elk effect op de virale load in het plasma een gevolg zijn 
van de ribavirine behandeling en niet het gevolg van het herstel van het immuunsysteem. In 
de 4 patiënten die beschreven zijn in hoofdstuk 4 bleek dat er geen effect op de virale load 
aantoonbaar was tijdens ribavarine behandeling. In drie gevallen was er zelfs een toename in 
de virale load tot hoge aantallen viruskopieën in het plasma. Hieruit kon worden 
geconcludeerd dat ribavarine geen antiviraal effect op HAdV heeft, en dus niet geschikt is 
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om patiënten met een HAdV infectie te behandelen in afwezigheid van immuunreactieve 
cellen. 
Het gebrek aan goede antivirale geneesmiddelen voor de behandeling van ernstige HAdV 
infecties bij kinderen na SCT, alsmede het feit dat enkele patiënten waren beschreven met 
een gunstig effect van het geven van donorlymfocyten op het klaren van een HAdV infectie, 
hebben ons ertoe aangezet om de mogelijkheid van adoptieve overdracht van immuniteit 
(door middel van HAdV-specifieke T cellen) van de stamceldonor naar de patiënt te 
onderzoeken. Deze benadering van het overdragen van immuniteit is al eerder succesvol 
gebleken bij de bestrijding van andere virale infecties, zoals infecties met het Epstein Barr 
virus of het cytomegalovirus, bij patiënten na SCT. Er zijn meerdere eisen waaraan moet 
worden voldaan om deze benadering te kunnen toepassen: (i) de T cellen die worden 
gegeven aan de patiënt moeten specifiek zijn voor HAdV, en bij voorkeur ook nog in staat 
zijn om verschillende serotypen (varianten) van het virus te herkennen; (ii) T cellen die 
reactief zijn tegen weefselantigenen op cellen van de patiënt (alloreactief genaamd) moeten 
niet meer aanwezig zijn in de celpopulatie die overgebracht wordt naar de patiënt; (iii) er 
moeten voldoende T cellen kunnen worden gegenereerd; en (iv) levend infectieus virus mag 
niet aanwezig zijn in de celpopulatie, omdat dit mogelijk een verergering van de infectie bij 
de patiënt zou kunnen veroorzaken. Om aan deze eisen te voldoen, hebben we de 
mogelijkheden onderzocht om HAdV5 (serotype 5) te inactiveren en tevens onderzocht hoe 
groot het percentage gezonde donoren is dat respondeert tegen dit geïnactiveerde HAdV5 
(Hoofdstuk 5). HAdV5 bleek gemakkelijk geïnactiveerd te worden met de fotosensitizer 
methyleen blauw (MB), wat belangrijk is voor de veiligheid van adoptieve immuuntherapie 
(dus geen overdracht van levend virus). De proliferatieve respons (de deling van T cellen als 
respons op het virus) was vergelijkbaar na stimulatie met infectieus virus en MB-
geïnactiveerd virus. T cellen gekweekt met MB-geïnactiveerd virus waren ook nog in staat 
om infectieus virus te herkennen, wat aangeeft dat de antigenen (eiwitten van het virus waar 
de T cellen op reageren) behouden blijven na inactivatie met MB. Na 28 dagen kweken van 
cellen uit bloed van de donor in aanwezigheid van virus was de alloreactieve T cel respons 
sterk verminderd, terwijl de HAdV-specifieke respons was toegenomen. Deze resultaten 
suggereren dat MB-geïnactiveerd HAdV5 een veilige bron voor stimulatie van T cellen is, 
waarmee T cellen kunnen worden gegenereerd die levend virus kunnen herkennen (wat 
uiteindelijk aanwezig zal zijn in de patiënt). De HAdV-specifieke T cellen waren 
voornamelijk cellen van de CD4+ T cel populatie, die IFN-γ uitscheiden (een cytokine met 
antivirale werking). Om deze cellen verder te kunnen bestuderen werden T cel klonen 
gegenereerd, wat inhoudt dat de cellen zo ver verdund worden dat de functie van de 
nakomelingen van één unieke T cel onderzocht kan worden. Met behulp van deze T cel 
klonen is vastgesteld dat een T cel in staat is om meerdere serotypen van HAdV (er zijn 
momenteel 51 serotypen bekend) te herkennen, wat aangeeft dat de T cel respons 
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kruisreactief is (dus T cellen gestimuleerd met HAdV5 kunnen bijvoorbeeld ook HAdV35 
herkennen). 
Een andere mogelijkheid voor T cel stimulatie, waarbij het gebruik van (in)actief virus wordt 
vermeden, is het kweken van T cellen in aanwezigheid van bepaalde peptiden 
(eiwitfragmenten) van het virus. Om vast te stellen welke peptiden van het virus een T cel 
respons kunnen opwekken, hebben we een paar eiwitten van HAdV gemaakt. Van één van 
deze eiwitten zijn ook kortere overlappende peptiden gemaakt, elk met een lengte van 30 
aminozuren en met een overlap van 15 aminozuren tussen de verschillende peptiden. Deze 
eiwitten en peptiden zijn vervolgens getest in een panel van gezonde donoren om te bepalen 
welke peptiden bij de meeste personen een T cel respons opwekken (Hoofdstuk 6). Het is 
gebleken dat één van de structurele eiwitten, het hexoneiwit, door de meeste personen 
herkend werd, en dan met name het geconserveerde deel van het hexoneiwit (met de grootste 
overeenkomt tussen de verschillende varianten van het virus). Dit kan ook verklaren waarom 
de meeste T cel klonen kruisreactief waren, aangezien deze T cellen ook peptiden in het 
geconserveerde deel herkenden. De 5 peptiden die het meest frequent herkend werden door 
CD4+ T cellen van gezonde donoren werden vervolgens gebruikt om T cellen te stimuleren 
in kweek. Na 28 dagen kweken waren de T cellen in staat om infectieus virus van 
verschillende serotypen te herkennen. Deze peptiden zouden dus goed gebruikt kunnen 
worden om T cellen te kweken voor adoptieve immunotherapie aangezien deze peptiden 
relatief eenvoudig te produceren zijn en duidelijke voordelen hebben boven het gebruik van 
intact virus. 
Het was echter nog onbekend of CD4+ HAdV-specifieke T cellen een antivirale functie 
hebben, met andere woorden of deze cellen daadwerkelijk in staat zijn om het virus op te 
ruimen. Dit is natuurlijk van groot belang voor het succes van immunotherapie in een patiënt 
met een ernstige HAdV infectie. De CD4+ T cel klonen, die waren gegenereerd in het 
onderzoek beschreven in Hoofdstuk 5, hebben we daarom onderzocht op hun antivirale 
functie zoals weergegeven in Hoofdstuk 7. Hiervoor is een test opgezet waarin het effect 
van het toevoegen van T cellen op de adenovirale replicatie (ontstaan van nieuwe 
virusdeeltjes) in geïnfecteerde cellen werd bestudeerd. Wanneer HAdV-specifieke T cellen 
werden toegevoegd aan geïnfecteerde B cellen werd de virale uitgroei sterk verminderd tot 
minder dan 1% van de uitgroei. Dit suggereert dat deze T cellen inderdaad antivirale 
activiteit bezitten. De remming van virale replicatie werd hoogstwaarschijnlijk veroorzaakt 
door het direct vernietigen (lyseren) van de geïnfecteerde B cel. Tenslotte zijn de resultaten 
van dit proefschrift en het belang hiervan voor de behandeling van patiënten met ernstige 
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De resultaten die in dit proefschrift zijn samengebundeld, had ik nooit kunnen behalen 
zonder de hulp van vele anderen. Om mijn dank aan al die mensen samen te vatten in één 
pagina is niet gemakkelijk, maar ik zal het proberen!  
In mijn eerste maanden als AIO was ik de enige persoon die aan adenovirus werkte, maar in 
de loop van het eerste jaar is dit groepje snel uitgebreid tot het volwaardige ‘adeno-clubje’ 
met Tamara, Louise en Claudia. Allereerst gaat heel veel dank uit naar Tamara, die zonder 
klagen de ene na de andere neutralisatie test inzette, wanneer we weer eens hadden besloten 
dat het toevoegen van die éne extra conditie toch echt nodig was…. Ik weet niet hoeveel 96-
wells platen je hebt gescoord voor CPE, maar ik ben je ontzettend dankbaar voor je enorme 
inzet, en dat je mijn paranimf wilde zijn! Louise, als post-doc in de club heb ik veel steun 
aan je gehad en veel van je geleerd, onder meer hoe je georganiseerd een labjournaal bij kunt 
houden (ik hoop dat ik het ooit eens leer…). Claudia, bedankt voor alle ‘DC’ discussies en 
succes met de laatste loodjes, ik weet zeker dat het je lukt!  
Heel veel dank ook voor de studenten die mij meegeholpen hebben aan dit onderzoek: 
Jessica, Sebastiaan, Eduard en Ragad. Jessica, ik was nog een ‘groentje’ als AIO en heb 
samen met jou veel geleerd, maar het vooral ook heel gezellig gehad! Sebas, dank voor je 
volhardende T cel kloneringen, er is toch maar een mooi paper uit voortgekomen. Ik ben blij 
dat je de immunologie leuk genoeg vond om er zelf een AIO in te worden. 
Naast de adeno-club zou ik graag ieder lid van ons lab persoonlijk willen bedanken, maar 
door de groei die daarin heeft plaatsgevonden is dat haast niet mogelijk. Nicola, samen 
begonnen op 1 oktober 2000, dat schiep meteen een band. Bedankt voor al je support 
gedurende deze jaren! Monique, kamergenootje vanaf dag 1, en tevens steun en toeverlaat 
voor praktische tips (wat is de verdunning voor… hebben we dit….ook?). De late uurtjes 
werden er altijd gezelliger op met z’n tweeën. Els, ook al ben je halverwege van kamer 
verhuisd, je bent en blijft toch een beetje m’n labmoeder (als ik je zo mag noemen?!); bij jou 
heb ik toch wel m’n hart uit kunnen storten in de goede en minder goede momenten! En als 
je nog een zaak met lange broeken weet, hou ik me aanbevolen. Mede-AIO’s Cristiana, 
Claudia en Dirk, bedankt voor alle discussies en zeker de even belangrijke gezelligheid. 
Succes met jullie onderzoek! Alle overige immuno’s (Remy & Geertje, Anja, Jacqueline, 
Alfons, Jessica, Suzy, Gerda, Manja, Wendy, en alle (ex-) studenten) ontzettend bedankt 
voor de gezelligheid, de onmetelijke steun die ik van jullie heb gehad en de lol tijdens het 
werk en buiten het werk. In de loop van de jaren zijn we uitgegroeid tot een groot maar 
enorm leuk team, dat ik heel moeilijk zal vinden om te verlaten! Arjan, bedankt voor je inzet 
vanuit de kliniek, en je niet-aflatende interesse in het onderzoek. René, je commentaar op 
proeven en papers waren altijd weer in staat om mij met een andere blik naar mijn resultaten 
te kijken, dank daarvoor. 
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Naast het immunologisch lab Kindergeneeskunde heb ik veel samengewerkt met de afdeling 
Medische Microbiologie, met name Louis, Eric, Carolien, Thijs en Erik. Bedankt voor jullie 
hulp als ik weer eens een uitslag van een patient wilde weten. Ook Maaike en Liz, bedankt 
voor de samenwerking en mooie papers die daaruit gekomen zijn! 
Veel dank ook aan mijn vriendinnen-club Yvette, Diana, Martha, Nicole, Neeltje en Ilse. 
Tijdens eetafspraken en weekendjes weg boden jullie altijd een luisterend oor, gaven jullie 
me het inzicht om wat meer te relativeren, en bovenal was er de broodnodige ontspanning!! 
Tenslotte wil ik graag mijn geweldige ouders en zus bedanken, die me aldoor gesteund 
hebben, ook door de moeilijkste tijden heen. We zijn een hechte familie en mijn tijdelijke 
vertrek naar het buitenland doet daar niets aan af. 
And then last but not least, many thanks to Andrew, for your never-ending support and trust 
in me, and for the joy you bring to my life! 
 
 
        Veel liefs, 
   





De schrijfster van dit proefschrift werd geboren op 22 augustus 1977 te Noordwijkerhout. De 
middelbare school werd doorlopen op Atheneum College Hageveld in Heemstede van 1989 
tot 1995. In datzelfde jaar begon zij de studie Biomedische Wetenschappen in Leiden, 
waarin zij onderzoekservaring opdeed tijdens stages op de afdelingen Klinische Oncologie 
(bij Corlien Aarnoudse/ Peter Schrier) en Reumatologie (bij Paulien Goossens/ Tom 
Huizinga) in het LUMC, Leiden, en in the Department of Respiratory Medicine, Rayne 
Laboratory, (bij Jean-Michel Sallenave) Edinburgh, Schotland. Haar afstudeerstage deed zij 
op de afdeling Immunobiologie (bij Kiki Tesselaar/ René van Lier) op het CLB in 
Amsterdam, waar zij onderzoek deed naar de effecten van CD27-CD70 interactie. Het 
diploma werd cum laude behaald in september 2000.  
Aangezien het vakgebied van de immunologie haar grootste interesse had, begon zij 
vervolgens aan een AIO onderzoek op het Immunologisch Laboratorium van de afdeling 
Kindergeneeskunde in het LUMC. Het onderzoek zoals beschreven in dit proefschrift is 
verricht van oktober 2000 tot en met maart 2005, waarin tevens de opleiding tot 
Immunoloog (SMBWO) werd voltooid. Vanaf 1 juni 2005 zal zij beginnen als postdoc onder 
de leiding van Dr. Steven Rosenberg in the National Cancer Institute, wat een onderdeel is 
van the National Institutes of Health (Bethesda, Washington, USA). Hier zal zij gaan werken 
aan het optimaliseren van immunotherapie voor patiënten met kanker.   
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